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ABSTRACT  
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells.  
Preservation of beta cell function reduces the risk of the complications of T1D.  
Regular exercise preserves beta cell function rat models of T1D and patients with 
other forms of diabetes.  We wished to examine whether exercise could preserve 
beta cell function in T1D and whether this was influenced by adipokine receptor 
expression and function. 
We undertook a qualitative study to explore barriers to exercise in patients newly 
diagnosed with T1D. This showed that patients lacked confidence managing diabetes 
for exercise, and were poorly supported by healthcare professionals.  
Using these results, we then undertook a pilot clinical trial aiming to determine 
recruitment and retention, adherence to exercise, and exploring whether exercise 
preserves beta cell function in patients newly diagnosed with T1D. We show 
successful recruitment to an unsupervised exercise intervention study. We did not 
detect a beneficial effect of exercise on beta cell function in this pilot trial, but 
identified several areas that will need to be addressed in designing a larger scale 
study. 
Finally, we demonstrate improved adiponectin receptor expression and adiponectin 
mediated suppression of T cell endothelial migration in the months after diagnosis 
with T1D.   
  
 
 
ACKNOWLEDGEMENTS 
This work would not have been possible without the help and support of a great many people 
to whom I would like to extend my heartfelt thanks.  Firstly, my deepest gratitude to my 
supervisor, Dr Parth Narendran, whose valuable advice, patience and kind support was 
invaluable throughout this project.  I would also like to express utmost  thanks to Dr George 
Dowswell, whose calm and helpful advice guiding me in qualitative research was also very 
much needed. 
My thanks also go to everyone who was involved in the Extod study.  Firstly the patients who 
gave me their time and thoughts, but also the very many colleagues, who made this work 
possible.  My particular thanks go to Dr Rob Andrews and Nikki Sawyer, who constantly 
supported the study with advice on clinical research practice and practical help with study 
set-up and monitoring.  I am also grateful to the NIHR for funding the trial. 
I would like to thank all in the IBR laboratories who helped, especially Dr Myriam Chimen 
who taught me all of the laboratory techniques with such patience, but also everyone who 
helped with reagents, advice, time and moral support. 
I am very grateful to Professor Sheila Greenfield for reviewing the qualitative work and 
advising on the Extod study and to Chris Shaw, Sam Sheppard and David Bartlett for their 
samples from the Sports Science study. 
To all my friends, colleagues and family who have listened to and supported me through this, 
thank you.  And finally, my husband Phil, for always believing in me, I would not have 
completed this without you. 
 
 
 
TABLE OF CONTENTS 
1 Introduction ........................................................................................................ 1 
1.1 Type 1 Diabetes ............................................................................................ 1 
1.2 Epidemiology of T1D ..................................................................................... 2 
1.3 Pathophysiology ............................................................................................ 4 
1.4 The natural history of T1D ............................................................................. 5 
1.4.1 Immunity in T1D ..................................................................................... 6 
1.4.2 Decline in beta-cell function after diagnosis of T1D ................................ 9 
1.4.3 Factors affecting C-peptide levels in T1D ............................................... 9 
1.5 Insulin resistance ........................................................................................ 14 
1.6 The effects of exercise ................................................................................ 16 
1.7 Activity levels and barriers ........................................................................... 19 
1.8 Potential mechanisms involved in beta-cell preservation in T1D ................. 22 
2 Hypothesis and Aims ....................................................................................... 24 
3 Extod (Exercise in Type One Diabetes) Study Design and Primary Outcomes 25 
3.1 Introduction ................................................................................................. 25 
3.2 Methods ...................................................................................................... 25 
3.2.1 Study overview ..................................................................................... 25 
3.2.2 Phase 2 design ..................................................................................... 27 
3.2.3 Data collection ...................................................................................... 33 
 
 
3.2.4 Data and Statistical Analysis ................................................................. 40 
3.2.5 Trial conduct ......................................................................................... 42 
3.2.6 Ethical and regulatory matters .............................................................. 49 
3.2.7 Study oversight and monitoring ............................................................ 50 
3.2.8 Sponsorship ......................................................................................... 50 
3.2.9 Funding ................................................................................................ 50 
4 Extod Trial Progress ........................................................................................ 51 
4.1 Review of trial ............................................................................................. 51 
4.1.1 Trial progess ......................................................................................... 51 
4.1.2 Recruitment .......................................................................................... 51 
4.1.3 Review of study .................................................................................... 53 
4.1.4 Impact of changes to study on recruitment ........................................... 56 
4.1.5 Drop-out ............................................................................................... 59 
4.1.6 Adherence to study arm ........................................................................ 61 
4.1.7 Return rates of participant diaries/activity monitoring ............................ 61 
4.1.8 Adverse events ..................................................................................... 62 
4.2 Discussion................................................................................................... 64 
4.2.1 Primary outcome 1: Recruitment/Uptake .............................................. 64 
4.2.2 Primary outcome 3: Study completion rates .......................................... 66 
4.2.3 Adverse events ..................................................................................... 66 
4.2.4 Recommendations for future studies .................................................... 67 
 
 
5 Attitudes and barriers to exercise in people with a recent diagnosis of T1D – 
Qualitative study ..................................................................................................... 69 
5.1 Introduction ................................................................................................. 69 
5.2 Methods/Materials ....................................................................................... 69 
5.2.1 Recruitment .......................................................................................... 69 
5.2.2 Interviews ............................................................................................. 70 
5.2.3 Analysis ................................................................................................ 71 
5.3 Results ........................................................................................................ 72 
5.3.1 Participants ........................................................................................... 72 
5.3.2 Themes ................................................................................................ 74 
5.3.3 Suggestions to improve activity levels .................................................. 90 
5.3.4 Case Studies ........................................................................................ 94 
5.4 Discussion................................................................................................... 97 
5.5 Summary .................................................................................................. 101 
5.6 Recommendations .................................................................................... 101 
6 Baseline characteristics of participants .......................................................... 103 
6.1 Introduction ............................................................................................... 103 
6.2 Methods .................................................................................................... 103 
6.2.1 Participants ......................................................................................... 103 
6.3 Results ...................................................................................................... 104 
6.3.1 Demographics .................................................................................... 104 
 
 
6.3.2 Diabetes presentation ......................................................................... 106 
6.3.3 Anthropomorphic and biochemical measures ..................................... 107 
6.3.4 Antibody status ................................................................................... 109 
6.3.5 Baseline Physical Activity ................................................................... 110 
6.3.6 Baseline C-peptide ............................................................................. 113 
6.3.7 Randomised patients .......................................................................... 114 
6.4 Discussion................................................................................................. 116 
6.4.1 Demographics .................................................................................... 116 
6.4.2 Anthropomorphic measures ................................................................ 117 
6.4.3 Antibody status ................................................................................... 117 
6.4.4 Physical activity .................................................................................. 118 
6.4.5 Stimulated C-peptide .......................................................................... 120 
6.5 Recommendations .................................................................................... 121 
6.5.1 Antibody measurement - requirement for randomisation ..................... 121 
6.5.2 Measures of physical activity .............................................................. 122 
6.5.3 Meal stimulated C-peptide .................................................................. 122 
7 Increasing physical activity ............................................................................. 124 
7.1 Introduction ............................................................................................... 124 
7.2 Methods .................................................................................................... 124 
7.3 Results ...................................................................................................... 124 
7.3.1 Motivational Interviewing .................................................................... 124 
 
 
7.3.2 Anthropometric data over course of study ........................................... 126 
7.3.3 Metabolic parameters ......................................................................... 129 
7.3.4 Activity levels ...................................................................................... 131 
7.3.5 Insulin resistance ................................................................................ 134 
7.4 Discussion................................................................................................. 136 
7.5 Recommendations for further work ........................................................... 137 
8 Beta-cell function ........................................................................................... 139 
8.1 Introduction ............................................................................................... 139 
8.2 Methods .................................................................................................... 139 
8.2.1 Subjects .............................................................................................. 139 
8.2.2 C-peptide measurement ..................................................................... 139 
8.2.3 Statistical analyses ............................................................................. 139 
8.3 Results ...................................................................................................... 140 
8.3.1 Measuring beta-cell function ............................................................... 140 
8.3.2 Factors associated with beta-cell function at baseline......................... 142 
8.3.3 Change in beta-cell function during the study ..................................... 151 
8.4 Discussion................................................................................................. 160 
8.5 Recommendations for future work ............................................................. 164 
9 Adiponectin, exercise and diabetes ................................................................ 165 
9.1 Introduction ............................................................................................... 165 
9.1.1 The adiponectin receptor .................................................................... 165 
 
 
9.1.2 The role of adiponectin in insulin resistance and glucose metabolism 166 
9.1.3 The role of adiponectin in immunity .................................................... 167 
9.2 Methods .................................................................................................... 171 
9.2.1 Subjects .............................................................................................. 171 
9.2.2 Materials ............................................................................................. 172 
9.2.3 Isolation of PBMC from venous blood ................................................. 174 
9.2.4 PCR for adiponectin receptor expression............................................ 174 
9.2.5 Flow cytometry ................................................................................... 175 
9.2.6 Quantification of Serum Adiponectin ................................................... 176 
9.2.7 T cell transmigration studies ............................................................... 176 
9.2.8 T cell proliferation ............................................................................... 178 
9.2.9 Ethics.................................................................................................. 180 
9.3 Results ...................................................................................................... 180 
9.3.1 Healthy Subjects from the Sports Science Study ................................ 180 
9.3.2 Subjects with type 1 diabetes ............................................................. 192 
9.4 Discussion................................................................................................. 200 
9.4.1 The effect of exercise on serum adiponectin in T1D ........................... 200 
9.4.2 The effect of exercise on adiponectin receptor expression on PBMC . 201 
9.4.3 The effect of exercise on response of T cell proliferation to adiponectin
 ………………………………………………………………………………..202 
 
 
9.4.4 The effect of exercise on the suppression of endothelial transmigration to 
adiponectin ..................................................................................................... 203 
9.4.5 Summary ............................................................................................ 203 
9.5 Recommendations for future work ............................................................. 204 
10 Conclusions ................................................................................................... 205 
10.1 Evaluating the barriers to exercise in patients with newly diagnosed T1D
 ………………………………………………………………………………….205 
10.2 Determining whether patients newly diagnosed with T1D can be 
encouraged to take up and adhere to a programme of at least moderate intensity 
exercise for a period of one year, and the rate of exercise uptake in the non-
intervention arm. ................................................................................................. 207 
10.3 Determining whether adherence to this programme of exercise preserves 
beta cell function................................................................................................. 209 
10.4 Investigating the effect of exercise on immunity in patients newly 
diagnosed with T1D. ........................................................................................... 210 
11 References .................................................................................................... 213 
12 Appendices .................................................................................................... 226 
13 Presentations – Publications/Posters ............................................................. 251 
 
 
  
 
 
TABLE OF TABLES 
Table 1-1 Summary of barriers to exercise identified in the general population and 
other disease groups ............................................................................................... 21 
Table 3-1 Overview of study visits ........................................................................... 47 
Table 3-2 Summary of amendments with dates ...................................................... 49 
Table 4-1 - Exclusions based on eligibility criteria ................................................... 59 
Table 4-2 - Study completion rates stratified by treatment site ................................ 60 
Table 5-1 - Demographics of individual participants for Qualitative study. ............... 73 
Table 5-2 - Description of individual participants current and previous activity ........ 75 
Table 5-3 - Description of barriers to exercise cited by participants ......................... 81 
Table 5-4 – Identifying participants to confidence group .......................................... 90 
Table 6-1 - Demographics of Screened Participants in the Extod study ................ 105 
Table 6-2 - Presentation of diabetes ..................................................................... 106 
Table 6-3 - Anthropomorphic measures in screened participants at baseline ........ 108 
Table 6-4 - Biochemical measures in screened participants at baseline ................ 108 
Table 6-5 - GADA status of screened participants ................................................. 109 
Table 6-6 - Mean antibody titre in participants with positive autoantibodies........... 110 
Table 6-7 - Baseline physical activity measures .................................................... 111 
Table 6-8 - Measures of beta-cell function and insulin resistance.......................... 113 
 
 
Table 6-9 - Baseline demographic data for randomised participants ..................... 115 
Table 7-1 - Mean weight and BMI at baseline and after 6 and 12 months. ............ 128 
Table 7-2 - Proportion of participants achieving activity targets. ............................ 132 
Table 8-1 - Mean AUC C-peptide is associated with antibody status.   .................. 148 
Table 9-1 - List of main reagents ........................................................................... 173 
Table 9-2 - List of Antibodies ................................................................................. 176 
 
 
 
  
 
 
TABLE OF FIGURES 
Figure 3-1 - Schematic overview of trial .................................................................. 27 
Figure 4-1 - Recruitment to phase 2 of Extod study over time ................................. 52 
Figure 4-2 - Recruitment to Extod during study period.. .......................................... 53 
Figure 4-3 - CONSORT Flowchart for Extod Study ................................................. 57 
Figure 4-4 - Prevelance of hypoglycaemia during the study .................................... 62 
Figure 6-1 – Scatter diagram comparing physical activity measures used in Extod 
study. .................................................................................................................... 112 
Figure 7-1 - Participant time spent on post-randomisation visits. ........................... 125 
Figure 7-2 - Changes in waist circumference, WHR, and body compositio............ 127 
Figure 7-3 - Weight and BMI changes over the course of the study ...................... 128 
Figure 7-4 - Changes in blood pressure and resting heart rate during the study ... 129 
Figure 7-5 - Changes in lipid profile and glycaemia during the study ..................... 130 
Figure 7-6 – Change in MVPA during the study.. .................................................. 133 
Figure 7-7 – Change in fitness during the study.   ................................................. 134 
Figure 7-8 – Change in measures of insulin resistance over the study .................. 135 
Figure 8-1 - Association between measures of beta cell function .......................... 141 
Figure 8-2 –Association between baseline mean AUC C-peptide and gender and 
age. ....................................................................................................................... 143 
Figure 8-3 - Effect of smoking on baseline mean AUC C-peptide .......................... 145 
 
 
Figure 8-4 – Relationship between mean AUC C-peptide and BMI, weight  and WHR.
.............................................................................................................................. 146 
Figure 8-5 - Association between mean AUC C-peptide at baseline and antibody 
status .................................................................................................................... 147 
Figure 8-6 - Relationship between mean AUC C-peptide at baseline and HOMA2 IR 
and WHR .............................................................................................................. 149 
Figure 8-7 - Scatter diagrams showing relationship between mean AUC C-peptide at 
baseline estimated VO2max. ................................................................................ 150 
Figure 8-8 – The change in mean C-peptide at each time point during the MMTT 151 
Figure 8-9 - The effect of exercise on beta-cell function ........................................ 152 
Figure 8-10 - Relationship between beta-cell function and age and gender .......... 154 
Figure 8-11 - Association between ethnicity and mean AUC C-peptide ................. 155 
Figure 8-12 - Relationship between change in mean AUC C-peptide, smoking status  
and alcohol consumption ...................................................................................... 156 
Figure 8-13 - Association between change in mean AUC C-peptide and presentation 
with T1D. ............................................................................................................... 157 
Figure 8-14 - Relationship between change in mean AUC C-peptide over the study 
and HbA1c ............................................................................................................ 158 
Figure 8-15 - Effect of antibody status on C-peptide decline. ................................ 159 
Figure 9-1 – AdipoR expression on PBMC pre and post training in healthy people.
.............................................................................................................................. 181 
Figure 9-2 – The relationship between change in fitness and change in AdipoR 
expression on PBMC. ........................................................................................... 182 
 
 
Figure 9-3 - Typical results from flow cytometry for adiponectin receptor expression.
.............................................................................................................................. 183 
 Figure 9-4 - Adiponectin receptor expression on PBMCs before and after exercise 
training by flow-cytometry...................................................................................... 184 
Figure 9-5 – Distribution of AR2 receptors by PBMC subset. ................................ 186 
Figure 9-6 – CD4+ T cell proliferation to various stimuli. ....................................... 188 
Figure 9-7 Percentage inhibition of proliferation .................................................... 189 
Figure 9-8 – Phase contrast microscopy of HDMEC ............................................. 190 
Figure 9-9 - Endothelial transmigration under three conditions .............................. 191 
Figure 9-10 - Change in endothelial transmigration after training in one participant191 
Figure 9-11 – Serum Adiponectin in participants in the Extod trial. ........................ 193 
Figure 9-12 – Relationship between AdipoR dCT and age, BMI, fitness and 
glycaemic control. ................................................................................................. 194 
Figure 9-13 – Increase in AdipoR in patients with T1D after exercise training ....... 195 
Figure 9-14 – Relationship between change in AdipoR2 and age, change in fitness, 
weight and glycaemic control ................................................................................ 196 
Figure 9-15 - AdipoR expression determined by flow cytometry. ........................... 197 
Figure 9-16 – Inhibition of T cell proliferation with adiponectin was not affected by 
study arm. ............................................................................................................. 198 
Figure 9-17 – Comparison of endothelial transmigration of PBL in healthy subjects 
and T1D patients, before and after exercise training. ............................................ 199 
  
 
 
LIST OF ABBREVIATIONS 
ADA American Diabetes Association 
AdipoR Adiponectin receptor 
ANOVA Analysis of variance 
AUC Area under the curve 
BMI Body mass index 
bpm Beats per minute 
CD Cluster of differentiation 
cDNA Complementary deoxyribonucleic acid 
CFSE Carboxyfluorescein succinimidyl ester 
CI Confidence interval 
CRF Case report form 
DCCT The Diabetes Control & Complications Trial 
DKA Diabetic ketoacidosis 
dNTP Deoxyribonucleotide triphosphate 
EDTA Ethylenediaminetetraacetic acid 
FCS Fetal calf serum 
GAD Glutamic acid decarboxylase 
HbA1c Glycated haemoglobin 
HDL(-C) High density lipoprotein (cholesterol) 
H-DMEC Human Dermal Microvascular Endothelial Cells 
HOMA Homeostasis model assessment 
IA-2 Islet antigen-2 
INF-γ Interferon-γ 
IQR Interquartile range 
IR Insulin resistance 
MFI Mean fluorescence intensity 
MMTT Mixed meal tolerance test 
mRNA Messenger ribonucleic acid 
NK Natural killer 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PIC Patient Identification Centre 
PPD Purified protein derivative to mycobacterium TB 
RCT Randomised controlled trial 
RPE Rating of perceived exertion 
 
 
RPMI Roswell Park Memorial Institute 
SD Standard deviation 
SOP Standard operating procedure 
T1D Type 1 diabetes 
TNF-α Tumour necrosis factor-α 
UCPCR Urinary C-peptide:creatinine ratio 
UK United Kingdom 
VO2max Maximal oxygen uptake 
WHR Waist-hip ratio 
ZnT8 Zinc transporter 8 
   
1 
 
1 INTRODUCTION 
1.1 Type 1 Diabetes 
Type 1 diabetes (T1D) is a metabolic disorder which results from destruction of the 
pancreatic beta cells causing insulin deficiency and hyperglycaemia (American 
Diabetes Association 2013).  It is thought that autoimmunity to the beta cell is 
activated in a genetically susceptible individual after exposure to an unknown 
environmental trigger (Atkinson & Eisenbarth 2001). An affected individual requires 
life-long insulin treatment to control blood glucose and reduce the risk of 
complications. 
 
For the individual patient, insulin deficiency eventually will result in diabetic 
ketoacidosis (DKA).  Without insulin replacement, a diagnosis of T1D is inevitably 
fatal.  Hospital admission with DKA still occurs in approximately 3.3% of patients with 
T1D (Health and Social Care Information Centre 2012), despite modern insulins and 
regimes. In spite of considerable advances in its management, the life-expectancy of 
those diagnosed with T1D remains shortened by more than 20 years when compared 
to healthy individuals (Department of Health 2001).  The additional risk of mortality, 
above that of the general population is 135% in T1D in England and Wales (Health 
and Social Care Information Centre 2012). 
The excess mortality in T1D in the UK is now largely due to cardiovascular disease 
(Roper et al. 2002) rather than the acute metabolic derangement associated with 
insulin deficiency.  However, considerable morbidity and mortality result from the 
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microvascular complications; nephropathy, neuropathy and retinopathy.  A major 
goal of T1D management is a reduction in these long-term complications.  One way 
of reducing the risk of developing microvascular complications is intensive glycaemic 
control (The Diabetes Control and Complications Trial Research Group 1993; The 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications (EDIC) Research Group 2002); however, in clinical practice optimal 
glycaemic control is often difficult to achieve.  The general principles of treatment are 
diet and insulin therapy.  These are broadly the same treatments have been in use 
since 1922, when insulin was first used in humans; although there have been 
considerable developments since, in insulin preparations and regimes. 
 
1.2 Epidemiology of T1D 
In 2010, diabetes mellitus was estimated to affect 285 million people worldwide, the 
vast majority of these will have type 2 diabetes (Shaw et al. 2016).  In the UK, 
approximately 290,000 adults have a diagnosis of T1D and the total cost to health 
services and the economy in 2010/11 was £1.9 billion (Hex et al. 2012).  
T1D presents most commonly in children with incidence rising from birth and peaking 
between the ages of 10 and 14 years (Diabetes UK 2012).  Although the incidence of 
T1D declines with age, approximately one quarter of people with T1D are diagnosed 
in adulthood (Maahs et al. 2010).   
Large numbers of studies have observed that the prevalence of T1D is increasing 
(particularly among the young) (The DIAMOND Project Group 2006) and age at 
diagnosis is decreasing (Patterson et al. 2009).  Data collected by the EURODIAB 
3 
 
group, estimates that the prevalence in European children under the age of 15 years 
will increase by 70% by 2020 (compared to 2005 rates) (Patterson et al. 2009).   
Globally there is a great variability in the incidence of T1D.  The World Health 
Organisation reported rates of 0.1/100,000 per year in China and Venezuela, 
increasing to 40.9/100000 per year in Finland (The DIAMOND Project Group 2006).  
The discrepancy in incidence rates between countries is intriguing.  On the whole, 
rates are lower in less well developed countries.  This may in part be due to poor 
case ascertainment in countries without comprehensive healthcare systems and 
registries, as well as, high childhood mortality from other causes, infectious diseases 
for example.  The same group has documented a global increase in T1D incidence. 
It is not clear what is driving the increase in rates of T1D, although a number of 
theories have been postulated.  These include altered exposure to environmental 
triggers; early exposure to cow’s milk or enterovirus, or lack of exposure to protective 
infections; the “hygiene hypothesis” (Gale 2002).  In some areas of the world it may 
be an indication simply of improved case identification.  It is also possible that rising 
rates of obesity, as well as being implicated in increased rates and earlier onset of 
type 2 diabetes, are responsible for at least some of the rise in T1D incidence.   A 
Finnish study demonstrated that rapid childhood growth was associated with a 20-
40% increase in risk of T1D and obesity after the age of three years doubled the risk 
(Hyppönen et al. 2000).   
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1.3 Pathophysiology 
T1D is an autoimmune process whereby the immune system targets proteins found 
in the beta cells of the pancreas.  Beta cells are insulin producing cells which are 
located, along with other hormone-producing cells in the islets of Langerhans.  A 
lymphocytic infiltrate, predominantly composed of CD8+ T cells, is seen in the islets 
of patients with T1D.  This histological finding is known as insulitis (Hanafusa & 
Imagawa 2008).  
In normal physiology, insulin is produced in response to a rise in blood glucose.  
Insulin acts to reduce blood glucose through suppression of glucagon secretion and 
increasing glucose uptake and storage by tissues such as the liver.  These 
processes are impaired in T1D due to the lack of insulin, and therefore, blood 
glucose rises (Ozougwu et al. 2013).  
Beta-cell function in its simplest sense is the ability of pancreatic beta-cells to 
produce insulin in response to rising blood glucose and, therefore, maintain 
normoglycaemia.   Cleavage of the prohormone, proinsulin, results in the release of 
C-peptide alongside insulin and in equimolar amounts. The half-life of insulin in the 
circulation is short (around four to six minutes) and its significant first-pass hepatic 
metabolism means that insulin is a less than ideal measure (Palmer et al. 2004).  
Therefore, in the assessment of beta cell function, C-peptide is measured as a 
surrogate for insulin production.  
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1.4 The natural history of T1D 
T1D develops after the autoimmune destruction of pancreatic beta cells is triggered 
in a predisposed individual.  The clinical features of diabetes; thirst, polyuria, fatigue 
and weight loss; are as a result of sustained hyperglycaemia and develop only once 
considerable beta cell function has been lost.  It is estimated that at diagnosis, an 
individual with T1D has around 25-50% of their beta cell function remaining (Sherry 
et al. 2005). 
With the initiation of insulin therapy and improvement in blood glucose levels, there 
may be a transient improvement of beta-cell function which results in a period of 
partial remission of T1D, known as the ‘honeymoon’.  During this period, insulin 
requirements are considerably reduced and it is sometimes possible to stop insulin 
treatment altogether (Abdul-Rasoul et al. 2006).  The ongoing autoimmune process 
results in further loss of pancreatic beta cells, eventually resulting in an absolute 
insulin deficient state.  This process takes a variable length of time, with some 
patients still having low level but detectable insulin secretion many years after the 
diagnosis of T1D (Keenan et al. 2010; Scholin et al. 2004).   
Significant beta-cell function is seen in the majority of patients with a shorter duration 
of disease, one study puts the proportion of patients with C-peptide greater than 
200pmol/l two years after diagnosis, at around two thirds (Greenbaum et al. 2012). 
While it is possible to identify some individuals at high risk of developing T1D, 
through family history and autoantibodies, the majority of people who are diagnosed 
do not have a relative with T1D.  Therefore, an ideal time to study factors potentially 
affecting beta cell function is soon after diagnosis.  The ultimate goal is to find a beta-
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cell preserving therapy that could one day be used to prevent T1D in susceptible 
individuals. 
Residual insulin secretion at diagnosis and persistence of beta cell function are 
recognised to be beneficial to people with T1D.  Analysis of data from the Diabetes 
Control and Complications Trial (DCCT) demonstrated that a cut off level of C-
peptide of 200pmol/l conferred glycaemic benefit in fasting glucose and HbA1c 
(Palmer et al. 2004).  Higher initial C-peptide levels and persistence of detectable C-
peptide is also associated with a reduction in the complications of diabetes; 
retinopathy, nephropathy and hypoglycaemia (Lachin et al. 2013; Steffes et al. 2003).  
This is, therefore, a therapeutic goal endorsed by the Medicines and Healthcare 
products Regulatory Authority and United States Food and Drug Administration.  
There are hopes that therapies such as monoclonal antibodies to CD3 and CD20, will 
preserve beta cell function in early T1D but these have not demonstrated lasting 
benefit and are not yet in clinical use (Skyler 2015; Ludvigsson 2009; Phillips et al. 
2011).  The utility of these therapies may be limited by their side effects; mainly, 
immunosuppression leading to secondary malignancies and infection, and an 
immunomodulatory therapy with long-lasting effects has yet to be discovered (Ben 
Nasr et al. 2015). 
 
1.4.1 Immunity in T1D  
A diagnosis of T1D is made clinically (National Institute for Clinical Excellence 2015), 
and is based on the clinical presentation of an individual.  It can be difficult however, 
to differentiate between different types of diabetes, particularly in patients who 
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present in adulthood, and studies suggest that around 7% of patients diagnosed with 
type 2 diabetes have evidence of immune driven beta-cell loss (Seissler et al. 1998) 
and the proportion is higher in younger age groups (Turner et al. 1997).   
 
1.4.1.1 Cellular immunity in T1D 
In the Eisenbarth model (Atkinson et al. 2015) of the autoimmune pathogenesis of 
T1D, auto-antigens from damaged beta cells are processed by antigen presenting 
cells (APCs).  Dendritic cells, B lymphocytes and macrophages may act as APCs.  
Auto-reactive CD4+ (helper) and CD8+ (cytotoxic) T cells occur due to failures in 
thymic and peripheral tolerance, and are stimulated by activated APCs in the 
pancreatic lymph nodes and the autoimmune process is triggered.  Autoreactive T 
cells then migrate to the pancreatic islets where cytotoxic cells destroy cells through 
Fas-Fas ligand triggered apoptosis or perforin dependent mechanisms (Moriwaki et 
al. 1999). CD4+ and CD8+ cells produce cytokines, for example, INF-γ which induces 
Fas expression on beta cells and promotes inflammation through mononuclear cell 
recruitment, macrophage activation and production of TNF and IL-1β, thus mediating 
apoptosis (Lehuen et al. 2010).  This model is consistent with post mortem studies of 
the pancreatic tissue of patients with T1D, where an immune cell infiltrate consisting 
of CD3+ T lymphocytes (predominantly CD8+ T cells), dendritic cells and 
macrophages has been found (Hanafusa & Imagawa 2008; Bottazzo et al. 1985) 
along with a reduction of beta cell numbers. 
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Evidence for the role of autoimmunity and, more specifically, T lymphocytes in the 
development of T1D comes from a number of other observations. 
Relapse of T1D in recipients of pancreatic transplants, is associated with a 
mononuclear cell infiltrate in biopsies of the transplanted pancreases and 
ameliorated by immunosuppression (Sibley et al. 1985).  Circulating autoreactive T 
lymphocytes to glutamic acid decarboxylase (a pancreatic protein) have been 
identified in patients with T1D and their first degree relatives (Honeyman et al. 1993).  
In the NOD mouse, T1D may be transferred by CD4+ and CD8+ T cells, but only in 
combination (Phillips et al. 2009), indicating a role for both subsets in T1D 
pathogenesis.   Finally, anti-CD3 monoclonal antibody therapy (targeting T 
lymphocytes) can suppress beta cell destruction in patients with T1D (Skyler 2013).   
 
1.4.1.2 Autoantibodies in T1D 
Autoantibodies that may be identified in the serum of patients with T1D are targeted 
towards beta cell proteins such as glutamic acid decarboxylase (GADA), tyrosine 
phosphate-like antigen IA-2 (IA-2A) and the zinc transporter ZnT8 (ZnT8A) (Bonifacio 
& Bingley 1997; Wenzlau et al. 2007).  The same autoantibodies may also be 
identified in individuals at risk of developing T1D, such as the relatives of people with 
T1D, where the number and titre relate to the risk of progression to T1D (Bingley et 
al. 1994; Achenbach et al. 2004).  There has been considerable work examining 
relatives of patients with T1D to identify people at high risk of progression, however, 
the majority of people have no family history of T1D at presentation (Achenbach et al. 
2005). 
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In adult patients with recently diagnosed T1D antibody positivity has been reported at 
over 80% (Williams et al. 2012; Vermeulen et al. 2011). 
 
1.4.2 Decline in beta-cell function after diagnosis of T1D 
At diagnosis, individuals affected by T1D are estimated to have approximately 25-
50% of their beta cell function remaining (Sherry et al. 2005).  C-peptide levels fall 
(before and) after diagnosis, however C-peptide decline is not thought to be linear.  
The decline in beta-cell function after diagnosis is variable; a biphasic pattern to beta-
cell function loss has been described, with slower decline in the second year after 
diagnosis (Greenbaum et al. 2012).  The overwhelming majority of patients with a 
short duration of T1D will have significant C-peptide levels (i.e  greater than 
200pmol/l, the level at which clinical benefit in terms of microvascular disease and 
retinopathy has been demonstrated); 66% at 24months (Greenbaum et al. 2012) and 
92% of patients with a diabetes duration of under 5 years (The Diabetes Control and 
Complications Trial Research Group 1987).   
 
1.4.3 Factors affecting C-peptide levels in T1D 
A number of factors are associated with the rate of beta cell loss.  In patients with 
T1D, the presence of islet autoantibodies is associated with a higher rate of beta cell 
loss after diagnosis (Sherry et al. 2005).  Another important factor is glycaemic 
control, with higher levels of glycaemia associated with accelerated loss of beta cell 
reserve.  Although this phenomenon was first described in the DCCT (The Diabetes 
Control and Complications Research Group 1998), it has been demonstrated in later 
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studies as well (Dost et al. 2007; Greenbaum et al. 2009), an indication perhaps that 
the general tightening of glycaemic control since the DCCT was reported has not 
eliminated this effect.   
 
The literature on factors affecting beta cell function is rather conflicting and 
heterogeneous.  The majority of the data is from observational studies in children as 
well as data from the DCCT and the control arms of various intervention studies 
(predominantly these studies include a majority of children and young adults).  Little 
is known about the factors affecting beta-cell function in patients diagnosed with T1D 
as adults. 
Some studies attempt to determine the effect of various factors on beta-cell function, 
both at diagnosis and over varying lengths of time (measured by C-peptide release to 
various stimuli), while others have concentrated on the presence and duration of 
(partial) remission of diabetes.  The definition of partial remission varies in these 
studies, however, it is usually defined as well controlled diabetes and low insulin 
requirements (less than 0.3 units/kg (Bonfanti et al. 1998) to less than 0.5units/kg 
(Dost et al. 2007; Bowden et al. 2008)).  Well controlled diabetes may be defined as 
an HbA1c less than 7% (42mmol/mol) (Dost et al. 2007), 8% (64mmol/mol) (Bowden 
et al. 2008) or in normal range (Bonfanti et al. 1998).  Although the two concepts are 
not interchangeable (remission is binary and beta-cell function is a continuous 
variable), the presence of partial remission is associated with higher basal and 
stimulated C-peptide levels (Bonfanti et al. 1998; Lombardo et al. 2002). 
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The following have all been reported to affect either baseline C-peptide, rate of 
decline of c-peptide or presence and duration of honeymoon in T1D: 
- Gender  
- Age 
- Number and titre of autoantibodies. 
- Duration of symptoms prior to diagnosis 
- Presentation of diabetes (i.e. either in DKA, or hyperglycaemic but not 
acidotic).  
- Blood glucose at presentation 
- Smoking status 
- HbA1c, and 
- Length of time from diagnosis 
 
1.4.3.1 Gender and Age 
Clinical remission rates and duration may be influenced by gender.  Several studies 
have demonstrated that males are more likely to experience a remission period 
(Bober et al. 2001) and experience a longer duration of clinical remission (Dost et al. 
2007; Pilacinski et al. 2012). Studies which looked at C-peptide rather than 
remission, however, reported that male gender was associated with lower baseline 
C-peptide levels in children (Sochett et al. 1987) and adults (Karjalainen et al. 1989).   
Older age at diagnosis confers an advantage in greater rates (Bonfanti et al. 1998; 
Lombardo et al. 2002; Bowden et al. 2008) and duration (Dost et al. 2007) of 
remission, as well as baseline C-peptide level (Karjalainen et al. 1989) and 
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persistence of C-peptide (Sochett et al. 1987; Greenbaum et al. 2009).  There is 
some discrepancy here too, however.  One group (Pilacinski et al. 2012) found no 
relationship with rates/length of partial remission in adult patients and others (Torn et 
al. 2000; Steele et al. 2004)  found that age is not related to decline in beta cell 
function. 
In the DCCT, participants who had diabetes for under five years at study entry were 
more likely have a stimulated C-peptide >200pmol/l (known as a ‘responder’) if they 
were female (The Diabetes Control and Complications Research Group 1998).  In 
addition, participants under the age of 18 were less likely to be a ‘responder’ at study 
entry and less likely to have maintained that status after 5 years. 
 
1.4.3.2 Autoantibodies 
Presence of GAD antibodies has been associated with lower C-peptide six months 
post-diagnosis and decreased rates of clinical remission in children and adolescents 
(Bonfanti et al. 1998) but not in adults (Steele et al. 2004; Pilacinski et al. 2012).  
There are conflicting results reported with respect to islet cell antibody status/IA-2A, 
with some groups reporting no effect on C-peptide (Karjalainen et al. 1989; Torn et 
al. 2000) and others finding an increased insulin secretory response in participants 
with positive islet cell antibodies (Steele et al. 2004).  In general, antibody negative 
patients have higher levels of C-peptide than those with detectable antibodies (Torn 
et al. 2000). 
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1.4.3.3 Presentation of diabetes and duration of symptoms 
It has been suggested that the presentation of diabetes (i.e. with or without acidosis) 
and the length of time that the patient has noticed osmotic symptoms prior to 
diagnosis is associated with clinical remission of diabetes and persistence of C-
peptide. The studies showing this are all of children only.   One study (Abdul-Rasoul 
et al. 2006) showed that lower blood glucose (suggesting earlier presentation to a 
clinician) and higher pH at diagnosis were associated with a greater chance of 
remission.  In addition, longer duration of symptoms prior to diagnosis was 
associated with a longer duration of remission (Abdul-Rasoul et al. 2006). In adults, 
patients not presenting with diabetic ketoacidosis or ketonuria were more likely to 
have a longer remission period than those who did (Pilacinski et al. 2012).  Similarly, 
lower blood glucose at presentation was associated with higher C-peptide at 
diagnosis (Sochett et al. 1987) and lower pH at diagnosis with a lower C-peptide 
three months after diagnosis (Bonfanti et al. 1998) i.e. a faster progression of beta 
cell decline was seen in those with a greater degree of acidosis at presentation. 
 
1.4.3.4 Cigarette Smoking 
The only study to look at factors influencing clinical remission in adults focussed on 
smoking.  The authors (Pilacinski et al. 2012) reported that non-smokers experienced 
an increased chance of being in remission one year after diagnosis than smokers. 
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1.4.3.5 Glycaemic control/HbA1c 
Lower HbA1c has been demonstrated to be associated with longer duration of 
remission in children (Dost et al. 2007), with higher initial C-peptide levels (The 
Diabetes Control and Complications Research Group 1998) and with preservation of 
beta cell function (Greenbaum et al. 2009). 
 
1.4.3.6  Length of time from diagnosis 
Shorter duration of diabetes was associated with higher C-peptide levels in the 
DCCT (The Diabetes Control and Complications Research Group 1998).  
Greenbaum et al. 2012 describe a biphasic decline in C-peptide, with a slower rate of 
fall in the second year after diagnosis than the first. 
 
1.5 Insulin resistance 
Hyperglycaemia in T1D is primarily due to insulin deficiency; however, resistance of 
peripheral tissues to insulin action may also cause elevated circulating blood 
glucose.  Insulin resistance is commonly associated with obesity, where diminished 
insulin signalling in adipose tissue, skeletal muscle and liver results in impaired 
glucose metabolism (Kahn & Flier 2000).  Levels of obesity are rising both in the UK 
and worldwide (Health and Social Care Information Centre 2015) and reflect the 
rising incidence of conditions associated with insulin resistance such as metabolic 
syndrome, impaired glucose tolerance and type 2 diabetes (Ozougwu et al. 2013).  
Could the rise in obesity and insulin resistance be contributing to the increase seen in 
rates of T1D? 
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This is the premise underpinning the ‘Accelerator’ hypothesis; which argues that both 
type 1 and type 2 diabetes result from a combination of insulin resistance, beta cell 
apoptosis and beta cell autoimmunity (Wilkin 2001). The proportions of each of these 
three factors variably combine to give the different clinical pictures currently known as 
type 1 or type 2 diabetes.  The observation that there is considerable overlap 
between the two forms of the disease in terms of age of onset (Mølbak et al. 1994; 
Rosenbloom et al. 1999), presence of ketoacidosis (Aizawa et al. 1997), antibody 
status (Turner et al. 1997) and eventual beta-cell failure, adds weight to this theory.   
 
Insulin resistance has been implicated in the development and progression of T1D in 
a number of studies.  The importance of insulin resistance in T1D gained recognition 
in the early 1980’s.  Insulin resistant individuals with T1D were found to be less likely 
to experience clinical remission or “honeymoon” (Yki-Jarvinen & Koivisto 1986).  
Subsequently, prospective controlled studies have gone on to demonstrate that in an 
at-risk population, (relatives of patients with T1D with islet autoantibodies), 
progression to diabetes is associated with greater insulin resistance (Fourlanos et al. 
2004; Bingley et al. 2008; Xu et al. 2007).   
The gold standard for measuring insulin resistance is the euglycaemic 
hyperinsulinaemic clamp (DeFronzo et al. 1979).  This is a complex and time 
consuming test, and often surrogate markers of insulin resistance are used, such as 
waist-to-hip ratio or BMI.  The homeostasis model assessment (HOMA) is a 
mathematical model that quantifies insulin resistance using fasting insulin and 
glucose.  First described in 1985, it correlates well with the euglycaemic clamp 
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(Matthews et al. 1985) and has since been updated to a more sophisticated 
computer model (Wallace et al. 2004). 
Therapies targeting insulin resistance have been used in the treatment and 
prevention of type 2 diabetes for many years (UK Prospective Diabetes Study 
(UKPDS) Group 1998; Diabetes Prevention Program Research Group 2002).  In 
addition, the benefits of lifestyle measures aimed at improving insulin sensitivity such 
as weight loss and physical activity are well documented in this patient group 
(Krotkiewski et al. 1985; Umpierre et al. 2011; Andrews et al. 2011; Chimen et al. 
2012).  Exercise training can also reduce insulin resistance.  Exercise training is also 
associated with improved insulin sensitivity in normal weight (King et al. 1987) and 
obese subjects (DeFronzo et al. 1987), as well as those with T1D (Yki-Jarvinen et al. 
1984).  Furthermore, as insulin resistance is also implicated in the development of 
T1D, it is interesting to consider that these therapeutic interventions may also 
influence the progression of this disease. 
 
1.6 The effects of exercise 
Physical inactivity is a leading risk factor for disease globally, accounting for more 
than 3 million deaths worldwide in 2010 (Lim et al. 2012). Regular physical activity 
can reduce the risk of developing cardiovascular disease, type 2 diabetes, cancer, 
obesity, mental health disorders and musculoskeletal problems (Chief Medical 
Officers of England 2011). 
In patients with type 2 diabetes, exercise training improves glycaemic control, 
reduces fat mass and visceral adiposity and improves lipid profile (Thomas et al. 
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2006) and in those with T1D the proven benefits of exercise include weight reduction, 
reduced insulin requirements and improvements in lipid profile and blood pressure 
(Chimen et al. 2012).  Exercise does improve glycaemic control in patients with type 
2 diabetes (Umpierre et al. 2011). The same is not true of patients with T1D, 
however, with no evidence of exercise training having an effect on glycaemic control 
(Kennedy et al. 2013) 
 
In view of the undoubted health benefits of regular physical activity, the Chief Medical 
Officer has produced guidelines for physical activity for adults in the UK (Chief 
Medical Officers of England 2011), these are given below.  Similar recommendations 
are given by the Association of British Clinical Diabetologists and the American 
Diabetes Association for people with diabetes (Nagi & Gallen 2010; American 
Diabetes Association 2010).   
 
Chief Medical Officer’s recommendations for adults aged 19-64: 
1. Daily activity with at least 150 minutes of moderate intensity physical activity 
per week, made up of bouts of at least ten minutes (eg 30 mins on at least five 
days a week). 
2. Or, 75 mins vigorous intensity activity spread across the week or an equivalent 
combination of moderate and vigorous intensity activity. 
3. Activity to improve muscle strength on at least two days a week. 
4. Minimise sedentary time. 
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Exercise has been shown to improve beta-cell function in animal studies.  These 
suggest a beneficial effect of exercise training on both beta-cell mass and function in 
90% pancreatectomised and streptozotocin-induced diabetic rats (Choi et al. 2005; 
Choi et al. 2006; Coskun et al. 2004; Park et al. 2007).  Exercise also appears to 
increase the insulin content and secretion of the pancreatic islets in streptozotocin-
induced diabetic rats (Huang et al. 2011).  In humans, exercise is associated with 
preservation of beta-cell function in healthy people (Boulé et al. 2004),  people with 
impaired glucose tolerance and patients with type 2 diabetes (Dela et al. 2004; 
Bloem & Chang 2008)(reviewed in Narendran et al. 2015).  There is no published 
evidence of the effect of physical activity on beta-cell function in T1D in humans.  
It is not clear whether there are specific activities that have a greater effect on beta-
cell preservation; studies demonstrating improvements in humans have included both 
cardiovascular (cycle ergometer (Boulé et al. 2004)(Dela et al. 2004) and treadmill 
walking (Bloem & Chang 2008)), and resistance exercises (isometric muscle 
strengthening (Grøntved et al. 2013)). 
Moreover, there is some evidence that higher levels of physical activity are 
associated with benefits in prevalence of microvascular complications in T1D.  Higher 
levels of self-reported physical activity in the past are associated with lower rates of 
nephropathy, neuropathy and retinopathy in humans (Kriska et al. 1991; Wadén et al. 
2008).  In contrast, a post hoc analysis of data from the DCCT trial did not find any 
association between baseline leisure time physical activity and rate of subsequent 
development of retinopathy (Makura et al. 2013), perhaps supporting the suggestion 
that microvascular complications impair an individual’s ability to exercise rather than 
a direct effect of exercise on complication rates. 
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1.7 Activity levels and barriers 
Despite the recommendations of the Chief Medical Officer and clear evidence of 
benefit, many people fail to achieve suggested minimum levels of physical activity. 
Self-reported physical activity data from 2012, demonstrated that only 67% of men 
and 55% of women achieved this minimum level of activity, with higher proportions in 
younger age groups and reducing with increasing age (Health and Social Care 
Information Centre 2015).  Objective measures of physical activity, such as data from 
accelerometer studies, demonstrate a much more sedentary population.  In 2008, the 
Health Survey for England included both self-reported measures of physical activity 
and accelerometer data and while 39% of men and 29% of women reported 
undertaking at least 150 mins of exercise each week, accelerometer data (in a sub-
group) showed only 6% of men and 4% of women met this target (Aresu et al. 2008).  
Activity levels tend to be over-estimated by self-reported measures compared to 
objective measures such as accelerometry, due to recall and social desirability 
biases (Aresu et al. 2008). 
 
Estimates of physical activity vary for patients with T1D.  In a Canadian population 
only 36.3% of patients met relevant physical activity guidelines (more than or equal to 
600 MET.min.wk-1) (Plotnikoff et al. 2006). A similar proportion (30/77 participants, 
39%) were classed as ‘active’ in a Scottish study (Thomas et al. 2004), this included 
everyone who reported taking part in exercise or sport in the previous two weeks and 
may therefore represent an overestimate when compared to other studies.  Studies 
in other populations have demonstrated a more active group.  A Finnish study 
reported that only 23% of patients with T1D were sedentary (Wadén et al. 2008), and 
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in the Diabetes Control and Complications Trial only 19% did not meet the ADA 
guidelines (Makura et al. 2013). In a large European T1D population, 36% of 
participants played sports less than once a week (Tielemans et al. 2013).  All of 
these studies relied on self-reported activity levels and, as above, may well be over-
estimates of actual activity. 
 
The Health Survey for England, a large scale annual survey, surveyed attitudes and 
barriers to exercise in 2007 (Chaudhury et al. 2008).  In this survey of over 6,800 
adults, the most often cited reasons for not meeting physical activity guidelines were 
work commitments and lack of leisure time for men and women respectively.  Other 
barriers identified in this report included lack of money, caring for children or older 
people, lack of local facilities, having no-one to exercise with, and not having the right 
clothes or equipment.  More than two thirds of adults stated that they wanted to 
increase their physical activity levels.   
People with chronic disease conceivably may have additional barriers to exercise 
related to the physical and psychological impact of their diagnosis.  When specific 
patient groups are studied, three classes of barriers are identified;  
 General barriers, which are similar to those seen in the general population 
in the Health Survey for England (particularly lack of time). 
 Barriers that may be common to any patient with chronic disease, such as 
depression and fatigue (Courneya et al. 2005; Korkiakangas et al. 2009).  
 Barriers specific to that patient group, such as fear of hypoglycaemia for 
patients with type 2 diabetes (Korkiakangas et al. 2009).   
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Table 1-1 below summarises the barriers reported for the general population, 
patients with type 2 diabetes, chronic pain, stroke and those who have survived 
colorectal cancer. 
General barriers Work commitments 
Lack of leisure time 
Lack of money 
Caring for children and older people 
Lack of local facilities 
Having no-one to exercise with 
Not having the right clothes or equipment 
(Courneya et al. 2005; 
Chaudhury et al. 2008; 
Rimmer et al. 2008; 
Korkiakangas et al. 2009; 
Slade et al. 2014) 
Barriers related to 
chronic disease 
Fatigue 
Depression 
Co-morbidity 
Physician recommendation 
(Courneya et al. 2005; 
Korkiakangas et al. 2009) 
Disease specific barriers   
Type 2 diabetes Being too overweight 
Unwilling to exercise with people who 
don’t have diabetes 
Fear of hypoglycaemia 
Lack of physician advice 
Lack of personal knowledge 
(Korkiakangas et al. 2009) 
Chronic pain Diagnostic uncertainty 
Fear of movement/pain aggravation 
(Slade et al. 2014) 
Survivors of 
colorectal cancer 
Non specific treatment side effects 
Surgical complications 
Diarrhoea 
Nausea 
Mouth sores 
Blood clot 
(Courneya et al. 2005) 
Stroke Exercise won’t improve my condition 
Don’t feel trainer in facility is able to help 
Not comfortable exercising in facility 
(Rimmer et al. 2008) 
Table 1-1 Summary of barriers to exercise identified in the general population and 
other disease groups 
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It is important to examine barriers to exercise in specific populations; as is shown in 
Table 1-1, patients with one disease may have different barriers to those with 
another.  Even amongst patients with diabetes there may be different barriers; being 
overweight has been associated with increased barriers to activity in adolescents 
(Deforche et al. 2006) and while many patients with type 2 diabetes are overweight, 
this is not true of patients with T1D. 
Little is known about the attitudes and barriers to exercise in T1D.  Two studies of 
patients with T1D in Canada (Dube et al. 2006; Brazeau et al. 2008) identified fear of 
hypoglycaemia as the strongest barrier to regular exercise in T1D.  Questionnaire 
studies, such as these Canadian studies, may identify important barriers to increased 
physical activity but provide little explanation and cannot identify strategies to 
overcome them.  A qualitative interview study performed in the UK, by our group, 
suggests that although fear of hypoglycaemia is a factor when patients with T1D 
consider exercise, external factors , such as lack of time, work pressures and bad 
weather were greater barriers to physical activity (Lascar et al. 2014).  This finding is 
in common with the studies described above in patients with type 2 diabetes and 
other chronic diseases where general barriers to exercise were more frequently cited 
than disease specific ones.  No studies have looked at patients with newly diagnosed 
T1D. 
 
1.8 Potential mechanisms involved in beta-cell preservation in T1D 
The effects of exercise on the endocrine system include an increase in levels of 
growth hormone and glucagon-like peptide 1.  These, in conjunction with a rise in 
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certain interleukins (for example IL-1 and IL-6) are thought to improve beta cell mass 
(Narendran et al. 2015). 
Exercise is recognised to have an anti-inflammatory effect as well as effects on the 
immune system (Gleeson 2007) and, therefore, may slow the loss of beta cells.  
Exercise alters levels of adipokines, cytokines secreted by adipose tissue, in 
particular, it induces an increase in adiponectin concentrations (Ben Ounis et al. 
2009).  The anti-inflammatory and glucose lowering effects of adiponectin have been 
well described (Mantzoros et al. 2005; Yamauchi et al. 2002; Berg et al. 2001) and 
both are mechanisms by which beta-cell function may be preserved in T1D.   
We have chosen to examine the effect of exercise on adiponectin receptor 
expression and T cell immunity in T1D as part of this study.  Previously our group 
(Pang 2010) has demonstrated that adiponectin influences T cell proliferation in 
health but not in T1D and that adiponectin is involved in suppression of T cell 
migration across endothelial cells (Chimen et al. 2015).  The final part of this study 
aims to investigate whether exercise up-regulates adiponectin receptor expression, 
whether this occurs in T1D, and whether this translates into changes in T cell 
proliferation and endothelial transmigration. 
 
This study is a multi-centre randomised clinical trial designed to investigate effect of a 
year long exercise programme on beta cell function and autoimmunity in patients 
newly diagnosed with T1D.  
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2 HYPOTHESIS AND AIMS 
My hypothesis is that exercise preserves beta cell function in adult patients with 
newly diagnosed T1D.   
My aim is to collect the data required to design and undertake a formal trial to 
determine whether exercise preserves beta cell function in adult patients with newly 
diagnosed T1D 
My specific objectives are: 
1. To evaluate the barriers to exercise in patients with newly diagnosed T1D. 
2. To determine whether patients newly diagnosed with T1D can be 
encouraged to take up and adhere to a programme of at least moderate 
intensity exercise for a period of one year, and monitor the change in 
exercise behaviour in the non-intervention arm.  
3. To determine whether adherence to this programme of exercise preserves beta 
cell function. 
4. To investigate the effect of exercise on immunity in patients newly diagnosed 
with T1D. 
 
I will achieve these objectives through the EXTOD study which is outlined below.  
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3 EXTOD (EXERCISE IN TYPE ONE DIABETES) STUDY DESIGN AND 
PRIMARY OUTCOMES 
 
3.1 Introduction  
The Extod (Exercise in type 1 diabetes) study was a mixed methodology pilot study 
to investigate recruitment, retention and adherence to an intervention aimed at 
increasing physical activity in adult patients newly diagnosed with T1D.  It is intended 
that the results of this trial will go on to inform a larger study, adequately powered to 
assess the effect of exercise on beta cell function in adult patients with T1D.   
This chapter describes the design of the Extod study and discusses the primary 
outcomes of recruitment and retention to an exercise intervention study in T1D. 
 
3.2 Methods 
 
3.2.1 Study overview 
The study was designed in two parts.  Firstly, a qualitative study (Phase 1); to 
investigate attitudes to exercise, current exercise behaviours and thoughts on trial 
design with participants potentially eligible for an exercise trial.  Subsequently, a 
randomised controlled trial (Phase 2) with an intervention aimed at increasing 
exercise levels in a group of participants newly diagnosed with T1D. 
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3.2.1.1 Phase 1 
Phase 1 was designed as a qualitative study to evaluate the attitudes and barriers to 
exercise in adult patients with newly diagnosed T1D, as well as to discuss trial design 
and conduct with potential and actual trial participants.  This part of the study is 
discussed in detail in Chapter 5. 
 
3.2.1.2 Phase 2 
Phase 2 was designed as a multicentre randomised controlled trial.  Participants 
were randomised in a 1:1 ratio to either an intervention aimed at increasing physical 
activity or usual care.  The primary outcomes were to assess recruitment and drop-
out rates as well as uptake and adherence to additional exercise in both the 
intervention and control groups.  The secondary outcome was to evaluate the effect 
of increased exercise on beta cell function in adults recently diagnosed with T1D. 
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Figure 3-1 - Schematic overview of trial 
 
3.2.2 Phase 2 design 
Participants were randomised into an intervention group and a control group in a 1:1 
ratio.  Randomisation was minimised on the basis of site (“West Midlands” and 
“Other”), fitness and 90 minute stimulated C-peptide.  Randomisation occurred at visit 
4 after baseline and screening data had been gathered. 
 
3.2.2.1 Intervention  
The intervention consisted of additional support aimed at increasing exercise levels 
through the use of motivational interviewing techniques, additional contact with the 
study team to review exercise diaries and goals, and additional support and 
Visits 1-3 
Screening 
Visit 4 
Randomisation 
Visits 5-10 
Visit 11/12 
outcome 
measures 
Diagnosis 
of T1D 
Visits 13-15 
Visit 16/17 
outcome 
measures 
Start 
Consent 
No later than 3 
months after insulin 
initiation 
6 months after 
randomisation 
12 months after 
randomisation 
28 
 
information with regards to the management of blood glucose and insulin around 
exercise.  Motivational interviewing is a method of encouraging participants to set 
their own goals with the aim of increasing their physical activity levels (Miller 1996).  
Motivational interviewing has been demonstrated to be effective at changing 
behaviour in many areas of lifestyle including exercise participation (Hettema et al. 
2005). 
Exercise interventions in clinical trials are often supervised.  This allows trial 
personnel to observe and record the amount of exercise undertaken by each 
participant and to control/increase the intensity of work during the study in a 
controlled manner.  It is however, labour intensive for study personnel, less 
amenable to multi-site studies and may restrict participants to certain hours to 
undertake their exercise programme.  In addition, results obtained in this way may 
not be achievable outside of a clinical trial setting, where individuals must motivate 
themselves to exercise. 
The aim was to use an intervention that could be replicated in clinical practice, setting 
negotiated and realistic targets. Participants were asked to self-monitor their physical 
activity levels by recording exercise in a diary and encouraged to discuss the diary 
with the research nurse at each visit.  The exercise diary also recorded exercise 
intensity which was measured by the use of a wrist worn heart rate monitor (Polar 
Electro UK) provided by the study.  A small number of these monitors had the facility 
to record this information and be downloaded to allow later correlation with the 
exercise diaries.  Using the heart rate monitors, participants were asked to increase 
their exercise intensity to a target of 75% estimated maximal oxygen uptake. 
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All members of the study team involved in delivering the intervention attended a two-
day motivational interviewing techniques course (provided by Dr Melvin Hillson, 
Exeter University) and were given the opportunity to attend face-to-face training on 
the management of T1D around exercise as well as provided with a written guidance 
document on this (both developed by the study team). 
Participants were encouraged to increase their exercise duration and intensity over 
twelve weeks according to a graded program (Appendix C ).  Any activity could be 
undertaken and all activities took place outside of the hospital setting.  The aim of the 
intervention was to increase and maintain physical activity to at least 150 minutes per 
week, aiming for 240 minutes per week of vigorous intensity exercise.  Those 
participants who did not reach the goal of 150 minutes exercise per week were 
offered additional support, for example, assistance with gym membership, supervised 
exercise classes (through exercise on prescription) or advice from a personal trainer. 
 
3.2.2.2 Usual care 
The visit schedule for participants in the usual care arm was arranged to mimic 
normal diabetes care.  Additional visits were necessary to perform the assessments 
of beta cell reserve (through a mixed meal test) and fitness.  This group did not, 
however, attend the additional visits aimed at increasing activity and did not receive 
information about insulin and carbohydrate management and exercise routinely 
(unless this discussion was initiated by the participant).  The printed information 
booklet was only offered to participants randomised to the intervention arm. 
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3.2.2.3 Trial Procedures  
3.2.2.3.1 Dietary advice   
All participants received standardised dietary advice at visit 4, prior to randomisation.  
The study dietitian assessed the patients’ current level of understanding against a 
standardised list of competencies agreed by the trial team. A list of the competencies 
is given in Appendix D .  Further sessions were scheduled with the dietitian if 
required. 
Following randomisation, the intervention group were given further information 
specifically relating to carbohydrate intake and insulin dose adjustment around 
exercise.  A copy of the written advice given to participants can be found in Appendix 
E . 
 
3.2.2.3.2 Glycaemic control and insulin regime 
Intensive glycaemic control has been demonstrated to protect patients with T1D from 
microvascular complications (The Diabetes Control and Complications Trial 
Research Group 1993).  In addition, glycaemic control seems to influence beta cell 
decline (Dost et al. 2007; Greenbaum et al. 2009).  Therefore, during the study we 
aimed to maintain optimal glycaemic control within both study groups (target HbA1c 
<48mmol/mol where appropriate (as per National Institute of Clinical Excellence 
Clinical Guidance 15 (National Institute for Clinical Excellence 2004)).  All diabetes 
management was undertaken by the study team to ensure that treatment was 
standardised across all sites. 
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All participants had to agree to treatment using a multiple daily injection (MDI) insulin 
regime or continuous subcutaneous insulin infusion.  This was to facilitate both the 
achievement of optimal glycaemic control and insulin dose adjustment during 
exercise for those randomised to the intervention group.  Those participants not 
already taking MDI insulin had their insulin regime changed during the screening 
phase (i.e. prior to randomisation) and maintained on this throughout the study. 
Participants both groups were asked to self-monitor their blood glucose using their 
own glucometer.  This information was recorded in diaries and collected by the study 
team at each visit.  The blood glucose diary was reviewed by the research nurse at 
each visit and advice given on insulin dose adjustment to maintain glycaemic control. 
 
3.2.2.4 Outcomes 
3.2.2.4.1 Primary outcomes 
The primary outcomes for this study were: 
1) the proportion of patients with T1D who started the intervention. 
 
Data were collected at each site regarding numbers of patients diagnosed with 
T1D, those approached with information about the study and the reasons for 
not entering the study (if given). 
 
2) the proportion of participants in the intervention arm who adhered to the 
required intensity of exercise. 
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This was discussed at each visit with the participants in the intervention group.  
It was assessed by means of exercise diaries, heart rate monitoring (including 
a number which recorded data and were downloaded), accelerometer data, as 
well as, fitness testing at baseline, six months and twelve months.  
 
3) the proportion that dropped out. 
 
Participants who withdrew or were lost to follow-up were recorded and the 
reason for withdrawal (if given). 
 
4) the rate of exercise uptake in the non-intervention arm 
 
Participants in the control group were asked to wear an accelerometer for one 
week every three months during the study.  During this week, they also 
completed a diary, to capture all activities, including swimming, which cannot 
be recorded on an accelerometer (which is not waterproof).  In addition, a 
fitness test was performed at baseline and after six and twelve months so that 
VO2max could be estimated. 
 
3.2.2.4.2 Secondary outcome 
The secondary outcome for the study was to investigate the rate of loss of beta cell 
function. 
This was assessed by mixed meal test at baseline, after six months and twelve 
months.  The mixed meal test is the recommended test to assess beta cell function in 
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T1D trials (Greenbaum and Harrison 2003).  The protocol for this test was based on 
that used by the UK islet transplant service (personal communication from S 
Eckholdt, 2011). 
3.2.3 Data collection 
3.2.3.1 Recruitment data 
All sites (Participant Identification Centres (PICs) and full treatment sites) kept and 
returned an anonymised log of patients diagnosed with T1D.  The logs recorded the 
outcome of any approach inviting the patient to enter the research study.  The logs 
were collected centrally and collated to produce the Consort diagram. 
 
3.2.3.2 Clinical data 
Weight, height, blood pressure, bioimpedance, resting heart rate, waist and hip 
circumference were measured at baseline and after six and twelve months.  These 
measurements were standardised between study sites by the use of standard 
operating procedures.  
Waist circumference was measured at the midpoint between the lowest rib and the 
iliac crest and hip circumference at the level of the greater trochanter (World Health 
Organization 2008).  The measurements were taken (to the nearest centimetre) three 
times and an average of the three readings was used for analysis. Waist-hip ratio 
(WHR) was calculated from these. 
Height was measured to the nearest centimetre using a stadiometer and weight was 
measured using a calibrated set of scales or stadiometer to the nearest kilogram.  
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Body fat percentage was measured using a calibrated stadiometer (this was not 
available in every site). 
Body mass index (BMI) is calculated from weight and height measurements (BMI = 
weight/height2). 
Blood pressure and resting heart rate was measured three times (at each visit) after 
5 minutes of rest using a calibrated automated blood pressure monitor.  The 
averages of each of systolic and diastolic blood pressures (SBP and DBP) were used 
for analysis. 
Information about diagnosis, date of transfer to insulin, mode of presentation and 
family history of diabetes were collected during the screening study visits as 
recommended (Greenbaum and Harrison 2003). 
 
3.2.3.3 Physical activity measures 
It is difficult to accurately assess behaviour, such as physical activity.  One concern is 
that it is altered by observing behaviour, an example of observer bias, when an 
individual is aware that they are entering a trial of physical activity, consciously or 
unconsciously, activity levels are altered.  Different methods have been used to 
assess physical activity in trials with exercise interventions.  These include subjective 
measures, such as self-report, activity diaries and questionnaires, and/or objective 
measures, such as accelerometer data or supervised exercise programmes.  
Additionally, surrogate measures such as change in fitness (either measured or 
estimated VO2max) are often used.  Each of these has advantages and 
35 
 
disadvantages, subjective measures in particular may be subject to recall bias, 
however none are ideal and often multiple measures are used. 
 
In order to assess the best way to evaluate physical activity in a trial of patients with 
T1D, a number of ways of assessing physical activity were used at baseline: 
1. Participants were asked to evaluate how much exercise they undertook each 
week before and after their diagnosis of T1D.  The question asked was 
‘On average, how many times in a typical week did you participate in 
moderate intensity exercise and how long were these periods in minutes?’ 
2. Participants completed a questionnaire to evaluate their current level of activity 
(International Physical Activity Questionnaire (IPAQ) Long Last 7 Days Self-
Administered Format) (Craig et al. 2003). 
3. Participants were asked to wear an accelerometer (GT3XE-Plus Triaxial Activity 
Monitor, Actigraph, USA) for a week before visit 1 and a week after visit 1.  During 
this time they were asked to also keep a diary of any physical activity undertaken. 
4. Estimated VO2max was calculated using a cycle ergometer using two methods 
(Astrand-Ryhming and YMCA/ACSM) (American College of Sports Medicine 
2000).  The method had to be safe for patients and utilise available equipment in 
clinical sites, therefore, we chose a submaximal test and estimation of VO2max 
from heartrate rather than direct measurement of VO2max (as the equipment for 
this was not available in most centres). A detailed description of the procedure is 
given in section 3.2.3.6. 
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3.2.3.4 Monitoring physical activity during the study 
Physical activity during the study was assessed in the following ways: 
3.2.3.4.1 Self-report 
At each visit, participants in the intervention group were asked if they had achieved 
their target physical activity levels 
3.2.3.4.2 Diaries/heart rate monitoring 
Participants in the intervention arm only, were asked to complete diaries recording 
the type and length of exercise they undertook each week.  They were provided with 
a heart rate monitor (FT4/FT7, Polar Electro UK Ltd) and asked to record their 
average heart rate for each session as well as their rating for perceived exertion 
(RPE) (Borg 1998). 
3.2.3.4.3 Accelerometry 
All participants (both in the intervention and control groups) were asked to wear an 
accelerometer (Actigraph models GT3X and GT3XE-Plus Triaxial Activity Monitor, 
Actigraph, Actigraph, Pensacola, Florida, USA) during waking hours for one week 
before visits 8, 11, 14 and 16 (corresponding to 3, 6, 9 and 12 months) (in addition to 
the baseline measures).  During this time they were asked to also keep a diary of any 
physical activity undertaken. Accelerometer measured activity has been validated 
with measured oxygen consumption (VO2max), showing excellent correlation  
(Freedson et al. 1998).  Data from the accelerometer downloads is given as the 
number of minutes spent in moderate-vigorous physical activity (MVPA). 
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3.2.3.4.4 Fitness testing 
Fitness was estimated through VO2max using a cycle ergometer using the same 
protocol at baseline, 6 months and 12 months (described in section 3.2.3.6). 
 
3.2.3.5 Laboratory data 
3.2.3.5.1 Routine laboratory studies 
Routine laboratory studies for patients with T1D include HbA1c and lipid profile.  
HbA1c was measured every three months during the study to aid achievement of 
optimal glycaemic control.  Lipid profile was measured every six months.  These 
samples were analysed in local NHS hospital laboratories as per usual diabetes care. 
3.2.3.5.2 Autoantibodies 
Serum from blood taken at visit 1 was sent for analysis of three autoantibodies 
associated with T1D. Measurement of antibodies to glutamate decarboxylase 
(GADA), the protein tyrosine phosphatase islet antigen (IA-2A) and zinc transporter 8 
(ZnT8A) were analysed at the Research Laboratories, School of Clinical Sciences, 
University of Bristol, UK (Southmead Hospital, Bristol.  The methodology of this 
assay has been previously described (Bingley et al. 1997; Long et al. 2011) 
3.2.3.5.3 Mixed meal test 
Samples of plasma, serum and urine obtained during the mixed meal test were 
analysed for C-peptide, glucose and insulin at the Clinical Biochemistry laboratories 
of the Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.  Insulin and C-
peptide were measured using a direct electrochemiluminescence immunoassay.  The 
methodology of this assay has been previously described (McDonald et al. 2012). 
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3.2.3.6 Testing of fitness and beta cell function 
3.2.3.6.1 Estimated VO2max 
Fitness was assessed by two methods during a single exercise test (Astrand-
Ryhming and YMCA/ACSM) (American College of Sports 2000).  Heart rate was 
measured during the test using a Polar heart rate monitor (FT4 model, Polar Electro 
UK).  Calibrated cycle ergometers were used for this test, the make and model used 
varied between sites, depending on availability, but participants used the same 
ergometer throughout the study to minimise inter-subject variability. 
Method 1 
Participants were asked to cycle at a fixed workload for six minutes and the average 
heartrate in the last two minutes was recorded.  If the average heartrate was less 
than 120bpm the test was repeated at a higher workload, if it was between 120 and 
140bpm the participant carried straight on to part 2 of the test and if it was above 
140bpm, the test was discontinued. 
The estimated VO2 max was then calculated by the use of a nomogram (American 
College of Sports 2000). 
Method 2 
In this part of the test the workload was progressively increased at the beginning of 
three minute stages.  In each stage the workload and average heartrate of the last 
30seconds were recorded.  The increments continued until the participants had 
reached 85% of their age-predicted maximal heart rate (calculated as 220-age). 
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These readings were plotted on a graph and the maximum workload predicted at 
maximal heart rate.  Estimated VO2 max was then calculated using the following 
equation: 
VO2 max (ml
.kg.min-1) = 3.5 + 3.5 + (1.8 x workload max/body mass) 
3.2.3.6.2 Assessment of beta-cell function 
The recommended test for measurement of beta-cell function in trials in early T1D is 
the mixed meal tolerance test (MMTT) (Palmer et al. 2004)(Greenbaum et al. 2008).  
Classically the oral stimulus (meal) used is liquid Sustacal (Boost), however, due to 
difficulties with the supply of this, a measured dose of Fortisip (Nutricia, Wiltshire, 
UK) was used following the protocol used by the UK Islet Transplantation Consortium 
(personal communication from S Eckholdt, 2011). 
Some sources advocate the use of a four-hour rather than a two-hour MMST 
(Greenbaum & Harrison 2003) as the peak C-peptide release in T1D can occur later.  
However a two-hour test was chosen in this study to reduce the time burden on 
participants and as this is the recommended test. 
Participants were asked to fast from midnight and to withhold any insulin doses on 
the morning of the test (basal insulin was not withheld).  Capillary blood glucose was 
checked prior to the start of the test and the test was rescheduled if the reading was 
not between 3.5 and 15 mmol/l. 
A stimulus in the form of 240mls Fortisip was given orally, and blood samples were 
collected at -10, 0, 15, 30, 60, 90 and 120 minutes.  Additional fasting samples were 
taken for glucose, insulin.  The samples were spun and frozen at -80°C for later 
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analysis.  Analysis of all these samples was performed at the Biochemistry 
Department of the Royal Devon & Exeter Hospital, UK. 
 
The MMTT takes at least two hours to perform and must be undertaken in a setting 
where venepuncture/cannulation is available as well as facilities to process the 
samples once taken.  More recently there has been interest in development of 
surrogate markers of beta-cell function which are easier to obtain, fasting C-peptide 
and urinary C-peptide:creatinine ratio (UCPCR) have both been used.  UCPCR has 
been demonstrated to have a good correlation with meal-stimulated C-peptide in 
patients with T1D (R. E. J. Besser et al. 2011).  At the end of the MMTT, the 
participant was asked to provide a sample of urine.  This sample was frozen and 
stored for later analysis for UCPCR to compare with the traditional MMTT. 
 
3.2.4 Data and Statistical Analysis 
3.2.4.1 Sample size calculations 
It was calculated that a minimum of 60 participants (30 in each study arm) were 
required to provide data to achieve the primary outcomes. We predicted a 30% 
recruitment rate (95% CI 22% to 39%), a 90% exercise adherence rate (95% CI 76% 
to 97%) in the intervention arm and a 15% drop out rate (95% CI 5% to 30%).   
Our study estimated a confounding effect of 10% increase in exercise in the ‘usual 
care’ group with a 95% confidence interval of 2 to 27%. 
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These calculations were performed by Roger Holder at the Birmingham Primary Care 
Clinical Trials Unit. 
3.2.4.2 Calculations and analyses 
The majority of data are presented descriptively, for example, mean and standard 
deviation or 95% confidence interval (95% CI).  Where data are not normally 
distributed, median and range are presented and these are identified in the text.  
Graphs represent mean ± standard deviation (unless specified otherwise). 
To assess for associations, Pearson’s correlation coefficient is used.  Non-parametric 
data has been log-transformed prior to analysis or Spearman correlation is used, 
where this has been done, it is specified within the text of the thesis. 
Groups have been compared using Student’s t test and Chi-squared analysis or the 
non-parametric equivalent.  Two way repeated measures ANOVA was used for 
longitudinal data 
Mean area under the curve (AUC) was calculated for meal stimulated C-peptide.  
This is the recommended model for use in clinical trials in T1D (Palmer et al. 2004; 
Greenbaum & Harrison 2003).  AUC was calculated using the trapezoid method 
(Allison et al. 1995) using GraphPad Prism software (GraphPad Software Inc., USA).  
Mean AUC was calculated by dividing AUC by the length of the test (120minutes). 
Homeostasis Model Assessment (HOMA) was used as an estimate of insulin 
resistance (HOMA-IR), insulin sensitivity (HOMA-S) and beta cell function (HOMA-B) 
respectively.  The online HOMA2 calculator was used (Wallace et al. 2004) available 
from https://www.dtu.ox.ac.uk/homacalculator/download.php (last accessed 27th July 
2016). 
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Accelerometer download data was evaluated by Professor Ashley Cooper, Centre for 
Exercise, Nutrition and Health Sciences at the University of Bristol, UK. 
Data were analysed using GraphPad Prism 7.00 (GraphPad Software Inc., USA). 
 
3.2.5 Trial conduct 
3.2.5.1 Participant identification 
Patients with a diagnosis of T1D within the previous three months were recruited 
from secondary care providers between April 2011 and February 2014.  Nineteen 
hospital Trusts across the UK were involved either as identification centres or full 
treatment sites.  The centres involved were: 
o University Hospital Birmingham NHS Foundation Trust 
o University Hospital Bristol NHS Foundation Trust 
o Taunton & Somerset NHS Foundation Trust  
o Gloucestershire Hospitals NHS Foundation Trust 
o North Bristol NHS Trust 
o Yeovil District Hospital NHS Foundation Trust * 
o East and North Hertfordshire NHS Trust * 
o Mid Yorkshire Hospitals NHS Trust * 
o Oxford University Hospitals NHS Trust * 
o Royal United Hospital Bath NHS Trust * 
o Weston Area Health NHS Trust 
o Sandwell and West Birmingham NHS Trust 
o The Royal Wolverhampton NHS Trust 
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o The Dudley Group of Hospitals NHS Foundation Trust 
o Worcestershire Acute Hospitals NHS Trust 
o George Eliot Hospital NHS Trust 
o Heart of England NHS Foundation Trust 
o Royal Devon & Exeter NHS Foundation Trust 
o Walsall Healthcare NHS Trust 
Those sites marked in bold were full treatment sites, the remaining sites were patient 
identification centres (PICs).  Sites indicated with an * joined the study in autumn 
2012 as a means of improving recruitment rates.  
The study was publicised by Diabetes UK on their website and in their magazine 
from May 2012, and on the diabetes.co.uk and Juvenile Diabetes Research 
Foundation website from July 2013.    
Prospective participants were also identified through the ADDRESS-2 study from 
April 2013.  This study aimed to recruit patients with recently diagnosed T1D and 
their relatives to provide a database of potential participants to early intervention 
trials.  The ADDRESS-2 study team contacted participants with details of the Extod 
study and information on the contact details of their nearest study site.   
 
 
3.2.5.2 Eligibility criteria 
Subjects were eligible for the study if they satisfied the following inclusion and 
exclusion criteria: 
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3.2.5.2.1 Inclusion criteria 
The inclusion criteria were that participants should be 
1. aged between 16 and 60 years.  
2. randomised (or interviewed) within twelve weeks of diagnosis. 
3. safe to exercise (as determined by the physician). 
4. willing to self-monitor blood glucose and record the results. 
5. willing and able to take insulin as part of a multiple dose injection 
regime. 
6. sedentary (exercising for no more than 150 minutes a week according 
to self-report) (later changed to able to increase their current levels of 
exercise (as judged by the participant)). 
7. detectable C-peptide value 90mins after meal stimulation (defined as 
>200 pmol/l) (not required for interview study)  
8. GAD antibody positive (later removed as an inclusion criterion). 
3.2.5.2.2 Exclusion criteria 
1. uncontrolled blood pressure (greater than 180/100 mmHg) 
2. concomitant therapy that affects heart rate (beta blocker, Calcium 
channel antagonist) as this would affect the ability to estimate VO2max 
and monitor exercise intensity using heartrate monitors 
3. psychological or physical disease that prevents exercise 
4. pregnancy or planning pregnancy (as preconception and diabetes in 
pregnancy care both require specialist input) 
5. major surgery or other planned event that would prevent exercise for 
more than six weeks 
45 
 
3.2.5.3 Randomisation 
Participants were randomised in a 1:1 ratio to intervention or usual care groups.  
Randomisation was stratified by site and minimised on 90 minute stimulated C-
peptide level and estimated VO2max.  As the expectation was to recruit 60 
participants, with approximately half coming through the West Midlands sites and half 
from the other sites, site was defined in two groups; ‘West Midlands’ and ‘other’.  The 
minimisation criteria were 90minute stimulated C-peptide above or below 600pmol/l 
and estimated VO2max, criteria set on gender specific levels (above or below 42.8 
ml.kg.min-1 (males), 34.6 ml.kg.min-1 (females)), these were determined by Dr Keith 
Stokes/Dr Dylan Thompson (Sports Sciences Department, Bath University, personal 
communication). 
Randomisation was organised and supervised through the University of Birmingham 
Primary Care Clinical Trials Unit, using an on-line randomisation programme with a 
telephone service used as a back-up.  Randomisation was performed by the study 
dietitian at visit 4, after standardised dietary advice had been given. 
 
 
3.2.5.4 Blinding 
Due to the nature of the study, it was not possible for study participants or trial 
personnel to be blinded to the allocation. 
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3.2.5.5 Adverse event reporting 
Serious adverse events were notified immediately to the study team and discussed 
with the Chief Investigator.  All adverse events identified at study visits were logged 
and recorded within the trial database.  Hypoglycaemia incidence in the month prior 
to the visit was specifically identified and recorded in the trial database. 
Adverse events were discussed at the trial management and steering committee 
meetings. 
 
3.2.5.6 Visit Schedule 
An overview of the visits is given in Table 3-1. There were a total of seventeen visits.  
Randomisation occurred at visit 4.  Post-randomisation there were eight visits for all 
participants and a further five for those in the intervention arm only.  The additional 
visits scheduled for participants in the intervention arm could be undertaken over the 
telephone or in person; other visits had to take place in person.  All participants met 
with a study doctor at baseline, at six months and at the end of the study (after twelve 
months). 
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Visit Action Time 
(wks) 
Usual care Intervention 
1 Consent and screening    
2 Mixed meal test, baseline    
3 Fitness test, baseline    
4 Randomisation, dietitian visit 0   
5 Nurse visit  2   
6 Nurse visit or telephone 4   
7 Nurse visit or telephone 8   
8 3 month clinical assessment by diabetes nurse 12   
9 Nurse visit or telephone 16   
10 Nurse visit 20   
11 Mixed meal test and clinical assessment, mid-point 24   
12 Fitness test, mid-point 24   
13 Nurse visit or telephone 30   
14 9 month clinical assessment by diabetes nurse 36   
15 Nurse visit or telephone 42   
16 Fitness test, final 48   
17 Mixed meal test and clinical assessment, final 48   
Table 3-1 Overview of study visits 
 
3.2.5.7 Storage of samples 
Samples of serum and plasma were stored at -80°C at the study site immediately 
after processing, with the exception of two sites that did not have access to a -80°C 
freezer.  These sites (Mid Yorkshire and East & North Hertfordshire) processed the 
samples according to the SOP and then sent them overnight to the University of 
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Birmingham where they were stored at -80°C.  All unused samples were eventually 
transferred to the University of Birmingham laboratories for ongoing storage/analysis. 
 
3.2.5.8 Data recording and retention 
3.2.5.8.1 Case report forms (CRFs) 
Data gathered at each visit was recorded on visit specific CRFs.  This enabled inter-
person and inter-site standardisation of data gathering and avoided missing data. 
Each site retained the original CRFs with copies being held centrally.  Records will be 
stored for five years. 
3.2.5.8.2 Study database 
All visit data were entered by trial personnel onto a database, specifically designed 
for the study.  The database was held on the servers of the University of Birmingham 
Primary Care Clinical Trials Unit.  Access was password protected.  The data were 
monitored throughout the study and missing or invalid data queried with the 
appropriate site. 
3.2.5.8.3 Standard operating procedures (SOPs) 
Standard operating procedures for each visit, measurement (blood pressure, 
waist/hip circumference and bioimpedance) and all tests (mixed meal test, fitness 
test, venepuncture and sample processing) were used by all sites.  These are not 
provided in the appendix due to space limitation. 
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3.2.6 Ethical and regulatory matters 
A favourable ethical opinion was granted by Birmingham, East, North and Solihull 
Research Ethics committee in February 2010 (reference number 10/H1206/4).  The 
same committee reviewed and approved an amendment in August 2010; subsequent 
amendments in 2011-13 were reviewed and approved by National Research Ethics 
Service Committee West Midlands - Solihull.  The final amendment was approved in 
November 2013 and relates to protocol version 8. The project and amendments were 
approved by the research and development departments of the participating hospital 
trusts.   
Amendment 
No. 
Date 
approved 
Summary of amendment 
4 Oct 2011 Revised patient documentation approved 
5 Jan 2012 Continuous glucose monitoring, Yeovil and Bath to full study sites 
9 Nov 2012 Alteration to inclusion criteria (GAD antibody and existing exercise 
levels) 
10 Apr 2013 Approaching patients through ADDRESS-2 study, financial incentive 
to PIC site staff for recruitment 
11 Nov 2013 Addition of the option for patients completing the study to enter a 
follow-up phase 
Table 3-2 Summary of amendments with dates 
The study is registered with ICRCTN (International Standard Registered 
Clinical/soCial sTudy Number), registration number ISRCTN91388505. 
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3.2.7 Study oversight and monitoring 
The study was overseen by a management committee and a steering group.  The 
management committee met approximately every six months during the trial period.  
The management committee was composed of members of the research team, staff 
from the University of Birmingham Primary Care Clinical Trials Unit, as well as patient 
representatives.  The steering group met once a year to discuss trial conduct and 
progress.  
 
3.2.8 Sponsorship 
The study was sponsored and indemnified by the University of Birmingham. 
 
3.2.9 Funding 
Funding for the study was provided by a National Institute for Health Research, 
Research for Patient Benefit grant. 
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4 EXTOD TRIAL PROGRESS 
4.1 Review of trial 
4.1.1 Trial progress 
All eligible patients (as defined in section 3.2.5.2), identified at the participating 
centres, were invited to take part in the study. Recruitment to Phase 1 (qualitative 
study) opened in April 2011 and to Phase 2 in November 2011.  Once recruitment to 
both was open, those patients unwilling or unable to take part in Phase 2 were 
offered the opportunity to take part in the qualitative study. 
The final participant was recruited to Phase 2 in February 2014 and randomised in 
March 2014. 
 
4.1.2 Recruitment 
Recruitment to Phase 2 commenced in November 2011 and the first patient 
randomised in January 2012.  Progress of recruitment over time until completion of 
recruitment in February 2014 is shown in Figure 4-1 below. 
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Figure 4-1 - Recruitment to Phase 2 of Extod study over time 
 
Initial recruitment (up to summer 2012) was slower than originally anticipated.  Due to 
this, several changes to the study were implemented at the end of 2012.  The effect 
of these changes can be seen in Figure 4-2, with randomisation rates increasing from 
approximately one per month in 2012 to three per month in 2013. 
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Figure 4-2 - Recruitment to Extod during study period.  The black line indicates 
cumulative recruitment numbers (to Phase 2). A indicates when inclusion criteria 
were altered.  The red line indicates average recruitment rates for each calendar 
year and demonstrates the increase in recruitment from January 2013 onwards. 
 
4.1.3 Review of study 
Recruitment to Phase 2 was reviewed after 4 months. It was apparent that the 
recruitment target would not be achieved in the original timeframe. As such, a review 
of the study was undertaken and several changes to the study were implemented to 
improve recruitment rates.  These are discussed below. 
 
4.1.3.1 Additional sites 
Five additional treatment sites were added to the study in September 2012, these 
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University NHS Trust, Yeovil District Hospital NHS Foundation Trust and Royal 
United Bath NHS Trust.  Bath and Yeovil had been operating as Patient Identification 
Centres (PICs) until this point in the study. 
 
4.1.3.2 Alteration in the eligibility criteria 
Two of the inclusion criteria were altered to reduce the number of people who failed 
screening.  These are described below. 
 
4.1.3.2.1 Diagnosis of T1D 
The requirement for participants to have GAD antibodies detectable in their serum 
was removed; instead, the diagnosis of T1D was based on clinical judgement.  There 
were a number of reasons for this change; 
1. Outside of research projects, T1D is predominantly a clinical diagnosis and 
autoantibodies only measured if there is doubt in the diagnosis.  Removing 
this criterion makes the study more generalisable to the clinic population of 
patients with T1D. 
2. A significant proportion of people with a clinical diagnosis of T1D do not 
have detectable levels of GAD antibodies in their serum (i.e. GADA 
negative). The proportion of patients with T1D who are GAD positive has 
been estimated at around 80% (Long et al. 2012).   
3. The two week turnaround time for the GAD antibody analysis proved difficult 
to fit into a randomisation target of twelve weeks from diagnosis. 
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4.1.3.2.2 Current levels of physical activity 
During the review of the study, it was found that self-reported physical activity time 
was poorly correlated with the results of either the International Physical Activity 
Questionnaire (IPAQ) or the measured accelerometer data.  Therefore, this criterion 
was altered to include people who were willing and able to increase their current 
levels of activity. 
 
4.1.3.3 Use of Internet to advertise study 
The study was included on the Diabetes UK and Juvenile Diabetes Research 
Foundation research webpages with contact details for the investigators in 
Birmingham.  In addition, Diabetes UK featured the study in their “Balance” 
magazine.   Potential participants were linked with their closest site and any travel 
expenses incurred were reimbursed. 
In addition, the study was publicised on the Diabetes.co.uk website.  Diabetes.co.uk 
were payed a small fee for each participant identified in this way and who fulfilled the 
study entry criteria. 
 
4.1.3.4 Incentives for Patient Identification Centres (PICs) 
Referrals from PICs were initially much lower than anticipated (and far lower than 
potential participants identified at full study sites).  For every participant who attended 
a screening visit or interview, the referring team was sent an Amazon voucher as an 
incentive.   
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4.1.4 Impact of changes to study on recruitment 
All of these changes were introduced at around the same time (August-October 
2012); therefore, it is difficult to assess the individual impact each of these changes 
had on recruitment.  However, 
1. The additional sites accounted for 16 of the 89 participants who attended 
visit 1 and 13 of the 58 randomised participants. 
2. Six screened participants contacted the study as a result of the 
internet/“Balance” magazine advertising. 
3. Prior to the PIC incentive scheme (approximately the first year of 
recruitment) five participants attended a screening visit or interview.  In the 
second year of recruitment (after the Amazon vouchers were introduced), 
fifteen participants were recruited from PIC sites. 
 
Overall, from the start of recruitment to Phase 2 until the end of recruitment at the 
end of December 2013, 507 patients were identified as potentially suitable for the 
study.  This takes into account patients identified at all treatment sites, PICs (where 
data has been made available) and through the ADDRESS-2 database and 
diabetes.co.uk website.  A breakdown of outcome for all of these potential 
participants is shown in the CONSORT flow chart in Figure 4-3. 
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 Figure 4-3 - CONSORT Flowchart for Extod Study 
 
The recruitment rate for the study (including Phase 1 and Phase 2) was 14.4%.   
Once Phase 2 had commenced, potential participants who were ineligible for Phase 
2 (for example, because they were leaving the country or GAD antibody negative) 
Assessed for eligibility (n= 507) 
Excluded  (n=449) 
   Not meeting inclusion criteria (n= 128) 
   Declined to participate (n=165) 
   Uncontactable (n=117) 
   Withdrew prior to randomisation 
(n=13) 
   Recruited to Phase 1 study (n=15) 
   Unknown (n=9) 
23 patients 
(7 withdrew) 
Allocated to intervention (n= 30) 
20 patients 
(8 withdrew) 
 
Allocated to usual care (n= 28) 
  
Allocation 
6 months 
Randomised (n= 58) 
Enrollment 
21 patients 
(2 withdrew) 
20 patients 
12 months 
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were offered the option of taking part in Phase 1.  The uptake rate for the exercise 
intervention study was lower at 11.4%. 
 
4.1.4.1 Reasons for non-entry into study 
The most common reason for potential participants not to continue into the study was 
that they declined (165/507, 32.5%).  Most of these gave no reason, but of those that 
did give a reason, the most common was lack of time, either to attend study visits or 
increase their exercise levels. 
 
A further 25% (128/507) were found to not be eligible once contacted by the study 
team.  There were a number of reasons for this (shown in Table 4-1).  The most 
common reasons that potential participants were found to be ineligible for the study 
was late referral to the study team and that patients did not have T1D (i.e. they 
actually had a diagnosis of type 2 diabetes or steroid induced diabetes).  Before the 
inclusion criteria were broadened at the end of 2012, a few potential participants 
were excluded as they had already been found not to have GAD antibodies present 
or they were already very active.  Reasons categorised under ‘other’ in Table 4-1 
included patients who were felt to be clinically unsuitable by the clinical team 
responsible for their care or who were having difficulty accepting their diagnosis. 
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Reason for ineligibility Number 
More than 3 months since diagnosis 31 
Other 27 
Not diagnosed as T1D 23 
Doing more than 150mins/week exercise 16 
Out of age range (>60 years old) 12 
Unable or unwilling to exercise 10 
GAD antibody negative 6 
Planning pregnancy 3 
Table 4-1 - Exclusions based on eligibility criteria 
 
4.1.5 Drop-out 
Of the 58 participants randomised, seventeen withdrew from the study or were been 
lost to follow-up.  Fourteen of these participants withdrew soon after randomisation, 
with three continuing on until the six-month assessments, before withdrawing.  The 
dropout rates at six and twelve months (of those participants who were randomised) 
were 24% and 29% respectively.  There was no difference in the dropout rates 
between the study arms; a similar number of participants withdrew from both arms (9 
from the intervention and 8 from the control group).  Most withdrawals (11/17) were 
within one month of randomisation. 
There were several reasons for withdrawal from the study.  Three participants lost 
contact with the study team despite all attempts to contact them (by telephone, email 
or post).  Two participants were no longer eligible for the study, one as subsequent 
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testing (performed due to family history and antibody status) proved positive for 
monogenic diabetes (HNF-4α mutation) and another as they subsequently enrolled in 
another intervention study (and potentially received a medication affecting beta cell 
function).  The other seven participants withdrew.   
 
4.1.5.1 Completion rate 
Overall 54 participants completed either Phase 1 or Phase 2 out of 89 who attended 
for screening.  The overall study completion rate of those who consented was 60%.  
Despite the small numbers, this was similar across most study sites. 
Site Attended Interviewed Randomised Completed Phase 2 
QEHB 21 6 14 13 
WM PICs 14 2 8 5 
Taunton 10 1 8 5 
Other entry routes 9 0 6 2 
Bristol 8 1 5 3 
Wakefield 8 1 6 3 
SW PICs 6 2 1 1 
Gloucester 5 2 3 1 
Welwyn 4 0 4 4 
Oxford 4 0 3 2 
 
    
Total 89 15 58 39 
Table 4-2 - Study completion rates stratified by treatment site 
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However, participants who were identified through other routes (self-referrals through 
the internet, those identified through the ADDRESS-2 study, for example) were less 
likely to complete; only two of these nine participants did so.  Participants identified in 
Welwyn and at QEHB were more likely to complete (100% and 90% respectively). 
 
4.1.6 Adherence to study arm 
Adherence to the exercise program and uptake of exercise in the control arm will be 
discussed in Chapter 7. 
 
4.1.7 Return rates of participant diaries/activity monitoring 
At specific time points during the study the participants were asked to complete and 
return several diaries.  Return rates for the food diaries were 60% at each of the 
three time points, and for the sleep diaries the rates were 60, 70 and 65%, at 
baseline, after 6 months and after 12 months. 
Adherence to the activity monitoring fell slightly during the study, 86% returned a 
worn accelerometer at baseline, at 6 months the proportion was 74% and at 12 
months, 71%. 
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4.1.8 Adverse events 
4.1.8.1 Hypoglycaemia 
Two episodes of severe hypoglycaemia were reported; one each in two participants.  
One episode occurred in each arm of the study. 
There was no significant difference in minor hypoglycaemia events reported between 
the groups.  Participants experienced approximately one episode of minor 
hypoglycaemia per week.  The rates of hypoglycaemia reported are given in Figure 
4-4.  Rates of hypoglycaemia were highest at entry to the study and fell by three 
months in both groups.  There were small, non-significant increases in 
hypoglycaemia reported at towards the end of the study in the intervention group 
(mean number of hypoglycaemia episodes 2.35, 95% CI, 0.015 to 4.54, in the control 
arm and 3.38, 95% CI, 0.80 to 5.96,  in the intervention arm at twelve months).   
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Figure 4-4 - Prevalence of hypoglycaemia during the study. Mean number of 
hypoglycaemia episodes (capillary blood glucose <4.0mmol/l) reported in the 
previous month.  
63 
 
4.1.8.2 Other adverse events 
4.1.8.2.1 Serious adverse events 
Two serious adverse events occurred during the study, both relating to hospital 
stays.  One participant in the intervention arm required an overnight stay unrelated to 
either diabetes or exercise, the other, in the control arm, was admitted due to 
hyperglycaemia. 
4.1.8.2.2 Adverse events 
Overall, adverse events were reported more frequently in the intervention group than 
the control group (2.9 events per participant in the intervention arm and 0.9 events 
per participant in the control arm).  The majority of the events were minor illness or 
injuries not requiring any medical advice (e.g. viral illnesses).  Difficulties relating to 
diabetes were also reported more often in the intervention group, particularly 
hyperglycaemia and missed insulin doses.   
Illnesses and injuries requiring medical assistance ranged from dental infections to 
patella bursitis and skiing accidents.  Again, these were more frequently reported in 
the intervention arm. 
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4.2 Discussion 
This chapter describes the Extod study design, as well as, the primary outcomes of 
1) recruitment and 2) study completion rates.  The results of Phase 1, other primary 
outcomes (adherence and exercise uptake in the control arm) and the secondary 
outcome (the effect of exercise on beta cell function) are described in later chapters.  
4.2.1 Primary outcome 1: Recruitment/Uptake 
Recruitment to the study did nearly achieve the target of 60 participants randomised, 
although it took over twice as long as anticipated and required a further three 
treatment sites to achieve this.  In addition, widening of the inclusion criteria and 
incentivising referrals from PIC sites were necessary.  These changes to the study 
did appear to improve recruitment rates. 
In order to randomise 58 participants (and interview 15), over 500 patients were 
identified.  This gives an uptake rate of under 15%.  The largest group of people not 
taking part in the study were those who declined.  The study was not designed to 
pick up all the reasons for this but possible reasons for the low uptake are given 
below: 
 Age of participants.  Generally participants were of working age and 
difficulty fitting visits research around work may have been an issue 
 Difficulty adjusting to diagnosis.  Participants were in the main previously 
healthy and had to come to terms with the illness and treatments that 
were required, to take on research at this time may have been too much. 
 Logistical issues due to the limited number of sites. 
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Suboptimal recruitment of patients to clinical trials is a common problem, with around 
half of RCTs failing to recruit to target and half of trials who achieve their target 
numbers, failing to recruit in their originally anticipated time frame (Wilson et al. 2000; 
Bower et al. 2007; Raftery et al. 2008; Toerien et al. 2009).  It is difficult to assess 
how the Extod trial uptake compares to other T1D trials due to differences in 
reporting, intervention and study population.  For example, one study with a T1D 
population but with a differing intervention (five-day course) had uptake rates as low 
as 17% (DAFNE Study Group 2002).  Conversely, a recent RCT examining the effect 
of metformin in adolescents with T1D with a yearlong intervention reported that 163 
patients were screened to achieve 140 randomised participants (Libman et al. 2015), 
giving an uptake rate of 86%. However, this study did not report the total eligible 
population as we have done here.  A study with a similar intervention but different 
population, the Early Actid study, a trial of lifestyle intervention over 12 months in 
type 2 diabetes, had a recruitment rate of 36% (593/1634) (Andrews et al. 2011). 
Changes made to the study protocol did improve recruitment rates; but as they were 
all made at the same time, it is not possible to say which changes had the greatest 
effect.  Broadening the inclusion criteria and adding more sites, however, did help 
identify more potentially eligible participants.   Much of the research into identifying 
successful strategies to improve recruitment to RCTs concentrates on incentives for 
and characteristics of potential participants (Treweek et al. 2010; McDonald et al. 
2006).  There is some evidence that factors related to the study design and research 
team, for example, complexity of the study may also factor in recruitment problems 
(Fletcher et al. 2010).  Therefore, any future study should be designed with this in 
mind. 
66 
 
4.2.2 Primary outcome 3: Study completion rates 
Drop-out rates were high (14/58 by six months and a further three by twelve months).  
The completion rates were lowest in those participants identified outside of the study 
sites (via internet or other studies).  It is possible that distance from the study site 
may play a part in retention, (those participants identified at the study site were likely 
to be local).   Other reasons for withdrawal included problems relating to 
management of diabetes (for example, not wishing to monitor blood glucose and 
difficulty complying with insulin treatment) and loss to follow-up.  The loss to follow-up 
may in part be due to the fact that our study population was young and more mobile. 
In a meta-analysis of thirteen studies involving exercise interventions T1D, we 
identified completion rates of between 70-100% (Kennedy et al. 2013).  None of the 
studies included in this analysis had a duration of over 6 months.  The Extod study 
completion rate of 70% is at the lower end of this range, however, the duration of 
follow-up was twice as long as the next longest study.   
 
4.2.3 Adverse events 
Hypoglycaemia was not recorded at a higher frequency in the exercise arm.  This is 
reassuring and suggests that the advice given for insulin dose adjustment and 
carbohydrate intake around exercise was adequate.  In addition, episodes of severe 
hypoglycaemia were rare and occurred only once in each study arm.  This population 
of patients newly diagnosed with T1D are probably relatively protected from severe 
hypoglycaemia as their counter-regulatory hormone response is affected only later in 
the disease process.   
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The apparent increase in non-hypoglycaemia related adverse events in the 
intervention arm may be due to a number of factors.   
Firstly, the study was designed so that the intervention group had more frequent 
contact with the study team (eleven post randomisation visits compared to six).  
Actually the number of post randomisation visits that took place and during which 
data regarding adverse events was recorded (including the absence of adverse 
events) was nearly double on average (7.8 in the intervention arm and 4.1 in the 
control group). 
There may have been a bias towards reporting adverse events in the intervention 
group as the study was not blinded.  Therefore, particularly musculoskeletal injuries 
were perhaps more likely to be remembered and reported to the study team. 
 
4.2.4 Recommendations for future studies 
It is likely to be necessary to recruit a greater number of participants for a definitive 
study investigating the effect of exercise on beta cell function in T1D.  Consideration 
to the number and location of sites and more flexibility around the randomisation time 
(i.e. a longer eligibility period) might help improve recruitment rates from the point of 
view of the participant.  In addition, reducing study design complexity, through careful 
review of the pilot, may help study teams to recruit more successfully. 
Equally, consideration of the factors affecting retention in the study to improve the 
completion rates will reduce the numbers needed to recruit.  Recruiting only from the 
population local to study sites (rather than nationally via the internet or through 
distant PICs) may help retention rates.   
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A further qualitative study involving both the participants who completed and those 
who did not is planned to investigate the reasons behind both recruitment and 
retention issues. 
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5 ATTITUDES AND BARRIERS TO EXERCISE IN PEOPLE WITH A 
RECENT DIAGNOSIS OF T1D – QUALITATIVE STUDY 
 
5.1 Introduction 
 
The aim of this phase (Phase 1) of the Extod study was to explore the attitudes and 
barriers to exercise in adults recently diagnosed with T1D using an interview format.  
The outcomes of this study would inform the design of Phase 2 of the Extod study, 
exploring the ways to motivate patients with newly diagnosed T1D to increase their 
activity levels. The currently available knowledge of exercise in patients with T1D and 
other chronic diseases has been outlined in the introduction section 1.7. 
 
5.2 Methods/Materials 
5.2.1 Recruitment 
Participants identified as potentially eligible at one of the participating sites (see 
chapter 3) were approached by a member of the team (doctor, diabetes nurse or 
dietitian) at their local site and sent a participant information sheet.  All participants 
gave written informed consent.   
Prior to November 2011, all eligible participants (satisfying the clinical eligibility 
criteria) were offered an interview/focus group.  After this time, potential participants 
were offered the option of taking part either in this part of the study or the RCT.  In 
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addition, those participants who were screened out of, or prior to randomisation 
withdrew from, the RCT were offered the opportunity to participate in the interview 
study (e.g. as they were found to be negative for GAD antibodies). 
 
5.2.2 Interviews 
Participants attended either an individual interview or a focus group.  The format 
varied according to patient numbers/availability and geographical location.  Due to 
the sporadic nature of diagnosis/recruitment, wide geographical recruitment area and 
the time limitation (i.e. wishing to interview within approximately three months of 
diagnosis) it proved very difficult to arrange adequate focus groups with all potential 
participants as initially intended.  Therefore, six months into recruitment (during which 
time only one focus group with three attendees had been arranged), it was decided 
to offer individual interviews.   
Interviews took place either face-to-face or by telephone, depending on patient 
preference and geographical location. Interviews were semi-structured and lasted 
between 30 and 60 minutes.  Areas of discussion included current and past levels of 
exercise, understanding of exercise and exercise guidelines, barrier to increasing 
exercise levels and preferences for monitoring of activity in a trial setting (full 
interview schedule is given in Appendix H ).  Prior to commencing the interview, 
participants were asked to report the amount of moderate-intensity exercise 
undertaken in a week both before and after their diagnosis of T1D.  In addition, they 
completed a questionnaire to evaluate their current level of activity using the 
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International Physical Activity Questionnaire (IPAQ) Long Last 7 Days Self-
Administered Format. 
Participants were interviewed until saturation was achieved.   
5.2.3 Analysis 
The interviews were recorded and transcribed verbatim by a transcription company. 
The transcripts were checked and anonymised where necessary.  Data analysis was 
on-going during the collection period to enable full exploration of themes identified in 
earlier interviews and to identify when saturation had been achieved.  Saturation 
occurs when further data collection does not add any new information to that already 
gathered (Mason 2010).  The data were explored thematically  (Ritchie & Lewis 
2003). 
Themes and a coding frame were developed by reading and re-reading of the 
interview transcripts and through discussions between members of the research 
team (Amy Kennedy, Dr Parth Narendran and Dr George Dowswell).  Analysis was 
assisted by the software package N-Vivo 9 (QSR International, Victoria, Australia).   
Coding was an inductive process, that is, the codes were generated through reading 
and re-reading the interview transcripts rather than specified prior to analysis.  A 
combination of coding techniques were utilised, to fit the data.  First cycle coding 
methods used were a mixture of in vivo, initial coding, process coding.  For second 
cycle coding, a combination of axial and pattern coding was used (Saldaña 2008).     
Interviews were then analysed using a framework approach to further examine 
identified themes.  The framework method is a type of qualitative content analysis, 
where the data is summarised into a matrix.  The rows of the matrix represent the 
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cases and the columns the codes.  This facilitates constant comparison of the data 
both within and between subjects. Framework analysis of qualitative interviews is 
commonly used in the development of themes from semi-structured interviews (Gale 
et al. 2013). 
The use of quantities to represent data in qualitative research is fiercely debated 
(Maxwell 2010).  We have used them in selected instances in this study, however, it 
is important to avoid putting emphasis on these and recognise that these proportions 
cannot be generalised beyond the group studied here.  
 
 
5.3 Results 
5.3.1 Participants 
Eighteen people expressed an interest in the interview study.  Of these, fifteen 
participants were interviewed.  Of the three who did not participate, one person 
withdrew their consent prior to interview, and the other two did not attend at the 
scheduled time/weren’t available at the scheduled time and it was not possible to 
contact them or reschedule the interview in the eligibility period. 
The demographics of the interviewees are given in Table 5-1 below.  The majority 
were male (11 out of 15), which is a similar proportion to that found later in Phase 2 
of the study.  The median age of the group was 29 years with a range of 18-53 years. 
Twelve participants described themselves as of White-British ethnic origin and eight 
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were recruited through the West Midlands sites.  The median length of time from 
diagnosis to interview was 66 days. 
 
Participant Age Gender Centre Ethnic origin Interview 
Format 
Reported 
exercise, 
mins/week   
A 44 M Bir Asian or Asian 
British – Indian 
FG, Face-to-
face 
60 
B 22 F Bir White – British FG, Face-to-
face 
120 
C 53 M Bir White – British FG, Face-to-
face 
0 
D 51 M Bir Black or Black 
British – 
Caribbean 
I, Face-to-face 0 
E 24 M Bir White – British I, Face-to-face 60 
F 37 M Tau White – British I, Face-to-face 150 
G 20 M Glou White – British I, Face-to-face 30 
H 23 M Brist White – British I, Telephone 0 
I 50 M Bir White – British I, Telephone 40 
J 20 F Wake White – British I, Telephone 240 
K 47 F Glou White – British I, Telephone 360 
L 18 M Bir White – British I, Telephone 90 
M 39 M Tau Mixed - White 
and Black 
African 
I, Telephone  
N 29 F Bir White – British I, Telephone 50 
O 19 M Brist White – British I, Telephone 240 
Table 5-1 - Demographics of individual participants for Qualitative study. (FG = 
Focus group, I = Individual Interview) 
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5.3.2 Themes 
Five main themes were identified.  These were: 
1. Exercise context (attitudes to and current and previous exercise behaviour) 
2. Diabetes (impact of diagnosis and knowledge) 
3. Consequences of exercise 
4. Barriers to increasing exercise, and  
5. Confidence (in exercising and managing diabetes). 
 
5.3.2.1 Theme 1 - Exercise context 
All participants were already doing some form of exercise even those who had 
reported doing 0 minutes on the initial questionnaire.  Most wished to increase their 
activity levels; given that an inclusion criterion was that they should be willing to 
increase activity levels it is surprising that three (F, G and L) did not.  Five 
participants reported a reduction in the amount of time they spent exercising, and 
seven had changed the type or reduced the intensity of activities they were doing 
since their diagnosis with diabetes (see Table 5-2). 
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Participant Previous activities Current activities 
A Jogging, rope skipping, playing football Walking while at work (4-5hrs a 
day) 
B Walking at work, gardening, DIY jobs, gym, 
squash 
Occasional gym session, DIY 
C Physical job, gardening, DIY, repairs None 
D Regular attendance at the gym (cardiovascular 
and weight training) 
Walking 
E Marshall arts/boxing Active job 2 days a week 
F Walking while at work Walking while at work 
G Swimming. Jogging Swimming. Jogging  
H Combat karate Jogging, some weights 
I Walking/jogging outside Walking on treadmill 
J Gym Gym 
K Gardening Gardening, walking 
L Walking Walking 
M running Running 
N Rugby, football, cycling Cycling on static bike 
O Badminton/golf Badminton and golf 
Table 5-2 - Description of individual participants current and previous activity 
Participants were involved in a number of different activities (see Table 5-2).  They 
defined exercise as anything from ‘anything where you are moving’ (Participant K) to 
‘something strenuous, not associated with work’ (Participant E). Activity at work and 
doing household chores/repairs was classed as exercise by some. 
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Most participants were either unware that there is guidance on the minimum amount 
of exercise adults should undertake each week or uncertain as to the amount that it 
is recommended should be taken.  Many were pleasantly surprised that 
recommendations were not higher and felt that they should be able to achieve this 
even if they were not already doing so.  Some felt that a universal guideline was 
inappropriate as it could not take in the circumstances of the individual and that a 
personalised target would be preferable. 
‘Because each person should be done individually. And the doctor should say yes, you're 
capable of doing this. No, you're not...because he'll have your medical records, …….Not the 
government telling you, you should do this or you should do that.’ (Participant C) 
 
5.3.2.2 Theme 2 - Diagnosis of diabetes 
All participants wanted to talk about the impact that their diagnosis had had on them.  
The most common way that participants described the sudden nature of the 
diagnosis of T1D was as a ‘shock’ (A, D, H, I, K, M and N). 
‘suddenly it comes like this and it's a shock’ Participant A 
‘if somebody is told they're a diabetic, it's a shock’ Participant K 
 
Other ways of describing their feelings at diagnosis were as being ‘hit’ and as a ‘kick 
in the teeth’ (both participant C), and feeling ‘stunned’ (participant I).    Others 
emphasised the newness of their diabetes and anticipated that it would become 
easier to manage with time. 
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Several participants spoke about their diagnosis as a loss of normality (wanting to get 
back to a ‘normal life’), or of role (uncertainty about being able to work). 
‘I don't want to make my life any different, because it hasn’t changed so I want to keep it that 
way so that I end up controlling the diabetes, or I am at the moment so and I just want to carry 
on that way.’ Participant G 
 
Participants reported four different fears and anxieties related to their diagnosis with 
T1D.  These were concerns about managing new interactions with healthcare 
services, concerns about the impact on work, concerns for the future and concerns 
about blood glucose levels.  Some participants reported feeling overwhelmed by the 
amount of contact that they had with healthcare services since their diagnosis. 
 
‘Every other week I’m getting different, another letter through with different things which could 
be related to it’ Participant D 
‘there's too many things going on at the moment, I think for me.’ Participant K 
 
For several participants, the diagnosis of T1D had a negative impact on their work.  
Some had still not gone back to work and were anxious about their ability to cope.  
One (Participant N) had lost their job. 
‘I'm quite concerned about going back to work actually. Because I know that I'm going to be on 
the go all the time and whether I'm going to be able to cope with doing eight hours worth of 
walking on a daily basis’. Participant B 
‘That's the problem, going back into a job now, knowing if you can do it.’ Participant C 
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‘Well, they laid off me because I was - I, I hadn’t been very well anyway’ Participant N 
 
Some participants reported uncertainty about their future health. One participant 
(Participant D) had discussed this with their GP. 
‘I goes to him [the GP] ‘how long are you going to live on it?’  He goes ‘if you don’t look after 
yourself, he says, five years’. I thought, what! That’s a serious thing.’ Participant D 
it's just nobody has sort of come out and said like, 'This is exactly like, you know, what's going, 
what's going to happen and stuff like that.'  Participant F 
 
Some participants were concerned about blood glucose levels and many were 
anxious to get optimal glycaemic control.  Participants expected that their blood 
glucose levels would become ‘balanced’ with time and that they would then be able 
to keep them within a tight range.   
‘I'm finding it hard to get that balance of where I can just stay [with level blood sugars] and 
treating my levels.’ Participant B 
‘I'm trying to say I want it exactly right, I want to get it right, I want to know what I'm doing’ 
Participant K 
 
Importantly, all said that being diagnosed with diabetes had given them additional 
motivation to exercise than before diagnosis (even those who didn’t plan to increase 
their activity levels).  
‘I think it's a reason to exercise a little bit more’. Participant J 
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‘it's changed my ethos of taking time to do some exercise in some, you know, going for walks. 
It's changed my mind, my what I think.’  Participant K 
‘I mean generally the reason most diabetics start, or people in general start doing more 
exercise is because the fear.  At the end of the day I think it's the fear factor of being afraid 
that if I don't then my life is going to be worse,’ Participant E 
Twelve participants (all apart from F, G and L) stated that they wished to increase 
their activity levels, although some had more concrete plans to do so than others. 
‘I’ll be making a lot more than that target in about a months’ time, I will be going to do like a 
martial arts course, I'm going back to China for a year, I'll be living like at a martial arts camp 
for a year.’ Participant E 
‘but actually, I could do my 10 minutes [bout of exercise], because we do have a room that 
nobody ever goes into, erm, so I could do that here, and that’s a thought, maybe I could 
consider.’ Participant M 
 
5.3.2.3 Theme 3 - The consequences of exercise 
 
The perceptions of the consequences of exercising were mostly positive.  The 
positive outcomes of exercise cited included; health benefits, improved fitness, 
enjoyment, a feeling of wellbeing and weight loss. Some participants cited benefits of 
exercise specifically related to diabetes such as lower blood glucose and insulin 
requirements. 
Although health benefits were commonly mentioned as a motivation to exercise, 
often participants were vague about the nature of these and unable to give specific 
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examples.  A few mentioned positive effects on blood pressure, cholesterol and risk 
of heart disease.   
‘in terms of the actual specific benefits, I'm not… maybe one to … be able to rattle them off.’ 
Participant H 
 
Blood glucose lowering was seen to be a positive effect of exercise by some, 
however, for others this was a negative result as it was associated with 
hypoglycaemia.  Those participants were particularly concerned about the risk of 
hypoglycaemia and whether this would in fact counteract the health benefits of 
exercise, both directly as a consequence of hypoglycaemia and also secondary to 
the need to increase carbohydrate intake.    
Participant C in particular felt there was little point in exercising as although he had 
previously been active, this had not prevented him developing T1D. 
  
5.3.2.4 Theme 4 - Barriers to exercise 
 
Two main sub-themes emerged, medical barriers and the influence of healthcare 
practitioners (HCPs).  In addition individual barriers to increasing exercise mentioned 
by participants were noted.   
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Category Barrier (number of people mentioning) 
Medical Hypoglycaemia (both actual and fear of) (9) 
Lack of knowledge/confidence in managing diabetes (6) 
Fatigue (4) 
Advice from healthcare professionals to stop exercising (4) 
Planning for diabetes (e.g. checking blood glucose/preparing 
for hypoglycaemia (4) 
Other physical health problems (e.g. injuries) (3) 
Feeling overwhelmed by diagnosis (1) 
Time, work and environmental Work commitments (9) 
Family and other time commitments (6) 
Availability and location of facilities (4) 
Cost (4) 
Weather/season (3) 
Lifestyle (2) 
 
Social and personal Lack of fitness (3) 
Lack of motivation (2) 
Lack of enjoyment in certain activities (2) 
Laziness (1) 
Previous negative experience of exercise (1) 
Psychological Feeling uncomfortable exercising (e.g. at a gym) (2) 
Feeling scared of exercising on own (2) 
Feeling daunted at prospect of starting (2) 
 
Table 5-3 - Description of barriers to exercise cited by participants.  Barriers 
grouped into the following categories: medical; time, work and environmental; 
social and personal; and psychological.  Within each category barriers are listed in 
order of frequency. 
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5.3.2.4.1 Medical barriers to exercise 
Most of the medical factors cited as barriers to exercise were related to diabetes.  
The most frequently cited barrier in this category was hypoglycaemia (cited by nine 
participants).  For some this related to actual experience of hypoglycaemia during or 
after exercise, however, others were worried about hypoglycaemia but had not yet 
experienced this.  Six participants cited a lack of knowledge or confidence in 
managing diabetes around exercise.   Four people talked about the need to plan for 
exercise with diabetes, for example, checking blood glucose before and during 
activity and preparing for hypoglycaemia, as a discouraging factor.  Fatigue (which 
may be related to hyperglycaemia) was cited by four people.  Three people talked 
about other aspects of physical health being a barrier to exercise, they had all 
experienced an injury. 
 
5.3.2.4.2 Influence of healthcare practitioners 
HCP advice could be either positive or negative.  Four participants said that they had 
been advised not to exercise by HCPs.   
‘They advised me to do no exercise basically at the hospital until they felt like I could.’ 
Participant B 
 
Some participants (who were successfully exercising) described how helpful and 
supportive (of exercise) they had found healthcare staff. 
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 ‘I was a bit cautious, erm, about, erm, doing anything to start [laughs] with, really, but I spoke 
to the nurses and they were just, you know, within reason, they just said, ‘Carry on your life as 
normal,’ really’ Participant N 
‘because when I asked about the fact that I go running, ‘Yeah, that’s brilliant. That’s great,’’ 
Participant M 
 
However, one participant who was general positive about HCP support did comment 
that this wasn’t routinely offered. 
‘my team have been brilliant with me so far, and it’s perhaps something I haven’t remembered 
necessarily to ask when I’m there, but at the same time I’m not sure it’s that, sort of, offered 
that freely [right], erm, about exercise.’ Participant N 
 
 
Other participants, however, had received less helpful advice, with four even being 
advised not to exercise by healthcare practitioners.  This was cited by participants 
from more than one site. 
‘Because I was asking in the hospital, I kept going, have you got a gym here? ‘oh, you’ve got 
diabetes, you can’t be going to the gym’ and stuff like that.’ Participant D 
‘They advised me to do no exercise basically at the hospital until they felt like I could.’ 
Participant B 
‘I don't think you should be told not to do anything. I really don't’ (Participant B). ‘No, I think 
that's wrong. It's negative.’ Participant C 
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Several participants thought that they had been given conflicting advice about 
exercise and diabetes, and felt that some HCPs weren’t well informed about T1D.  
Participants found this frustrating . 
‘because it seems like, you know, everybody seems to have slightly different things to say 
about it, whoever I ask.’ Participant H 
‘I also have a problem though, that you’ve got doctors in a hospital telling one thing to you, not 
the diabetic team, another doctor telling you you're type 2.’ Participant K 
 
Importantly, those participants who reported doing most activity (J, K and O) were 
amongst the group who had had positive experiences. Conversely, those participants 
who reported doing no exercise at all (C, D, and H) had either been told not to 
exercise or received conflicting advice. 
 
5.3.2.4.3 Individual barriers to exercise 
Twenty-one different barriers to increasing exercise levels were mentioned (Table 
5-3) most commonly hypoglycaemia and work commitments (nine participants each).  
Barriers fell into four categories, either external (medical, time, work and 
environment) or internal (social and personal, psychological).  Participants tended to 
cite a variety of external factors, with only a few discussing internal barriers. 
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5.3.2.5 Theme 5 - Confidence 
The confidence of a participant both in their ability to perform activities and manage 
their blood glucose around exercise was a major factor in influencing a participant’s 
determination to increase their exercise levels. 
‘well…is there any way I could improve activity levels? I think probably once I get more 
confident, give me six months, you know I've not been a diabetic six months, I've got to settle 
in,’ Participant K 
 
When considering confidence, participants described three areas; managing 
diabetes, exercise and managing diabetes around exercise. 
Some participants felt they had little control over their diabetes, or that something 
had knocked their confidence, whereas others had developed or maintained 
confidence in their ability to cope with blood glucose fluctuations. 
 
‘when I was getting my - my insulin right, I was thinking yeah, this is quite simple to do and 
then it went off the swan, you know, swanny’ Participant L 
 ‘because I've had this problem where everything has gone a bit odd, for the last couple of 
weeks, I think it's set me back a bit and perhaps I want to be more confident, I want to make 
sure I've got my background insulin right’ Participant K 
I’m a lot more aware of being out on my- even just being out on my own, especially at the 
beginning, sort of, if I was asked to babysit and I, kind of, went, ‘Oh, are you sure you trust 
me? What if something happens to me?’ Participant N 
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Some participants lacked confidence in exercising prior to their diagnosis, others 
weren’t sure if there were any special considerations due to their diagnosis. 
‘I was never good [at exercise] at school’ Participant M 
 
Other participants discussed their confidence in exercising now that they had been 
diagnosed with diabetes. 
‘my confidence is, I at the moment, erm I've had a couple of sessions when I've been doing 
gardening and I've said oh, my legs feel a bit wobbly. Then I go and take a reading and then 
I've realised I'm like 3.5 reading, [right] and that worried me a little bit,’ Participant K 
‘Now I'm just - I'll get on with it like anything else really, but I'll just take in mind that it's 
something I need to think about when I'm preparing for a session.’ Participant E 
‘I’ve been given numbers to aim for at the start of exercise, so check before you start and if it’s 
about that then go ahead.  If it’s a bit lower then have a little snack of something.  I’ve got 
quite a lot of information about sport.’ Participant O 
 
There was a wide spectrum in the confidence levels amongst participants, from those 
for whom the anxiety around managing their diabetes during activity prevented most 
physical activities (e.g. participant C) to those who had confidence in their ability to 
manage their blood glucose and had concrete plans to increase their exercise levels 
(e.g. participants E and N). 
‘Nothing’s going to override my ambition to do what I want to do.’ Participant E 
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The biggest influences on participants’ determination to improve activity levels were 
motivation and confidence.  Participants broadly fell into three groups; those 
confidently building up their activity levels or who had concrete plans to do so 
(CONFIDENT), those keen to increase exercise levels but inhibited by their anxieties 
(mainly relating to diabetes management) (CONCERNED) and those not particularly 
interested in currently increasing activity levels (AMBIVALENT).  Even the 
participants with high confidence levels had concerns about some aspects of 
diabetes management. 
 
Several factors emerged that may contribute to an individual’s confidence levels.  
The most important to the majority of participants was information regarding the 
management of their diabetes around exercise.  In addition, time since diagnosis, 
experience (both prior experience of exercise and experiences since diagnosis) and 
confidence in and communication with the healthcare team were also important.  
Many participants mentioned information and education about the management of 
blood glucose during exercise in this context. 
While many participants felt that they had received inadequate information about the 
management of diabetes around exercise, some felt that they had got all the 
information they needed and one felt that they had had more than enough 
information. 
Information people said that they needed ranged from which exercises were suitable 
for someone with diabetes and which to avoid, to what to expect with blood sugars 
during exercise, to information on the benefits of exercise to people with T1D. 
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‘I need more explanation of - into things, what you can do and what you can't do.’ Participant 
C 
‘Erm so yeah, as I say, if I was better informed about what exercise could do to blood sugar 
levels, then maybe I'd have got back into it quicker.’ Participant H 
‘Yeah I wasn't aware, I thought that, as soon as I did exercise it would happen immediately as 
well, that my sugars would drop and then I'd go funny - so I'd thought I'd be fine the first time I 
went to the gym, because I thought oh, feel fine, after I'd done it, and then a couple of hours 
later I'd had a hypo, as I didn't realise, nobody told me that that would happen as well.’ 
Participant B 
‘so I assume err that there are, there are some benefits to it.’ Participant H 
‘Educating them that they understand the benefits of exercise; that maybe will encourage 
them to do it, really.’ Participant M 
 
 
Prior experience of exercise and experiences of exercise since diagnosis with 
diabetes could have either a positive and negative impact on participants’ confidence 
(see 5.3.4 Case studies in this chapter).  For example, participants with previous 
positive experiences of exercise (e.g. D, E and N) were more confident than those 
who hadn’t (e.g. M) and those who had experience problems with hypoglycaemia or 
performance since diagnosis (e.g. B) were also less confident. 
 
The relationship of the participant with their healthcare team was important with 
some participants getting a lot of support and information (e.g. N, O) and others 
having negative experiences such as being advised not to exercise (B, C, D), 
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information about activity and blood glucose management not being forthcoming (B) 
and getting different messages about diabetes from different healthcare practitioners 
(e.g. generalist verses specialist personnel) (participant K). 
 
 
Several participants felt that the information/knowledge about how to manage 
diabetes during exercise was out there but just not accessible. 
‘Information. Because I mean Olympic athletes are doing it, so they must have some kind of 
regulatory system that they know about that helps you while you’re exercising. I mean that 
would be helpful to disseminate that information’ Participant D 
‘I mean like yeah, if, if there was some like, you know, stuff like perfect rule book for if you do 
X amount of this type of exercise, you know, your blood sugar might be changing by such 
amount, or something like that.’  Participant H 
 
It was important to participants that they be seen as an individual and not as a 
‘person with diabetes’. 
‘because diabetes affects everybody in different ways. It's got to do.’ Participant C 
Some participants stressed the importance of being treated as an individual when 
planning education or giving advice (A, B, C, E, H, N, and O) 
‘Yes, yeah, because I mean I know, I know it's a different case for every person and all that 
sort of thing’ Participant H 
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‘that's just going to be an average of a load of research of a load of different people, but not 
everybody would fit into that category.’ Participant B 
Both the content and the timing of that advice were felt to be important.   
‘I mean I've - trying to like get a group together of like, you know, different people with all 
different sorts of backgrounds and lifestyles whatever and then trying to do something that's 
maybe like acceptable for all of them, when maybe some were quite fit beforehand and others 
[yeah] weren't at all, then err yeah, erm that could be a bit tough.’ Participant H 
 
Group Participants (number) 
CONFIDENT E, H, J, K, O (5) 
AMBIVALENT F, G, L (3) 
CONCERNED A, B, C, D, I, M, N (7) 
Table 5-4 – Identifying participants to confidence group 
 
5.3.3 Suggestions to improve activity levels 
Participants made a number of suggestions of ways to improve activity levels.  A few 
felt that they would not need any further encouragement or motivation as they had 
plans in place.  Ideas included additional education, supervised or group activity 
sessions, a programme of gradually increasing exercise, help with goal setting and a 
fitness advisor.  Although some participants had mentioned cost as a potential barrier 
to increasing activity levels, no-one felt that assistance with this would be particularly 
helpful. 
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5.3.3.1 Educational material 
Nearly all participants felt that education about diabetes management was vital in 
helping improve their exercise levels.  Some felt that they needed more than they 
had already been given, while others felt that they had had all they required but this 
had been important.  The participants who were most confident about increasing their 
activity levels tended to be happier about the information that they had received. 
 ‘some kind of health organisation to kind of bring forward a website or pamphlet or whatever 
about people who want to do sports with diabetes type 1 or even diabetes type 2 now and how 
to deal with certain things and prepare for them.’ Participant E 
 
Some participants (e.g. participant F) felt overwhelmed by the information they had 
already been given (although this had not specifically included management of 
diabetes during exercise) and did not want further information at this time, but 
thought that it might be useful in the future.  Other participants were happy with the 
timing of their education or would have preferred more information sooner. 
 
 
 
5.3.3.2 Supervised or group exercise 
Many participants suggested an exercise group, with other people with T1D, or 
supervised exercise sessions, with staff who training in the management of T1D.  
Having a trainer with specific expertise in T1D was important to most, as several 
92 
 
participants had experienced ill-informed remarks from members of the public, 
however, generally it was not felt that it would need to be a healthcare professional.  
One person suggested that although specific expertise in the trainer was desirable, if 
there was easy access to advice from the healthcare team, it may not be required.  
The proposal of group activity sessions was not universally liked and was rejected by 
some, who preferred to exercise under their own steam.   
‘My dad had a heart attack last year and he got help from the hospital and the hospital gym 
and he was monitored in a way that he could feel confident with going and doing exercise and 
helping him - help his heart and diabetics don't get that.’ Participant B 
 
5.3.3.3 Fitness advisor 
Regular contact with a fitness advisor, particularly one with knowledge of T1D, was 
suggested by some as a potential motivator to improve activity levels.  Even 
participants who were happy setting their own programme and targets felt that these 
regular checks would not be unhelpful.  Some participants wanted specific advice on 
a training programme, while others wanted the regular contact and reassurance of 
someone with greater experience advising them.  For some participants, it was very 
important that the advisor be able to guide them on diabetes management as well as 
exercise training. 
‘So you could see a nurse at the hospital or see like a fitness erm - fitness expert at a gym 
because then you're actually at the place you're going to do it, and you're seeing everybody 
else doing it, so you might go ‘I'll do it’.’ Participant D 
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5.3.3.4 Gradual introduction of exercise 
Help in the form of advice on types of activities, and how to build this up was 
suggested as potentially helpful by some. Others, generally those with previous 
experience of exercising successfully, felt that this would be unnecessary.  In 
addition, most welcomed the idea of some-one checking up on their progress and 
thought that they would find this motivating.  
‘I probably would want advice of how if they say I want you to increase erm from 30 minutes 
walking to an hour walking, or to doing abs in the gym from half an hour to 30 minutes, yeah,’ 
Participant K 
 
5.3.3.5 Targets 
On a similar note, in general participants felt that setting targets for them to achieve 
would motivate them to increase their exercise more.  In particular, if there was a 
regular check on progress with an advisor.   
‘I find targets very helpful because I know then - I know what I have to try and get to - I know I 
have to try and [hmm] reach really.  [yeah]  It's a bit of competition as well.’ Participant J 
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5.3.4 Case Studies 
 
5.3.4.1 Case study 1 – CONFIDENT exerciser  
 
Participant O 
O is already exercising for at least 2 hours a week.  He enjoys competitive sports, for 
example badminton and golf.  His main reasons for exercising are the enjoyment that 
it gives him and the social aspect of playing with other people. Since being 
diagnosed with diabetes about a month ago, he has felt more committed to ensuring 
that he takes regular exercise.  He has experienced hypoglycaemia during exercise 
but has subsequently received advice regarding insulin dose adjustment and 
carbohydrate intake which he had found really helpful.  He has also got a good 
relationship with his healthcare team and knows who to contact if he runs into any 
further problems.  When he exercises he feels that he is prepared and is confident in 
managing his blood glucose levels.  
‘you’ve just got to be prepared for [hypoglycaemia]’ 
‘if you’re supposed to do exercise and you’ve got [type 1 diabetes] then you need to be taught 
how to manage it’ 
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5.3.4.2 Case Study 2 – WORRIED about exercising 
 
Participant B 
B has always been active, she describes herself as ‘never still’.  She has an active 
job, which requires her to be out walking much of the day and in her leisure time she 
likes to swim, play squash and go to the gym several times a week.  She is keen to 
keep up her activity levels since being diagnosed with diabetes however, she was 
initially told not to exercise which she feels has adversely affected her confidence.  
She hasn’t tried to swim or play squash yet as she is worried about the effect this will 
have on her blood glucose.  She has not yet gone back to work and is concerned that 
she won’t be able to manage on her return. 
She has instigated a discussion about exercise with her healthcare team (she did not 
feel that it was forthcoming) and has tried to exercise on several occasions.  She is 
frustrated however with regular hypoglycaemia and poor performance.  She feels that 
hypoglycaemia is defeating the object of exercise as she has to eat more and is 
becoming worried that hypoglycaemia may be causing her some permanent harm 
that she is not yet aware of.   
‘that was quite scary, the fact that I don't even feel like I can go to the gym and look after 
myself and then, just in case I have [a hypo], because I'm going to be on my own’ 
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5.3.4.3 Case Study 3 – AMBIVALENT about increasing exercise levels 
 
Participant F 
F feels that he does enough exercise at present.  He estimates that the walking he 
does during working hours adds up to around 2 hours a week but he doesn’t do any 
leisure time activity.  The main reason that he doesn’t do more is a lack of motivation.  
He is struggling with his diagnosis and finding it difficult to manage the appointments 
he is required to attend with his healthcare team.  He feels that he has had more 
information than he is able to process at the present time and this has not included 
anything specifically about exercise.  He is not worried about hypoglycaemia but this 
may be because he has not yet experienced it.  
‘at the moment I’m not really thinking about it too much, ‘cause I’m trying to get my head round 
it [diabetes] still.’ 
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5.4 Discussion 
 
This is the first qualitative interview study to examine the attitudes and barriers to 
exercise in patients newly diagnosed with T1D.  We have identified five themes 
discussed by patients when they are asked about exercise levels.   These are; 
existing attitudes to exercise, feelings about diagnosis, perceptions about the 
consequences of exercise, barriers to increasing exercise and, confidence in 
managing blood glucose. 
Around half of participants reported a decline in activity levels around the time of their 
diagnosis.  This is an important finding, as if this is true in the wider population of 
T1D and it is not addressed, patients may be less willing to be active than the 
general population and not benefit from the health improvements associated with 
higher levels of activity.  It is reassuring that participants wanted to increase their 
exercise levels as a way to improve their health after a diagnosis of T1D and this 
should be encouraged.  It is possible that following diagnosis, patients are keen to 
improve their lifestyle, as is seen in studies of cancer survivors (Demark-Wahnefried 
et al. 2005; Satia et al. 2004), and HCPs could make use of the ‘teachable moment’. 
In general, exercise was felt to positively impact on health.  Some participants were 
unsure of the benefits or concerned they may harm themselves through exercise.  
These concerns could be addressed by the healthcare team during diabetes 
education. 
Many of the barriers identified here have been previously identified in healthy people, 
as well as people with other chronic diseases including those with longstanding T1D 
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(Brazeau et al. 2008; Plotnikoff et al. 2006; Chaudhury et al. 2008; Korkiakangas et 
al. 2009; Courneya et al. 2008; Rimmer et al. 2008; Slade et al. 2014).  However, our 
interviewees placed greater emphasis on fear of hypoglycaemia than previous 
studies of patients with longstanding T1D (Lascar et al. 2014). Furthermore, the 
finding that some diabetes patients are being advised not to exercise by HCPs has 
not previously been identified in T1D qualitative studies and was cited by participants 
from three different sites.  Physician advice has been previously mentioned only in 
the context of survivors of colorectal cancer (Courneya, Friedenreich et al. 2005).   
 
Increasing exercise uptake in patients with type 1 diabetes has clear health benefits 
and we should be encouraging all patients to undertake at least 150 minutes a week 
(the minimum level of activity recommended by the CMO) (Chief Medical Officers of 
England  Wales, and Northern Ireland 2011).  Those who are already successfully 
exercising at diagnosis of T1D should be encouraged to continue to do so.  For those 
whose activity levels are suboptimal, the time of diagnosis might be an ideal 
opportunity to reinforce the health benefits of exercise and effect behaviour change, 
a ‘teachable moment’.   
 
This study identifies a number of ways in which improvement in exercise levels might 
be facilitated in patients with newly diagnosed T1D.  In this group particularly, it is 
critical that confidence in managing diabetes around exercise is addressed. 
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Some interventions that were identified in this study and that may improve the 
confidence of people newly diagnosed with T1D and facilitate improved exercise 
levels were; consistent advice from HCPs, support from diabetes teams for exercise, 
patient education and time to adjust to the diagnosis. 
Participants were frustrated by being given conflicting advice or being told incorrect 
information (e.g. that you have type 2 diabetes) by HCPs.  There was an expectation 
that healthcare professionals will have a certain level of knowledge about diabetes, 
and this expectation is not being met.   
It may be that HCPs are uncertain about advising patients with T1D regarding blood 
glucose management during exercise.  Further work on knowledge and educational 
needs of healthcare staff was developed as a result of this study and is ongoing. 
It may also be that correct advice about management of diabetes around exercise 
was seen as contradictory.  This is not straightforward, and dependent on both the 
type of exercise undertaken and the length of time spent exercising, getting this 
information across to patients in a clearer way may be necessary. 
Those participants who were successfully exercising reported getting a lot of support 
from their diabetes team.  It is difficult to say whether this was the reason they were 
successfully exercising or whether because they were exercising they obtained the 
information that they required.  It was suggested by one participant that although the 
knowledge and support was there in the team it wasn’t forthcoming unless you 
brought up exercise specifically (which patients may not do if they have been advised 
not to exercise).  Diabetes teams should positively encourage exercise from 
diagnosis with T1D. 
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A lack of confidence in managing blood glucose levels around exercise was 
attributed to a lack of information by most people.  Resources for patients about 
blood glucose management around exercise are scarce and although several 
participants reported searching for these, only one had actually been given any 
written information.  Information on the health benefits of exercise in T1D would have 
been valued by the majority of study participants.   
A significant number of participants talked about the number of appointments that 
they had to attend since diagnosis, the fact that they were constantly injecting insulin 
and checking their blood sugar.  Their priority was to ‘get their diabetes right’ before 
adding more complexity into the mix.  Some patients will need more time than others 
to adjust to their illness.  Others will want to get back to normal as soon as possible 
and felt that exercise would help them regain ‘normality’. 
 
This study describes the attitudes and barriers to exercise in adult patients newly 
diagnosed with T1D; the first qualitative interview study to do so.  Recruitment was 
from five UK sites, covering both large teaching and district general hospitals, and 
participants spanned a large age range.  It has identified new themes and barriers as 
well as characterising potential interventions to increase activity levels in patients 
with T1D.   
It is likely however that the study participants were more interested in exercise than 
those who declined and interest in exercise education and management of diabetes 
around exercise may be lower in the general clinic population.   
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5.5 Summary 
Many barriers to exercise were identified by this group.  Some were not particular to 
diabetes e.g. time, cost and the weather.  Other factors were specific to people with 
diabetes and some specific to, or more significant for people newly diagnosed with 
diabetes (such as fear of hypoglycaemia and lack of confidence dealing with 
diabetes). 
Exercise should be encouraged from diagnosis (not discouraged and perhaps at this 
time they are more amenable lifestyle change. 
Advice needs to be made available both to healthcare professionals and patients with 
T1D.  Written guidelines for both healthcare professionals and patients have been 
developed as a result of this work (see Appendix E for participant booklet) and further 
study into attitudes and knowledge of both groups is underway.  We need to help 
patients develop confidence managing their diabetes both generally and around 
exercise, this is happening for some patients but not all. 
 
5.6 Recommendations 
1. Further research is required into the knowledge and education of both patients 
with T1D and healthcare professionals regarding the management of diabetes 
around exercise. 
2. The development of educational materials for patients and healthcare 
practitioners to aid the management of T1D around exercise. As a result of 
this study, we have developed a patient information booklet which guides 
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patients through blood sugar and carbohydrate management around exercise 
in diabetes (this was used Phase 2 and is shown in Appendix E ). 
3. Ensure easy access for patients with newly diagnosed T1D to their healthcare 
team especially when trying to increase exercise levels. 
4. An individualised approach to exercise advice and content and timing of 
education of patients with newly diagnosed T1D. 
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6 BASELINE CHARACTERISTICS OF PARTICIPANTS 
6.1 Introduction 
 
The purpose of this chapter is to discuss the characteristics of a group of adult 
patients with recently diagnosed T1D who joined an exercise intervention trial (i.e. 
Phase 2) and to review the inclusion/exclusion criteria and randomisation protocols 
used in the Extod study in the light of these. 
 
6.2 Methods 
Methods and analysis are as described in section 3.2. 
 
6.2.1 Participants 
Participants were recruited to the Extod Study as described in Chapter 3.  The data 
in this chapter relate to all patients who attended at least one screening visit. 
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6.3 Results 
 
77 participants attended at least one screening visit.   
Three participants who attended screening visits subsequently entered Phase 1.  The 
reasons for this were  
 participant’s GAD antibody result was negative (n=1),  
 participant changed their mind about progressing (n=1) and  
 participant decided to plan for pregnancy (n=1). 
Sixteen participants withdrew prior to randomisation or were found to be ineligible, 
leaving 58 people who were randomised.  
6.3.1 Demographics 
The characteristics of screened participants are detailed in Table 6-1There was a 
male preponderance in recruited participants.  The majority (67/77) of participants 
identified themselves as White British. Male and female participants were broadly 
similar in terms of age, ethnicity, family history and cigarette smoking.  Men tended to 
report a higher alcohol intake than women.  
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 Male Female All participants 
Number of patients (%) 49 (64) 28 (36) 77 (100) 
Age at diagnosis – yrs ±SD    
 mean 31.4 32.8 31.9 
 median 30 29 30 
 range 17-55 17-57 17-57 
Ethnicity – number of patients (%)    
 White British 43 (87) 24 (86) 67 (87) 
 Other 6 4 10 (13) 
 
Other White 
Black/Black British – African 
Asian/Asian British – Indian 
Mixed – White and Black African 
Mixed – White and Asian 
Other Mixed Background 
Other Ethnic background 
3  
1 
0 
1 
0 
0 
1 
0 
1 
1 
0 
1 
1 
0 
 
 
 
Family history, n (%) 18 (36) 15 (54) 33 (43) 
Smoking – number of patients (%)    
 Current 9 (18) 6 (21) 15 (20) 
 Ex 9 (18) 5 (18) 14 (18) 
 Never 31 (63) 16 (57) 47 (61) 
Alcohol consumption (units/wk)    
 Mean 5.8 4.5 5.4 
 Median 4 1.5 2 
 Range 0-28 0-30 0-30 
Table 6-1 - Demographics of Screened Participants in the Extod study 
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6.3.2 Diabetes presentation  
In this group of adults with newly diagnosed T1D, 16/77 (21%) presented in diabetic 
ketoacidosis (DKA).  Those presenting with DKA had a shorter duration of symptoms 
prior to diagnosis (5.7 vs 13.4 weeks, p<0.01).  There was no association between 
presentation at diagnosis of T1D and any of age, gender, ethnicity, BMI or family 
history. 
 
Male 
(n=49) 
Female 
(n=28) 
All 
participants 
N 
Presentation of diabetes – 
number of patients (%) 
  
  
 
Hyperglycaemia without 
acidosis 
38 (78) 23 (82) 60 (78) 77 
 Diabetic Ketoacidosis 10 (20) 6 (21) 16 (21) 77 
 uncertain 1 (2) 0 1 (1) 77 
Length of symptoms before 
diagnosis – weeks  
    
Mean 13.4 8.5 11.6 77 
Median 8 6 8 77 
Range 0-208 1-52 0-208 77 
Table 6-2 - Presentation of diabetes 
 
The onset of T1D is more insidious the older the patient is at presentation with 
patients reporting many weeks of symptoms.  There was no statistically significant 
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correlation between participant’s age and duration of symptoms prior to their 
diagnosis however, there was one outlier reporting four years of symptoms.  If this 
outlier is disregarded, the association between age and duration of symptoms is 
statistically significant (Pearson r=0.44, 95%CI 0.2375 to 0.605, r2=0.19) implying a 
longer duration of symptoms/onset of T1D with increasing age. 
 
6.3.3 Anthropomorphic and biochemical measures 
Mean BMI was slightly lower than that seen in the general population  (BMI from the 
Health Survey for England (HSE) 2013, an annual survey of 8000 adults in England,  
was 27.4 kg/m2 men and 26.9 kg/m2 women (Health and Social Care Information 
Centre 2014)) as was waist circumference (however, both rose with age in the HSE 
and the Extod study population was younger). 
Percentage body fat was higher in women than men. 
 
Blood pressure was lower in women than men and ten participants had a systolic 
blood pressure (SBP) greater than 135mmHg. 
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 Male Female All 
participants 
N 
Waist circumference (cm), 
mean 
89.3 81.3 86.4 77 
Waist-to-Hip Ratio, mean 0.93 0.84 0.90 77 
Weight (kg) 81.0 67.1 76.0 77 
BMI (kg/m2), mean 25.2 24.7 25.0 77 
SBP (mmHG) 126 117 123 77 
DBP 76 73 75 77 
Resting HR 71 73 72 77 
Body fat, % 18.2 30.0 22.7 59 
Table 6-3 - Anthropomorphic measures in screened participants at baseline 
 
Glycaemic control was slightly better in women than men at study entry (although the 
difference was not statistically significant). Serum total cholesterol was similar in both 
genders. 
 Male Female All 
participants 
N 
HbA1c at baseline (mmol/mol) 80 71 77 73 
Total Cholesterol (mmol/L) 4.48 4.41 4.46 62 
Table 6-4 - Biochemical measures in screened participants at baseline 
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6.3.4 Antibody status 
75 patients attended at least one screening visit and had antibody status determined.  
In total, 56 participants had at least one autoantibody detected (74.3%).  49 (65.3%) 
were positive for GAD antibody (defined as ≥33 DK units/ml), 32 (43.2%) for IA-2A 
and 29 (39.2%) for ZnT8A.  Of the 26 GAD negative patients, 7 had either IA-2, ZnT8 
or both antibodies present (3 had both, 3 had only ZnT8A and 1, only IA-2A).  These 
seven participants would have been excluded under the original inclusion/exclusion 
criteria, but were included in the study following the changes to the inclusion criteria 
in November 2012. 
 
 Male 
(n=49) 
Female 
(n=26) 
All 
participants 
N 
GAD antibody positive – 
number of patients (%) 
30 (61) 19 (73) 49 (65.3) 75 
Average titre (in those with 
positive GADA), GAD units 
367.32 540.26 434.38 49 
Number with at least 1 positive 
antibody 
34 22 56 (74.6) 75 
Table 6-5 - GADA status of screened participants 
 
Out of the 75 participants with autoantibody results, nineteen did not have any of the 
three autoantibodies detected (25.3%), 20 had just one (26.7%), 16 had two (21.3%) 
and 20 had all three (26.7%). 
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Antibody No with +ve abs, (%) Mean titre±SD (in antibody positive) 
GADA 49 (66.3) 434.4 ± 300.1 IU 
IA-2A 33 (44.6) 205.3±145.4 U 
ZnT8A 30 (40.5) 43.88±57.62 U 
Table 6-6 - Mean antibody titre in participants with positive autoantibodies 
 
Of the participants who did not identify themselves as White British (n=9), 5 were 
GAD antibody positive, and 3 had multiple antibodies present. 
 
6.3.4.1 Factors associated with positive antibodies 
Participants with at least one positive autoantibody were more likely to have a lower 
waist circumference (p=0.019), systolic BP (p=0.023), diastolic BP (p=0.011) and 
HOMA-IR (p=0.005).  Other factors, such as gender, ethnicity, presentation of 
diabetes, baseline mean AUC C-peptide, BMI, weight, and estimated VO2max were 
not significantly different between those who were antibody positive and those who 
were not. 
 
 
6.3.5 Baseline Physical Activity 
Baseline physical activity measures in screened participants are outlined in Table 
6-7. 
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 Male Female All 
participants 
N 
Reported time spent exercising 
prior to recruitment, mins 
    
Median 45 100 80 67 
Range 0-600 0-450 0-600 67 
MVPA, mins/week     
Mean ± SD 288.5±153.8 221.2±126.3 288.5±152.9 69 
Median 265 205 250 69 
Range 22-689 5-76 22-689 69 
Estimated VO2max, mls/kg/min, 
mean ± SD 
35.5±8.3 28.8±5.0 33.2±7.9 61 
Table 6-7 - Baseline physical activity measures 
We wished to determine whether once participants were recruited to the study 
activity levels increased.  Prior to visit 1, participants were sent an accelerometer to 
wear for one week.  This was repeated after visit one.  Paired data were obtained in 
only 17 subjects, however in these there was no difference in MVPA before and after 
visit 1 (mean MVPA 270.6 minutes/week (95%CI 173.3 to 368) prior to visit 1 and 
mean MVPA 270.6 minutes/week (95%CI 188.5 to 368.2) after visit 1). 
Overall participants reported a fall in exercise after diagnosis (see Figure 6-1D).  29 
participants (39%) reported a decrease in the amount of exercise taken per week 
after diagnosis whereas only 10 reported an increase (14%). 
Participants were on the whole active with 53/68 (78%) exceeding 150 minutes 
MVPA per week at baseline and 35/68 (51%) already doing in excess of 240 minutes 
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MVPA per week.  When asked to provide a figure for the amount of activity they were 
undertaking, 47/54 (87%) participants underestimated physical activity.  
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Figure 6-1 – Scatter diagram comparing physical activity measures used in Extod 
study. (A) MVPA before and after visit 1 (V1) is well correlated (r=0.9279, 95%CI 
0.8073 to 0.9741, r2=0.861 p<0.0001). (B) There is no correlation between MVPA 
(measured by accelerometer) and reported physical activity.  (C) Estimated VO2max 
and MVPA are correlated (r=0.38, 95%CI 0.1149 to 0.5955, p=0.0049).  (D) 
Participants reported a decline in physical activity after diagnosis with T1D (120 
minutes vs 60minutes, median number of minutes exercise per week before and after 
diagnosis), p=0.0047 (Wilcoxon signed rank test). 
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6.3.6 Baseline C-peptide 
Meal stimulated C-peptide was analysed on 66 participants at baseline.  All 
participants who underwent a MMTT had a stimulated C-peptide more than 
200nmol/l at 90 minutes (one of the inclusion criteria). 
 
 Male Female All 
participants 
N 
Mean 90min C-peptide – 
pmol/l ± SD 
1139±1091 985±385 1086±908 66 
Mean AUC C-peptide – 
pmol/l ± SD 
933±775.3 792.4±225 884±659.3 66 
Mean urinary C-peptide ± 
SD 
1.69±0.92 2.37±1.14 1.92±1.04 64 
Median HOMA2-IR (range) 0.70 (0.16-5.9) 0.58 (0.13-4.2) 0.68 (0.13-5.9) 65 
Table 6-8 - Measures of beta-cell function and insulin resistance 
 
One participant had a mean AUC C-peptide greater than 5000 pmol/l (more than 
twice as high as the next highest participant).  This subject was antibody negative 
and, in retrospect, is likely to have type 2 diabetes.    
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6.3.7 Randomised patients 
The demographic data of randomised participants are given in Table 6-9.  There are 
a number of areas where the two groups are not equal.  A lower proportion of 
antibody positive patients, fewer patients presenting in diabetic ketoacidosis, longer 
prodromal symptomatic period and fewer smokers have all been suggested to 
improve the rates of clinical remission, all of these factors were present in the control 
arm.  The higher proportion of female participants in the intervention group, however, 
is a predisposing factor to slower loss of beta cell function.   
It can be difficult to ascertain correctly whether or not a patient has T1D or another 
form, particularly soon after diagnosis, and particularly in adults who may have an 
indolent course of diabetes irrespective of which type they have, therefore, the fact 
that there are more antibody negative, fewer DKA presentations and longer 
symptomatic prodromal participants in the control arm may represent participants 
who actually may be better classed as having type 2 diabetes or another form.  
Indeed one participant, randomised to the control arm, was tested for maturity-onset 
diabetes of the young (MODY) mutations due to a strong family history and negative 
autoantibodies, tested positive for the HNF 4α mutation and was withdrawn from the 
study shortly after randomisation.  As demonstrated in section 6.3.6, one participant 
had a significantly greater mean AUC C-peptide (greater than 5000 pmol/l) than any 
other participant indicating substantial insulin resistance and likely type 2 diabetes.  
In addition, three other screened participants who were antibody negative also had a 
BMI of greater than 35 making type 2 diabetes a possible diagnosis.  Two of these 
were randomised, however, one withdrew shortly after randomisation and therefore, 
only one completed the study.     
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 Control  
(n=28) 
Intervention 
(n=30) 
Age – yr   
Mean ± SD 30.81±9.25 33.78±11.44 
median 29.84 30.86 
range 17-49 17-57 
Gender – number of patients (%)   
Male  24 (62) 15 (38) 
Female 4 (21) 15 (79) 
Ethnicity – number of patients (%)   
 White British 28 (56) 22 (44) 
 Other 2 (29) 5 (71) 
GAD antibody positive* – number of patients (%)
 
14 (35) 26 (65) 
Number of patients with at least one autoantibody (%) 17 (61) 27 (90) 
Days from diagnosis to randomisation    
 mean±SD (days) 84.70±18.71 77.56±20.22 
 range 45-126 15-115 
Weight at baseline (kg) 77.36±15.80 73.5±12.19 
BMI 24.69±4.15 24.83±3.40 
Mean 90min C-peptide ± SD (pmol/l) 1282±1335 955.1±395.6 
HbA1c at baseline (mmol/mol) 75.22±24.77 74.57±24.74 
Presentation of diabetes – number of patients (%)   
 Hyperglycaemia without acidosis 24 (52) 22 (48) 
 Diabetic Ketoacidosis 3 (27) 8 (72) 
 uncertain 1 (100) 0 
Length of symptoms pre-diagnosis – weeks (median, range) 8, 0-208 5.5, 1-52 
Smoking – number of patients (%) 2 (20) 8 (80) 
Table 6-9 - Baseline demographic data for randomised participants 
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6.4 Discussion 
In this chapter I have described the characteristics of adult patients with newly 
diagnosed T1D who are willing to participate in a trial of an exercise intervention.  To 
obtain fifty eight randomised participants, seventy seven people attended at least one 
screening visit (approximately 25% were either ineligible or withdrew during the 
screening visits).   
 
6.4.1 Demographics 
There were more male than female recruits. Diagnoses (in children) are 
approximately equal among both genders in the UK (The DIAMOND Project Group 
2006). It is possible that the higher number of male recruits was due to the nature of 
the intervention, with an exercise intervention study being more appealing to male 
patients than female patients. 
The majority of participants described themselves as of ‘white – British’ ethnic origin, 
despite the relatively large ethnic minority populations in some centres (e.g. 
Birmingham).  This is in keeping with the WHO observations in the DIAMOND study 
that European and North American populations have higher rates of T1D diagnoses 
than African and Asian populations.  
The proportions of patients who smoke were similar to that of the general UK 
population (Health and Social Care Information Centre 2014). 
A similar proportion of participants reported being diagnosed in DKA to that seen in 
other studies of patients with T1D (21% in Extod vs approximately 25% (Lokulo-
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Sodipe et al. 2014; Jefferies et al. 2015).  These studies were of children, and did 
however, report a higher incidence of DKA in very young children, under the age of 4 
years. 
 
6.4.2 Anthropomorphic measures 
Mean BMI was at the upper end of the normal range in both men and women, 
however, it was lower than that of the general UK population.  There are a number of 
reasons that this might be the case; prior to diagnosis many patients with T1D lose 
weight due to insulin deficiency, people willing to enter an exercise trial might be 
more health conscious than the average population and the age range of the group 
was lower than that used in the population study. 
Mean WHR was in the overweight range for both men and women (World Health 
Organization 2008). 
 
6.4.3 Antibody status 
Antibody positivity in the Extod cohort is lower than has previous been reported.  In a 
population of children and young adults (mean age 10.9 years, range 0.7-20.8 years) 
the prevalence of GADA, IA-2A and ZnT8 was 79.4%, 78.0% and 70.0% respectively 
(Long et al. 2012), compared to 65.3%, 44% and 40% in this study.  Antibody 
positivity is more frequent in younger children and a registry study in Belgium has put 
the proportion of patients over the age of 15 years with one detectable autoantibody 
at 82%.  Ours is comparable to this with 56/74 (76%) with at least one autoantibody 
detected. 
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If we were to exclude those cases those with BMI>35 and no detectable 
autoantibodies (n=4) (who may well be better classed as type 2 diabetes), and one 
who subsequently tested positive for the HNF 4α mutation, the prevalence in our 
cohort goes up to 71.0% (GADA), 47.8% (IA-2A) and 43.5% (ZnT8), still lower than 
that seen in Long et al. 2012.  As IA-2A and ZnT8 are generally seen later in the 
disease process, perhaps this is reflective of the slower progression of T1D usually 
seen in patients diagnosed at an older age, and they are less likely to be present 
around the time of diagnosis.  The mean age at diagnosis in this study was higher 
than that in other studies, most of which include children and/or adolescents who 
often make up the greatest proportion of the cohort. 
 
6.4.4 Physical activity 
This study is the first to measure physical activity in patients recently diagnosed with 
T1D.  The most active participant recorded 689 minutes and the least active 22 
minutes of MVPA per week at baseline on the accelerometer.  Activity levels were 
high in this group, with 78% exceeding the CMO’s recommended target of 150 
minutes of exercise per week.  Over-reporting of physical activity compared to 
objective measurement has been reported previously in the Health Survey for 
England 2008 (Health and Social Care Information Centre 2009), however, we found 
that participants tended to underestimate physical activity levels.  Additionally, 
participants reported a decrease in the amount of activity they performed since 
diagnosis with T1D, which corroborates a similar finding among the participants in 
the qualitative study (Chapter 5). 
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In those participants who wore an accelerometer before and after consent, there was 
no difference in measured physical activity.  At baseline, there was correlation 
between MVPA and fitness.  Self-report did not correlate with either measure.  Low 
correlation between different measures of physical activity has been demonstrated in 
healthy people (Ainsworth et al. 2000).   
 
At randomisation, one of the stratification criteria was fitness.  The cut off value for 
estimated VO2max was 42.8ml/kg/min for men and 34.6ml/kg/min for women with 
the aim of dividing the cohort in two.  Above this value participants were judged to be 
“more fit”. However, overall just 9/60 screened participants were in the “more fit” 
group.  The mean estimated VO2max was much lower than this cut off and therefore, 
use of a lower estimated VO2max for stratification would be appropriate in future. 
Compared to other RCTs recruiting adult patients with T1D for exercise interventions, 
our cohort was slightly less fit, particularly the men.  For example, in (Laaksonen et 
al. 2000) adult males with T1D had a baseline mean VO2max of approximately 43.4 
and 42.0mls/kg/min (intervention and control groups) and female patients with T1D 
(Wallberg-Henriksson et al. 1986), a baseline mean VO2max of 30.2 and 
28.0ml/kg/min  (also intervention and control groups).  Our mean VO2max at 
baseline was 35.5mls/kg/min in men and 28.8mls/kg/min in women. 
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6.4.5 Stimulated C-peptide  
None of the screened participants had a 90 minute meal-stimulated C-peptide of less 
than 200pmol/l.  This is recommended as an inclusion criterion for intervention 
studies in newly diagnosed T1D to ensure participants have adequate beta-cell 
function to preserve at the outset of the study (Greenbaum & Harrison 2003).  
However, the data presented here would suggest that most adult patients would have 
adequate beta-cell function within three months of diagnosis.  Either this does not 
need to be an inclusion criterion, or perhaps the eligibility period could be extended in 
studies of only adult patients with T1D.  A larger cohort of patients would be needed 
to verify this. 
During randomisation, one of the stratification parameters was 90 minute C-peptide 
of 600pmol/l.  The aim of this was to have approximately equal spread of participants 
with higher or lower stimulated C-peptide in both study arms.  However, analysis of 
this baseline data demonstrates that only 10/66 participants had a stimulated C-
peptide of less than 600pmol/l.  The median C-peptide in all screened patients was 
933pmol/l, in those who were antibody positive it was only slightly lower at 
878.5pmol/l.  To achieve an even split of this cohort into those with greater insulin 
secretion and those with less insulin secretion, a higher cut off of around 900pmol/l 
would have been more appropriate. 
 
At baseline meal-stimulated C-peptide was positively associated with 
anthropomorphic measures associated with insulin resistance, weight, BMI and 
WHR.  
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6.5 Recommendations 
6.5.1 Antibody measurement - requirement for randomisation 
The presence of one or more autoantibodies is recommended as an inclusion 
criterion for trials of preservation of beta-cell function in T1D (Greenbaum & Harrison 
2003).  It is not normally used for the diagnosis of T1D in the UK outside of clinical 
trials (National Institute for Clinical Excellence 2015).  Early in the course of the 
study, the trial team decided to remove this inclusion criterion from the Extod study.  
The outcome of this was a rate of antibody positivity of just under 75%. Using a 
clinical diagnosis, rather than antibody positivity, as the criterion for inclusion for the 
study means that the study population is more comparable to the population of T1D 
patients seen in clinical practice.  However, it does mean that there is more chance 
of participants entering the study who have another form of diabetes, such as the 
participant who was subsequently diagnosed with monogenic diabetes.  Removal of 
the antibody positivity criterion also had the advantage of speeding up the screening 
and randomisation process (as the antibody samples had a two week turnaround 
time for GADA only) reducing the number of participants who were excluded on the 
time from diagnosis criterion.  In addition, there were 7/75 participants who were 
GADA negative, but did have other antibodies detected.  These participants would 
have been excluded under the initial inclusion criteria. 
Nevertheless, given the imbalance in the study arms with regards to antibody 
positivity, further consideration of the use of this criterion either for inclusion or as a 
stratification at randomisation needs to be performed. 
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6.5.2 Measures of physical activity 
Participant’s estimation of their activity levels per week is not a reliable alternative to 
accelerometer measured MVPA or fitness (estimated VO2max).  The exercise 
question is of little use in determining physical activity and therefore should not be 
used in future studies. 
There was no difference in the accelerometer data before and after consent (visit 1).  
In a future study, this could be measured just once, e.g. after consent to reduce the 
burden on participants. 
Use of a lower estimated VO2max cut off for stratification would result in a more even 
split of participants (for example, 35mls/kg/min for men and 30 mls/kg for women). 
 
6.5.3 Meal stimulated C-peptide 
All participants had a 90 minute meal stimulated C-peptide of greater than 200nmol/l.  
This was one of the inclusion criteria and analysis of this introduced complexity and 
delay into the randomisation timescale (which was already tight).  Although this is 
recommended as an inclusion criteria (Greenbaum & Harrison 2003) for trials looking 
at beta-cell preservation in T1D, it may be that in trials of adults this is not necessary 
(as the numbers failing on this criteria would be small).  Alternatively, trials recruiting 
only adult participants could consider having a longer eligibility period, which would 
expand the pool of potential participants and reduce the time pressure on the 
screening process. 
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Reassessment of the value of stimulated C-peptide used for stratification during 
randomisation would be of worth.  A level of 900pmol/l (rather than 600pmol/l) would 
have led to a more equal split of the groups. 
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7 INCREASING PHYSICAL ACTIVITY 
7.1 Introduction 
The effect of the intervention on physical activity will be explored in this chapter. This 
will also explore anthropomorphic and biochemical changes. 
 
7.2 Methods 
The timing of measurement of physical activity and fitness, and the methods used for 
measuring these have been outlined previously (section 3.2.3.4) 
Support with statistical analysis for this chapter and chapter 8 was provided by 
Mohammed Mostazir and Rod Taylor from the Wellcome Trust Biomedical 
Informatics Hub, College of Life and Environmental Sciences, University of Exeter. 
 
7.3 Results  
7.3.1 Motivational Interviewing  
Overall, the intervention group had more contact with the study team than the control 
arm.  The mean total time for visits 2-17 was 759.4 minutes (95% CI 633.8 to 884.9) 
in the intervention arm compared to 652.6 minutes (95% CI 554.8 to 750.5) in the 
control group.  This is not surprising as additional visits were included for the 
intervention arm to discuss exercise.  When adjusted for the number of visits, the 
mean time per visit was lower in the intervention arm (68.1, 95% CI 61.4 to 74.8 
minutes) than the control group (81.7, 95% CI 76.7 to 76.7), this is likely to be due to 
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the fact that the additional visits tended to be shorter than those that were 
undertaken by both groups as at each visit the visit time in intervention group tended 
to be longer (see Figure 7-1C).  The mean additional time spent by the intervention 
group at joint visits was just 5 minutes. 
An average of 104 minutes was spent per participant in the intervention group for 
exercise motivation.  A greater amount of time was spent at the start of the 
intervention (Figure 7-1B). 
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Figure 7-1 - Participant time spent on post-randomisation visits. Mean visit time for 
each group (A).  Amount of time spent on exercise motivation in the intervention arm 
(B).  Breakdown of time spent by visit for each group (C). 
 
7.3.2 Anthropometric data over course of study 
There was no difference in waist circumference or WHR between the groups or 
across the study in either group.  Body fat percentage was higher in the intervention 
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group at all time points, probably due to the greater proportion of female participants 
in this group. 
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Figure 7-2 - Changes in waist circumference (A), WHR (B) and body composition (C) 
over the study 
 
Weight and BMI increased slightly in both arms over the course of the study.  Weight 
and BMI were higher in the intervention group at baseline and the difference in BMI 
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between the two groups was larger at the end of the study.  The difference was 
minimal and not clinically significant. 
 Weight, kg (mean ± SD) BMI (mean ± SD) N 
Control group    
Baseline 77.36±15.80 24.69±4.15 28 
6 months 78.98±14.11 25.02±4.22 21 
12 months 79.71±14.55 24.21±4.30 20 
Intervention group    
Baseline 73.50±12.19 24.83±3.40 30 
6 months 74.67±14.18 25.33±4.31 24 
12 months 75.14±13.13 25.57±4.18 21 
Table 7-1 - Mean weight and BMI at baseline and after 6 and 12 months. 
The mean weight gain was 2kg in the first 6 months and then 0.4kg in the second 
half of the study.  
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Figure 7-3 - Weight (A) and BMI (B) changes over the course of the study 
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Systolic blood pressure was slightly lower in the intervention arm at all time points.  
Diastolic blood pressure and resting heart rate were similar in both groups. 
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Figure 7-4 - Changes in blood pressure (systolic (A) and diastolic (B)) and resting 
heart rate (C) during the study 
 
7.3.3 Metabolic parameters 
7.3.3.1 Lipids 
There was a trend to lower total cholesterol and triglycerides in the intervention group 
during the study, while both of these parameters tended to increase in the control 
arm.  HDL cholesterol tended to be lower in the control arm at baseline and this 
130 
 
difference was maintained for the duration of the study.  The small cohort sizes mean 
that these trends were not statistically significant. 
Glycaemic control as represented by HbA1c was similar in both groups at each time 
point in the study. 
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Figure 7-5 - Changes in lipid profile (total cholesterol (A), HDL cholesterol (B), 
triglycerides (C)) and glycaemia (D) during the study 
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7.3.4 Activity levels 
As discussed in section 3.2.3.4, physical activity was assessed by participants’ self-
report, accelerometer and fitness. 
 
7.3.4.1 Adherence to exercise targets 
Sixty-one percent of participants reported meeting activity targets (at least 150 
minutes, aiming for 240 minutes of exercise per week) on average across the study.  
There was some variation between visits in the proportion of participants reporting 
meeting the target (range from 42% to 86%), however, overall the proportion did not 
substantially change with time. 
The data for this analysis are incomplete with many missing values (37% of data are 
missing).  Overall, 24% of participants admitted to falling below the activity targets, 
while 39% felt that they had achieved their target levels. 
 
7.3.4.2 Moderate-Vigorous Physical Activity  
Participants in the intervention arm increased MVPA by six months and maintained 
the increase at 12 months, although this increase was very much smaller than we 
had aimed to achieve (mean adjusted increase in MVPA amounted to approximately 
five minutes per day).  However, fitness also increased at six months and the 
increase was maintained for the duration of the study.  In contrast, MVPA and fitness 
was lower at six months in participants in the control arm and although there was a 
small increase by the end of the study, they remained less active and less fit than the 
intervention arm.  
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As discussed in chapter 6, physical activity levels were high at study entry.  The 
proportion achieving the target amount of physical activity remained approximately 
stable and was similar across both groups (82% control and 79% intervention groups 
achieved 150 minutes MVPA overall, 57% control and 56% intervention achieved 
240 minutes MVPA on average over the whole course of the study). 
 Baseline 6 months 12 months 
Control group, n 26 15 14 
Achieving 150 minutes/week, n (%) 21 (81) 13 (87) 11 (79) 
Achieving 240 minutes/week, n (%) 16 (62) 8 (53) 8 (57) 
    
Intervention group, n 28 18 15 
Achieving 150 minutes/week, n (%) 22 (79) 13 (72) 13 (87) 
Achieving 240 minutes/week, n (%) 13 (46) 11 (61) 9 (60) 
Table 7-2 - Proportion of participants achieving activity targets at baseline, 6 
months and 12 months.  MVPA was also assessed at 3 and 9 months (data not 
shown).  
 
Figure 7-6 shows the change in MVPA over the course of the study.  At baseline the 
weekly MVPA in the intervention group was lower than that of the control group (by 
35 minutes).   The absolute (unadjusted) difference in MVPA between the two groups 
was 28 minutes at 6 months and 32 minutes at 12 months.  Due to the wide 
distribution of MVPA, this difference was not significant.  When adjusted for baseline 
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MVPA, age and gender, the difference in MVPA between the intervention and control 
groups was just 5 minutes per day. 
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Figure 7-6 – Change in MVPA during the study.  Mean MVPA tended to fall in the 
control arm and rose in the intervention group, although this was not significant. 
(A) demonstrates the absolute change in MVPA per week over the study and (B) 
the change in MVPA per day adjusted for baseline value, age and gender. 
 
7.3.4.3 Fitness 
A similar trend was seen in estimated VO2max.  The intervention group started less 
fit and fitness increased, whereas the control group became less fit during the study 
follow-up.  This trend is shown in Figure 7-7, again substantial variability in values 
has led to wide confidence intervals and therefore, these changes are not significant.  
VO2max has been adjusted for age, gender and baseline value in these analyses.   
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Figure 7-7 – Change in fitness during the study.  Mean VO2 max tended to fall in the 
control group and rise in the intervention group (unadjusted) (A) and adjusted for 
age, gender and baseline value (B). 
 
 
7.3.5 Insulin resistance 
Measures of insulin resistance (fasting insulin and HOMA2-IR) were similar in the 
intervention and control arms at baseline.  During the study, the intervention group 
tended to have lower fasting insulin levels and lower HOMA2-IR scores, indicating a 
reduction in insulin resistance.  Conversely, these parameters tended to increase in 
the control arm during the study.  Fasting glucose remained constant in the two 
groups.  Again, the confidence intervals are wide, and the difference is not 
significant. 
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Figure 7-8 – Change in measures of insulin resistance over the study.  Fasting 
glucose remained unchanged (A), whereas fasting insulin fell in the intervention 
arm (B), HOMA2-IR (C) fell in the intervention arm. 
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7.4 Discussion 
Just under two thirds of participants reported meeting their exercise targets.  In fact, 
data from accelerometer suggests that around 80% were achieving at least 150 
minutes MVPA per week.  This contrasts with under 10% of the general population 
(Aresu et al. 2008).  Objectively, despite a small increase in MVPA, improvements in 
fitness and insulin sensitivity were seen in the intervention group.  The control arm 
did not appear to increase activity levels, the overall trend was for a reduction in 
MVPA, fitness and insulin sensitivity in this group indicating that there was little new 
exercise uptake. 
The increase in MVPA in the intervention arm, in contrast to the decrease in the 
control arm, resulted in a difference of 5 minutes per day.  This is a lower between 
group difference than we anticipated and is primarily due to the high levels of activity 
at baseline and in the control group throughout the study (mean MVPA was greater 
than 240 minutes per week in both groups at baseline, 6 months and 12 months).   
Activity levels achieved in the Extod intervention group (mean MVPA 42.7 minutes 
per day at six months and 41.3 minutes per day at twelve months) are comparable to 
those seen in a group of adolescents with T1D undergoing a 16 week community 
exercise prescription program where the mean MVPA was 42 minutes per day 
(Michaliszyn & Faulkner 2010). 
Fitness (estimated VO2max) did increase in the intervention arm, by just under 3% at 
six months and 8% at twelve months.  This increase is lower than that seen in other 
RCTs involving adult T1D patients with supervised exercise interventions.  These 
studies (lasting between three and five months) demonstrated an increase in 
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VO2max of between 6 and 13% (Laaksonen et al. 2000; Fuchsjager-Mayrl et al. 
2002; Wallberg-Henriksson et al. 1986). 
 
The increase in MVPA and fitness did not come at the expense of higher rates of 
hypoglycaemia (see Chapter 4).  In fact, all participants were active and the minor 
hypoglycaemia rate was less than one per week.  This is the first study to 
demonstrate that exercise can be safely performed by adult patients with recently 
diagnosed T1D. 
There did appear to be a change in insulin resistance.  Fasting insulin levels 
appeared to fall in the intervention group, while increasing in the control arm.  This is 
despite constant fasting blood glucose and similar improvements in glycaemic 
control.  This indicates an improvement in insulin sensitivity in the intervention group 
and is consistent with previous studies examining the effect of exercise on insulin 
resistance in T1D (Yki-Jarvinen et al. 1984; Wallberg-Henriksson et al. 1982). 
 
 
7.5 Recommendations for further work 
The initial aims of this study were to maintain a larger difference in physical activity 
between the control and intervention arms (the original aim was for a difference of 
150 minutes per week).   The actual difference in MVPA was much smaller and 
increases in fitness were also small.  A future study aiming to increase physical 
activity in this group will either need to recruit sedentary participants or to increase 
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physical activity in the intervention arm by a greater amount.  Recruiting sedentary 
participants may prove difficult, as demonstrated in Chapter 4, patients willing to take 
part in an exercise study may well be already comparatively active.  Comparisons of 
supervised and unsupervised exercise interventions are few.  One meta-analysis of 
the efficacy of interventions to increase physical activity, did find a larger increase in 
the one included trial of supervised exercise than in the studies of unsupervised 
motivational techniques (Foster et al. 2005).  Another study comparing a six month 
supervised exercise program with motivational behaviour change techniques found 
that, although total activity levels in both groups were similar, the supervised exercise 
groups performed more vigorous and very vigorous exercise (Dunn et al. 1999).  A 
supervised exercise program should, therefore, be considered in a future trial to 
improve both activity levels and intensity. 
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8 BETA-CELL FUNCTION  
8.1 Introduction 
The Extod study was a pilot feasibility study and the primary outcome measures were 
related to recruitment, adherence and exercise uptake.  Decline in beta-cell function 
was a secondary outcome and we wished to explore this outcome to enable us to 
design a larger trial including power calculations. 
 
8.2 Methods 
8.2.1 Subjects 
The subjects and methods used are as described in earlier chapters.  The subjects 
are either all screened participants or those that were randomised.  These groups are 
described in Chapter 3. 
 
8.2.2 C-peptide measurement 
Conduct of the MMTT and analysis of the samples is described in Chapter 3. 
All of the analyses in this chapter use mean AUC C-peptide, unless otherwise 
specified.   
 
8.2.3 Statistical analyses 
The intention-to-treat analyses (that is the analysis of the effect of group on beta cell 
function in the randomised Extod patients) were performed by Dr M Mostazir and 
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Professor R Taylor of the University of Exeter.  All other statistical analyses and 
graphical representation were performed by me. 
 
 
8.3 Results 
 
8.3.1 Measuring beta-cell function 
In this study, we measured C-peptide during the MMTT to obtain mean AUC C-
peptide as a marker of beta-cell function.  Other markers of beta-cell function that 
have been reported include; fasting C-peptide, peak C-peptide during the MMTT, 90 
minute C-peptide and UCPCR.  The peak C-peptide is the value peak value recorded 
during the 120 minute test. 
The relationship between these is shown in Figure 8-1. 
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Figure 8-1 - Association between mean AUC C-peptide during the MMTT and peak 
C-peptide (A), C-peptide at 90minutes (B), fasting C-peptide (C), and UCPCR (D) 
when measured during the baseline MMTT.  
 
Stimulated C-peptide is the recommended outcome measure for clinical trials of beta 
cell function in T1D (Palmer et al. 2004).  In this study, (log) mean AUC C-peptide 
was strongly correlated with both (log) peak C-peptide (r=0.9746, 95%CI 0.9587 to 
0.9844, r2=0.9499, p<0.0001) and (log) 90 minute C-peptide (r=0.9562, 95%CI 
0.9292 to 0.973, r2=0.9143, p<0.0001).  There was good correlation between AUC C-
peptide and both (log) fasting C-peptide (r=0.8437, 95%CI 0.7561 to 0.9016, 
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r2=0.7118, p<0.0001) and (log) HOMA2 B (r= 0.628, 95%CI 0.4535 to 0.7561, 
r2=0.3943, p<0.0001).  Correlation between mean AUC C-peptide and UCPCR was 
statistically significant (r=0.4373, 95%CI 0.2125 to 0.6181, r2=0.1912, p=0.0003), 
however, this relationship was the weakest of all measures.  Similar associations 
were seen between the parameters at later time points.   
In Figure 8-1 it can be seen that there is an outlier with mean AUC C-peptide of 
>5000pmol/l.  This individual was antibody negative and it is likely that this participant 
had type 2 diabetes.  Removing this individual from the analysis did not significantly 
affect the correlation results. 
 
8.3.2 Factors associated with beta-cell function at baseline 
8.3.2.1 Age and gender 
In our (adult) population, there was no significant difference in baseline C-peptide in 
males and females, mean AUC C-peptide in men was 346.3pmol/l (95% CI 282.9, 
409.6) compared to 369.4pmol/l (95% CI 274.2, 464.6) in women.  Age was not 
associated with baseline C-peptide, Spearman’s co-efficient r=-0.0157 (95% CI -
0.2780 to 0.2486). 
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Figure 8-2 – There was no association between baseline mean AUC C-peptide 
and either gender (A) or age (B). 
 
8.3.2.2 Ethnicity 
There does appear to be a lower mean AUC C-peptide at baseline in participants of 
White British origin and those of other ethnic origin, mean AUC C-peptide 859pmol/l 
(95%CI 288.5, 1042) compared to 1042pmol/l (95%CI 306.5, 739.5), p=0.02, 
although there is significant overlap of the confidence intervals.  Due to the low 
number of participants identifying their ethnic background as other than White British 
this was impracticable to breakdown further into specific ethnicities. 
 
8.3.2.3 Presentation of diabetes 
We determined the presentation of diabetes in the Extod cohort (i.e. whether with 
acidosis or not) by patient notes (where available) and history from the participant.  It 
was not possible to determine the presentation in one participant.  There was no 
difference in baseline C-peptide in those who had ketoacidosis at presentation (mean 
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AUC c-peptide 898.1pmol/l, 95%CI 656.6 to 1140) and those who presented with 
hyperglycaemia alone (mean AUC c-peptide 886.5pmol/l, 95%CI 686.8 to 1086). 
 
There does appear to be an association between the duration of symptoms 
experienced prior to diagnosis and baseline C-peptide levels, with those participants 
reporting a shorter duration of symptoms appearing to have a higher mean AUC C-
peptide at baseline.  This was not statistically significant (Spearman r=-0.2365, 
95%CI -0.4706, 0.02865, p=0.0713). 
 
 
8.3.2.4 Lifestyle factors 
Within the Extod cohort there was no difference in baseline C-peptide between the 
groups who smoked (mean AUC C-peptide 366.1 (95%CI 261.5, 470.6)), who had 
stopped smoking (mean AUC C-peptide 409.1 (95%CI 281.4, 536.9) and those who 
had never smoked (mean AUC C-peptide 338.8 (95%CI 268.2, 409.4) (shown in 
Figure 8-3) or with alcohol consumption (data not shown). 
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Figure 8-3 - Effect of smoking on baseline mean AUC C-peptide 
 
8.3.2.5 Anthropomorphic measures 
Significant association was seen between baseline mean AUC C-peptide and BMI, 
weight but not WHR. 
Log baseline AUC C-peptide (again discounting the prominent outlier) was 
significantly correlated with with log BMI (r=0.351, 95%CI 0.117 to 0.548, p= 0.0042, 
r2=0.123) and log weight (r=0.305, 95%CI 0.066 to 0.511, p= 0.013, r2= 0.093). 
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Figure 8-4 – Relationship between mean AUC C-peptide and BMI (A), weight (B) 
and WHR (C).  (D) demonstrates the effect of a prominent outlier (open circle) 
who is likely to have type 2 diabetes. 
 
8.3.2.6 Glycaemic control 
There was no relationship between HbA1c and mean AUC C-peptide at baseline. 
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8.3.2.7 Autoantibodies 
Mean AUC C-peptide at baseline was significantly greater in those participants with 
no detectable antibodies (1324pmol/l, 95%CI 713.4 to 1935) when compared with 
those with at least one autoantibody (743.1pmol/l 95%CI 657.5 to 828.6), p=0.0014.  
Mean AUC C-peptide was very similar in those with one, two or three autoantibodies 
(Figure 8-5A). 
Although mean AUC C-peptide (see Figure 8-5B) was consistently higher in antibody 
negative participants for each autoantibody, this was only statistically significant for 
ZnT8A (mean AUC C-peptide 672.2 vs 1031pmol/l, p=0.0024). 
0 1 2 3
0
1000
2000
3000
Number of antibodies detected
M
e
a
n
 A
U
C
 C
-p
e
p
ti
d
e
, 
p
m
o
l/
l
A
*
G
A
D
A
+
G
A
D
A
-
IA
-2
A
+
IA
-2
A
-
Zn
T8
A
+
Zn
T8
A
-
0
500
1000
1500
2000
2500
B
Antibody status
M
e
a
n
 A
U
C
 C
-p
e
p
ti
d
e
, 
p
m
o
l/
l **
 
Figure 8-5 - Association between mean AUC C-peptide at baseline in all screened 
participants and number of detectable autoantibodies (A) and antibody status for 
each measured autoantibody (B). 
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Number of antibodies present N (%) Mean AUC C-peptide, pmol/l 
0 19 (25.3) 1324±1147 (n=16) 
1 20 (26.7) 773.6±318.2 (n=17) 
2 16 (21.3) 738.9±243.3 (n=15) 
3 20 (26.7) 717.7±339.7 (n=18) 
Table 8-1 - Mean AUC C-peptide is associated with antibody status.  Not every 
participant who had samples taken for antibody assays attended for the MMTT, 
hence the different values of N. 
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8.3.2.8 Insulin Resistance 
Both weight-hip ratio (r=0.3961 95%CI 0.1684 to 0.5836, r2=0.1569, p=0.0011) and 
HOMA2-IR (r=0.5657, 95%CI 0.3716 to 0.7124, r2=0.32, p<0.0001) were significantly 
correlated with mean AUC C-peptide at baseline.  As the data were not normally 
distributed, mean AUC C-peptide and HOMA2-IR were logarithmically transformed 
prior to analysis. 
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Figure 8-6 - Relationship between mean AUC C-peptide at baseline and HOMA2 IR 
(A) and WHR (B).   
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8.3.2.9 Exercise 
There was no significant association between MVPA and mean AUC C-peptide at 
baseline.  Log baseline AUC C-peptide (discounting the outlier) was significantly, and 
negatively, correlated with log VO2max (r=-0.282, 95%CI -0.502 to -0.027, p= 
0.0308, r2= 0.079). 
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Figure 8-7 - Scatter diagrams showing relationship between mean AUC C-peptide 
at baseline and estimated VO2max.  The whole data set (A) with the prominent 
outlier represented by an open circle, and a close up of the data with the outlier 
removed (B). 
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8.3.3 Change in beta-cell function during the study 
8.3.3.1 Beta-cell function overall 
Figure 8-8 demonstrates that beta cell function declined overall during the year in 
those patients who were randomised.  In those patients with assessments of beta-
cell function at both baseline, six and/or twelve months, mean AUC meal-stimulated 
C-peptide fell by 0.8% by six months and 19.3% by the end of the study.  
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Figure 8-8 – The change in mean C-peptide at each time point during the MMTT 
(A) (only those with more than one measure are included in this graph).  Mean 
AUC C-peptide at baseline, 6 months and 12 months is shown in (B). 
 
8.3.3.2 Beta-cell function trends during the study 
The secondary outcome of the study was to investigate whether exercise had an 
effect on beta-cell function in patients with a recent diagnosis of T1D.   
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Mean AUC C-peptide was higher at baseline and remained constant in the control 
arm through the study.  In the intervention arm, there appears to be a downward 
trend in mean AUC C-peptide as the study progresses.  Due to the wide confidence 
intervals, particularly in the control group, this difference was not statistically 
significant.  Both groups appear to show a transient improvement in mean AUC C-
peptide at 6 months which is lost by twelve months when this is adjusted for baseline 
covariates (Figure 8-9).  
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Figure 8-9 - The effect of exercise on beta-cell function (intention to treat 
analysis).  (A) shows the change in unadjusted mean AUC C-peptide over time. In 
(B) mean AUC C-peptide has been adjusted for baseline value, gender, age, 
baseline HbA1c, antibody status, baseline MVPA and baseline VO2max.  
 
8.3.3.3 Responders 
In the DCCT, ‘responders’ were defined as participants who maintained a stimulated 
C-peptide of greater than 200pmol/l.  A further group of participants with a stimulated 
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C-peptide of greater than 500 pmol/l was also identified (The Diabetes Control and 
Complications Research Group 1998).  
In the Extod study, all screened participants had a 90 minute stimulated C-peptide of 
greater than 200pmol/l.  At 6 months, only 2 out of 42 participants (one from each 
study arm) had lost beta cell function such that 90 minute stimulated C-peptide was 
less than 500pmol/l, and by 12 months only these same two participants had 90 
minute stimulated C-peptide under 200pmol/l.   
Maintenance of C-peptide levels has also been used to assess response to beta-cell 
preserving therapies.  Herold et al. 2005 described ‘responders’ as those who 
maintained mean AUC C-peptide, that is there was a fall of less than 7.5% in mean 
AUC C-peptide of from the initial value.  There was no significant difference in the 
proportion of participants who maintained C-peptide by this definition between the 
two groups. 
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8.3.3.4 Factors affecting beta-cell function in the Extod cohort  
As the exercise intervention did not have a significant effect on beta-cell function in 
this group, factors other than exercise were examined in the whole group. 
 
8.3.3.4.1 Age/Gender 
There were significant associations between the change in mean AUC C-peptide and 
both age and gender (see Figure 8-10).  Percentage change in mean AUC C-peptide 
was significantly correlated with age (r=0.326, 95%CI 0.01996 to 0.5756, p=0.038, 
r2=0.106) in the group as a whole, but the relationship was only apparent in the 
control arm when the groups were analysed separately.  There was a trend towards 
a larger decline in beta-cell function in women over the course of the study, although 
this was not statistically significant.  
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Figure 8-10 - Relationship between beta-cell function and age (A) and gender (B) 
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8.3.3.4.2 Ethnicity 
The number of participants with other ethnicities in whom data was available at more 
than one time point was very few (n=5) and therefore, analysis of this is limited.   
There was, however, no apparent difference in decline in beta-cell function in 
participants who identified themselves as ‘White – British’ when compared to those 
who identified themselves with other ethnic backgrounds.   
0W 6W 12
W 0n 6n 12
n
0
500
1000
1500
2000
M
e
a
n
 A
U
C
 C
-p
e
p
ti
d
e
, 
p
m
o
l/
l
Baseline
6months
12months
White British Other
 
Figure 8-11 - Association between ethnicity and mean AUC C-peptide 
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8.3.3.4.3 Lifestyle 
There did appear to be a trend between percentage change in beta-cell function at 
the end of the study and smoking status, although this was not statistically significant.  
There was no significant relationship between alcohol consumption and decline in 
beta-cell function. 
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Figure 8-12 - Relationship between change in mean AUC C-peptide, smoking status 
(A) and alcohol consumption (B). 
 
8.3.3.4.4 Presentation 
The change in mean AUC C-peptide was greater in those who presented in DKA 
than those who presented with hyperglycaemia without acidosis (mean percentage 
change -47.5% (95% CI -58.37 to -36.63) in those presenting with acidosis compared 
to -13.43% (95% CI -23.8 to -3.09%) in those presenting with hyperglycaemia, 
p=0.0175).  There was significant correlation between percentage change in mean 
AUC C-peptide and the duration of symptoms prior to diagnosis (Spearman r=0.432, 
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95% CI 0.1339 to 0.6581, p=0.0048), but not in either arm individually.  This 
relationship remains significant when the outlying data point (symptoms of 4 years 
prior to diagnosis, not shown in figure) is removed from the analysis.  
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Figure 8-13 - Association between percentage change in mean AUC C-peptide over 
12 months and presentation (A) and duration of symptoms prior to presentation with 
T1D (B). 
 
8.3.3.4.5 Anthropomorphic measures 
There were no significant relationships between percentage change in mean AUC C-
peptide and baseline weight, BMI, WHR, body composition or HOMA-IR. 
 
 
8.3.3.4.6 Glycaemic control 
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There was negative correlation between HbA1c at 6 months and change in mean 
AUC C-peptide over the 12 months of the study (Spearman r=-0.449, 95%CI -0.6703 
to -0.1554, p=0.0032), suggesting that beta-cell function declines more rapidly in 
those participants with poor glycaemic control (see Figure 8-14A).  There was no 
statistically significant association between the change in mean AUC C-peptide at 12 
months and HbA1c at the end of the study, however, the numbers are very small and 
there is one outlier which skews the data (see Figure 8-14B). 
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Figure 8-14 - Relationship between percentage change in mean AUC C-peptide over 
the study and HbA1c at 6 months (A) and 12 months (B) 
 
 
 
8.3.3.4.7 Antibody status 
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There was no significant change in beta-cell function by six or twelve months in those 
participants with no detectable autoantibodies at study entry.  In comparison,  those 
participants with at least one detectable autoantibody had a significant decline in 
beta-cell function over the twelve months in the study (p=0.0097).  If the two groups 
(intervention and control) are analysed for the effect of antibody status separately, a 
similar relationship is seen in the control arm to that seen in the whole group (data 
not shown).  In the intervention arm, mean AUC C-peptide declined to a similar 
extent in both those with detectable autoantibodies and those without.  The number 
of participants in the intervention arm who did not have detectable autoantibodies 
was, however, small (n=4). 
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Figure 8-15 - Effect of antibody status on C-peptide decline.  
 
8.3.3.4.8 Physical activity and insulin resistance 
There was no association between MVPA at baseline, 6months or 12months and 
change in mean AUC C-peptide.  In addition, there was no significant correlation 
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between fitness or change in fitness at any time point, and change in mean AUC C-
peptide over the 12months of the study. 
 
8.3.3.4.9 Baseline C-peptide 
There was no significant correlation between percentage or absolute change in mean 
AUC C-peptide over the course of the study and the baseline mean AUC C-peptide.  
Equally, there was no significant difference in baseline mean AUC C-peptide 
between the ‘responder’ group and the ‘non-responder’ group. 
 
 
8.4 Discussion 
This study did not demonstrate an effect of exercise on beta-cell function in adult 
patients with recently diagnosed T1D.  It does, however, describe the rate of decline 
of beta-cell function and the factors that have affected decline in beta-cell function in 
a group of adult patients with recently diagnosed T1D. 
 
Measures of beta cell function showed good correlation particularly mean AUC C-
peptide and 90minute or peak C-peptide. These latter measures still require a meal-
stimulated test and, therefore, hold little advantage over mean AUC C-peptide in 
terms of burden on participant or research team.  UCPCR would be an easier way to 
assess beta-cell function, particularly if the sample could be obtained by the 
participant at home (as described in the study undertaken by a group from Exeter, 
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UK (R. E. Besser et al. 2011)).  In the Extod group there was not such good 
correlation between UCPCR and mean AUC C-peptide.  In the Exeter study, the 
association between UCPCR and 90minute C-peptide was best in those with least 
beta-cell function (a 90minute C-peptide of under 500pmol/l), it is therefore possible 
that UCPCR is less accurate in patients with higher meal-stimulated C-peptide.  
Hence, this test is less useful in assessing beta-cell function early in the disease 
process.   This is in keeping from the finding in the MonoPepT1De study, where 
UCPCR was less reliable in the first six months (Tatovic et al. 2016). 
 
Beta-cell function declined more dramatically in the second half of the study (in 
contrast to the decline seen in the TrialNet studies which showed a constant decline 
in the first year after diagnosis, with a slower rate of loss thereafter (Greenbaum et al. 
2012)).  This would suggest that any future study intervention study aimed at slowing 
the rate of decline of beta-cell function should continue for at least one year.  
 
We chose to stratify randomisation on baseline meal-stimulated C-peptide and 
fitness.  In this cohort, the only factors that were significantly related to greater loss of 
beta-cell function were age, presentation of diabetes, duration of symptoms prior to 
presentation and having at least one detectable autoantibody.  The caveat here is 
that this analysis was performed on the whole group (as the numbers involved were 
too small to analyse the arms separately), and any potential effect of the intervention 
is a confounding factor not accounted for. 
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Participants with positive autoantibodies at baseline had a significantly greater 
decline in beta-cell function over the course of the study.  This would suggest that it 
would be important to aim to randomise equal proportions of antibody positive 
participants to the usual care and intervention groups.  This could be done as 
originally intended, that is, to exclude antibody negative patients, or to use antibody 
status as a minimisation criteria on randomisation. 
If we refer back the baseline characteristics of the intervention and control groups 
(see Chapter 6), while the two arms of the study were reasonably equal in terms of 
age, there were differences in presentation of diabetes, duration of symptoms prior to 
diagnosis and autoantibody status.  The proportions of all of these variables were 
more favourable to the control arm. 
 
 
It is important not to conclude that this study conclusively answers the hypothesis 
that exercise affects beta-cell function in T1D for a number of reasons.  Firstly, this 
study was a pilot study to address issues of feasibility (recruitment, adherence and 
uptake) and was not sufficiently powered to address the secondary outcome.  
Secondly, (as discussed in chapter 0) the improvement in exercise level in the 
intervention group was much lower than expected, although improvements in fitness 
were of a similar level to that in other studies of T1D.  Thirdly, the intervention and 
control groups were not adequately balanced for important factors that may affect 
beta-cell function, particularly antibody status, which I have shown here, may have a 
significant effect on decline in beta-cell function.  Finally, the changes in insulin 
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resistance demonstrated in the intervention group (in Chapter 7) will have a 
significant effect on mean AUC C-peptide. 
The final point to note is that insulin secretion from the beta cell is stimulated by 
changes in blood glucose.  The amount of insulin secreted in response to increasing 
blood glucose is affected by the secretory capacity of the beta cells (beta-cell 
function) as well as peripheral insulin resistance.  The more insulin resistant an 
individual, the greater the insulin release for a given glycaemic stimulus.  An 
intervention which improves insulin sensitivity, can also demonstrate a reduction in 
insulin secretion (as measured, for example, by AUC C-peptide during a MMTT), 
however, this does not equate to a reduction in beta cell function.  In this study, the 
negative association between fitness and mean AUC C-peptide as well as the fact 
that mean AUC C-peptide declined irrespective of antibody status in the intervention 
arm, lends support to this.  Ideally, a method for correcting AUC C-peptide for insulin 
resistance in T1D is needed, as has been used previously in type 2 diabetes (Dela et 
al. 2004).  This is beyond the scope of the Extod study and further research is 
required to investigate a valid way of doing this. 
 
 
  
164 
 
8.5 Recommendations for future work 
 
Future studies of exercise and beta-cell function in adults with newly diagnosed T1D 
should: 
- Use meal-stimulated AUC C-peptide as the measure of beta-cell function 
- Have at least a one year intervention/follow-up time period 
- Aim to match intervention and control groups for age, autoantibody status and 
presentation of diabetes. 
Further research is required into methods for adjusting mean AUC C-peptide for 
measures of insulin resistance. 
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9 ADIPONECTIN, EXERCISE AND DIABETES 
9.1 Introduction 
Adiponectin is a 28kDa cytokine secreted predominantly by white adipose tissue and 
is involved in the regulation of energy homeostasis via lipid and glucose 
metabolism(Scherer et al. 1995).  It exists in three forms; a full-length, high-molecular 
weight protein, a medium-molecular weight hexamer and a low-molecular weight 
trimer (Ziemke & Mantzoros 2010).  In addition, the high-molecular weight form may 
be cleaved to form a smaller, globular fragment (Waki et al. 2003).  These different 
isoforms have different affinities for the two adiponectin receptors and appear to 
induce different metabolic pathways resulting in different actions dependant on 
receptor site (Yamauchi et al. 2002).  
Adiponectin is present in the circulation in humans in the greatest concentration of all 
the cytokines.  The level of circulating adiponectin is inversely associated with the 
degree of visceral adiposity, as well as affected by age and gender (Cnop et al. 
2003). 
 
9.1.1 The adiponectin receptor 
Two isoforms of the adiponectin receptor have been identified; known as AdipoR1 
and AdipoR2 (Kadowaki & Yamauchi 2005).  These are transmembrane G-protein 
coupled receptors and the binding of adiponectin stimulates several pathways, 
including the AMP-activated protein kinase and peroxisome-proliferator activated-
receptor α. AdipoR1 and AdipoR2 exist in most tissues, including pancreatic beta 
166 
 
cells, adipose tissue, skeletal muscle and peripheral blood mononuclear cells 
(PBMC) (Ziemke & Mantzoros 2010; Pang & Narendran 2008). AdipoR2 mRNA 
expression is positively associated with the level of circulating adiponectin and HDL 
and negatively associated with insulin resistance, obesity and glycaemia in human fat 
tissue (Bluher et al. 2007). 
 
9.1.2 The role of adiponectin in insulin resistance and glucose metabolism 
Reduced adiponectin concentrations are associated with obesity (Hu et al. 1996) and 
insulin resistance (Yamauchi et al. 2001).  Therefore, conditions associated with 
insulin resistance, including type 2 diabetes, cardiovascular diseases and non-
alcoholic fatty liver disease are associated with reduced adiponectin levels.  
Thiazolidinediones, a class of oral hypoglycaemic agent that ameliorate insulin 
resistance, increase the levels of adiponectin in patients with type 2 diabetes (Maeda 
et al. 2001). Furthermore, a causal relationship between higher levels of circulating 
adiponectin and greater insulin sensitivity, in part mediated by lower adiposity has 
been demonstrated (Gao et al. 2013). 
Administration of adiponectin has been shown to reduce blood glucose levels in wild 
type mice, mouse models of insulin resistance (ob/ob mice) and mouse models of 
T1D (insulinopaenic non-obese diabetic and streptozotocin-induced diabetic mice) 
(Berg et al. 2001; Yamauchi et al. 2001).  In these experiments, insulin levels 
remained low, indicating that improvements in insulin sensitivity were responsible for 
the blood glucose lowering effects of adiponectin rather than an increase in insulin 
secretion.   Adiponectin does, however, influence insulin secretion in mouse models 
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of insulin resistance and has an anti-apoptotic effect on beta-cells in vitro (Turer & 
Scherer 2012). 
Serum adiponectin is increased with physical training (Blüher et al. 2006).  Exercise 
upregulates adiponectin receptor expression in subcutaneous fat and skeletal 
muscle; indicating a potential role for adiponectin in the improvement in insulin 
resistance seen with increasing physical activity (Blüher et al. 2006; Bluher et al. 
2007). 
There is evidence to suggest that adiponectin plays a role in the autoimmune 
process in T1D.    In contrast to type 2 diabetes, serum adiponectin is elevated in 
T1D; moreover, higher levels of adiponectin in T1D have been associated with 
increased mortality (Forsblom et al. 2011).  Interestingly, adiponectin levels fall prior 
to the onset of T1D, perhaps mediating insulin resistance which has been identified 
as a risk factor for T1D (Fourlanos et al. 2004). 
 
9.1.3 The role of adiponectin in immunity 
In addition to actions on insulin sensitivity, adiponectin has effects on inflammation; 
affecting macrophage function and inhibiting the release of pro-inflammatory 
cytokines (Turer & Scherer 2012).  
9.1.3.1 Adiponectin receptor expression on PBMC 
AdipoR1 and AdipoR2 are expressed by PBMC (Pang & Narendran 2008).  High 
levels of adiponectin receptor expression are seen on monocytes and B cells; 
however, expression is also seen on T lymphocytes and natural killer cells (NK cells).  
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The presence of adiponectin receptors on these immune cells suggests a role for 
adiponectin in the immune response. 
Adiponectin receptor levels on PBMC are upregulated by physical activity in healthy, 
obese and type 2 diabetic subjects (Pang 2010).  In T1D, there is reduced 
expression of adiponectin receptors on monocytes (Pang et al. 2013) and B cells 
(Chimen et al. 2015) compared to healthy controls.  In monocytes this reduction was 
correlated with insulin sensitivity; that is, patients with a lower glucose disposal rate 
(more insulin resistant individuals) had lower adiponectin receptor expression on 
monocytes. 
 
9.1.3.2 Adiponectin and T cell proliferation 
The immune destruction of beta cells in T1D is T cell mediated. Although T cells 
express adiponectin receptors at only very low levels on their surface, they have high 
levels intracellularly and surface receptor expression is upregulated on antigen 
activated T cells (Wilk et al. 2011).   
Previously in our group, Dr Terence Pang has demonstrated that adiponectin can 
alter the expression of co-stimulatory molecules on APCs, affecting the ability of 
these cells to stimulate T cell proliferation (Pang et al. 2013).  In the same work, it 
was established that reduced adiponectin receptor expression on monocytes (as 
seen in T1D), is associated with attenuation of adiponectin mediated suppression of 
T cell proliferation (Pang et al. 2013).   
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9.1.3.3 Adiponectin and T cell trafficking 
Circulating lymphocytes must cross the vascular endothelium to enter inflamed 
tissue.  Leukocyte adhesion and transmigration occurs through a number of steps 
(Ley et al. 2007); including leukocyte rolling, activation, arrest and migration. These 
steps are mediated by activation of selectins, chemokine receptors and integrin 
molecules expressed on the cell surface (Kim 2014).  T cell migration is increased in 
areas of inflammation, stimulated by proinflammatory cytokines (INF-γ and TNF-α) 
which induce expression of chemokines and integrin molecules (Kim 2014).  
 
Adiponectin is involved in regulation of T cell transmigration in inflamed tissues. 
Increased endothelial adhesion and rolling of leucocytes has been demonstrated in 
the adiponectin knock-out mouse and this was ameliorated by the administration of 
adiponectin (Ouedraogo et al. 2007).  Dr Myriam Chimen, from our group, has 
demonstrated that endothelial transmigration of T cells during inflammation is 
inhibited by adiponectin.   The mechanism by which this occurs is mediated by a 
peptide from the 14.3.3 protein family (PEPITEM) which is secreted from B cells 
(Chimen et al. 2015).  Circulating adiponectin acts on adiponectin receptors on the B 
cell surface to stimulate PEPITEM release.  In turn, PEPITEM stimulates endothelial 
cells to release sphingosine-1-phosphate (S1P) which act on adherent T cells to 
inhibit transmigration. 
The reduced expression of AdipoR1 and AdipoR2 on B cells seen in T1D is 
associated with a reduction PEPITEM secretion from B cells and a release from the 
inhibition of T cell migration with adiponectin (Chimen et al. 2015).  In the same 
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study, similar findings were demonstrated in rheumatoid arthritis, another T cell 
mediated disease.   
 
While adiponectin appears to have a marked effect on aspects of the immune 
response responsible for T1D, other adipokines, such as leptin, have been 
demonstrated to have no effect on T cell proliferation and limited effect on T-cell 
transmigration (Chimen 2012). 
 
We hypothesise that serum adiponectin and adiponectin receptor expression on 
PBMC can be upregulated by exercise training patients with T1D, similar to the effect 
seen in other tissues (Bluher et al. 2007; Blüher et al. 2006), in healthy people and in 
response to changes in insulin resistance (Pang 2010).  Furthermore, we anticipate 
that by upregulating AdipoR1 and AdipoR2 expression on PBMC, we will see a 
functional impact; increased suppression of T cell migration and proliferation with 
adiponectin.  If demonstrated, suppression of migration and proliferation of T 
lymphocytes by adiponectin in T1D may elucidate a mechanism by which exercise 
could influence beta-cell function. 
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9.2 Methods 
9.2.1 Subjects 
9.2.1.1 Healthy Subjects 
Specimens were provided by Sam Shepherd/Professor Anton Wagenmakers of the 
Department of Sports science, University of Birmingham.  The study involved 
recruiting healthy, but sedentary, volunteers to undergo a 10-week exercise 
programme.  Participants exercised on a bicycle at either moderate intensity 45 
minutes, 3 times a week or underwent a programme of low-volume high-intensity 
interval training.  Subjects were all previously healthy and had normal glucose 
tolerance.  Samples were obtained in the resting state, before and after the exercise 
training period and analysed on the same day (with the exception of the PCR 
analysis). 
 
9.2.1.2 Subjects with type 1 diabetes 
Patients with recently diagnosed T1D were recruited through the Extod study.  All 
participants had venous blood samples taken at baseline and after six months.  
PBMCs from these samples were isolated and stored for future PCR analysis for 
adiponectin receptor expression.  In addition, fasting serum samples were stored and 
later used for adiponectin analysis. 
In addition those participants recruited to the Birmingham site were asked if they 
wished to participate in the Immunity study, for which they gave separate written, 
informed consent.  In the patients who gave consent for these additional samples, 
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whole blood was taken for adiponectin receptor flow cytometry, T cell proliferation 
and T cell transmigration. 
 
 
9.2.2 Materials 
A list of the reagents used for this part of the study is given in Table 9-1. 
 
  
173 
 
Reagent Supplier Catalogue 
number 
Use 
Histopaque 1119 Sigma-Aldrich 11191 PBMC Isolation 
Histopaque 1077 Sigma-Aldrich 10771 PBMC Isolation 
RPMI 1640 Gibco Invitrogen 21875 PBMC culture 
Human Adiponectin 
(recombinant) 
Enzo Life Sciences ALX-522063 PBMC culture 
Adiponectin Novonordisk  Transmigration 
CellGro SCGM CellGenix 20802 Cell culture 
FcR Blocking reagent Miltenyi Biotec 130-059-901 Flow cytometry 
Purified Protein Derivative (PPD) 
of M. Tuberculosis Tuberculin 
NIBSC PPDT Proliferation studies 
Bovine serum albumin (BSA) 
solution 
Sigma-Aldrich A8412 Transmigration 
EDTA Sigma-Aldrich E8008 Transmigration 
Tetanus Toxoid Protein Calbiochem 582231 Proliferation studies 
CD14 beads Miltenyi Biotec 130-050-201 PBL preparation  
LS Columns Miltenyi Biotec 130-042-401 PBL preparation 
RNeasy Mini Kit Qiagen 74104 RNA extraction 
M199 Gibco Invitrogen 31150-022  
2X Master Mix ABI P02016 qPCR 
Random Primers Promega C1181 qPCR 
Rnaseout. Recombinant 
Ribonuclease Inhibitor 
Invitrogen 10777-019 qPCR 
SuperScript II. RNase H- Reverse 
Transcriptase 
Invitrogen 18064-014 qPCR 
dNTPs Promega U120-3A qPCR 
Human Adiponectin Quantikine 
Kit 
R & D Systems DRP300 Adiponectin assay 
Table 9-1 - List of main reagents 
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9.2.3 Isolation of PBMC from venous blood 
Samples of venous blood were taken in EDTA.  PBMC were isolated by layering 
venous blood onto Histopaque 1119/1017 in equal quantities.  After centrifugation at 
800g for 35mins, the PBMC were collected and washed twice in RPMI 1640 media.  
The PBMC were then counted manually.   
The isolated PBMC were  
a) stored for later PCR analysis of adiponectin receptor expression, 
b) analysed for adiponectin receptor expression by flow-cytometry, 
c) cultured in various conditions to assess the effect of adiponectin on T cell 
proliferation, and 
d) utilised in assays of T cell transmigration across an endothelium. 
 
9.2.4 PCR for adiponectin receptor expression 
Real-time PCR was used to measure adiponectin receptor expression on PBMC. 
PBMC isolated from peripheral blood healthy volunteers and those taken from Extod 
trial subjects were snap frozen in liquid nitrogen and stored at -80°C. 
 
9.2.4.1 RNA extraction 
The frozen PBMC were lysed and mRNA extracted using the RNeasy Mini Kit 
(Qiagen). The manufacturer’s protocol was followed. A Nanodrop spectrofluorimeter 
(LabTech) was used to measure the concentration of mRNA following extraction. 
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9.2.4.2 Reverse transcription 
The RNA (1ug) was heated to 70°C with random primers (Promega) for 5 minutes. 
Then dNTPs (10mM concentration, Promega), Supercript buffer, Rnasout, 
Superscript reverse transcriptase (Invitrogen) were added.  This was heated to 37°C 
for one hour, followed by 95°C for 5 minutes to obtain cDNA. 
 
9.2.4.3 Real-rime PCR 
Quantitative PCR was performed in duplicate on a RT-PCR machine (ABI 7500, 
Applied Biosystems). 
Taqman gene expression assay kits (Hs00360422_m1 for AdipoR1 and 
Hs00226105_m1 for AdipoR2) were utilised along with Taqman Master Mix (Applied 
Biosystems).  Relative gene expression was calculated using the ΔΔCT normalised 
to 18s. Relative expression units (REU) were also calculated using REU=2ΔCT. 
 
9.2.5 Flow cytometry  
Flow cytometry was used to measure adiponectin receptor expression on PBMC and 
PBMC subsets as well as T cell proliferation.  The antibodies used for flow cytometry 
are given in Table 9-2.  Samples were assayed using a CyAn FACS analyser 
(Beckman Coulter) and Summit software.  Flowjo V5 (Mac) software was used for 
analysis.  Adiponectin receptor expression is given as percentage of positive cells of 
mean fluorescent intensity (MFI). 
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9.2.6 Quantification of Serum Adiponectin 
Serum adiponectin was measured in stored samples using a Quantikine ELISA 
Human Total Adiponectin/Acrp30 kit (R&D Systems). 
 
9.2.7 T cell transmigration studies 
9.2.7.1 Preparation of endothelial cells 
Primary HDMEC (Human Dermal Microvascular Endothelial Cells) were obtained 
from PromoCell (PromoCell GmbH, Heidelberg, Germany) and were cultured in the 
Antibody Supplier Fluorochrome Clone Catalogue 
number 
Rabbit anti-
AdipoR1 
Phoenix 
Pharmaceuticals 
Alexa 488/FITC  G-001-44 
Rabbit anti-
AdipoR2 
Phoenix 
Pharmaceuticals 
Alexa 488/FITC  G-001-23    
Anti-human 
CD8a 
eBioscience eFluor 450(PB) OKT8 48-0086 
Anti-human CD4 BD Pharmigen APC RPA-T4 555349 
Anti-human CD4 eBioscience eFluor 700 RPA-T4 46-0049 
Anti-human CD4 eBioscience APC-eFluor 780 OKT4 47-0048 
Anti-human CD3 eBioscience Per-CP-Cy5.5 OKT3 45-0037 
Anti-human 
CD19 
eBioscience PE-Cy7 HIB19 25-0199 
Anti-human 
CD14 
eBioscience APC 61D3 17-0149 
Anti-human 
CD56 
eBioscience PE CMSSB 12-0567 
Table 9-2 - List of Antibodies 
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manufacturers Endothelial Cell Growth medium.  The cells were passaged four times 
before use.   
 
9.2.7.2 Isolation of Peripheral Blood Lymphocytes (PBLs) 
PBL were isolated from the PBMC by subtraction of monocytes.  PBMC were labelled 
with CD14 microbeads and incubated at 4°C for 15 minutes.  The cells were then 
washed in MACS buffer and added to the LS column (Miltenyi Biotech) within a 
magnetic field.  The column was washed three times with MACS buffer.  Unlabelled 
cells (PBL) passed through the column and were collected and counted. 
 
9.2.7.3 Endothelial Transmigration 
HDMEC (adult) (PromoCell) were inspected to ensure there was an adequate 
endothelial coverage and that the cells were suitably primed.  Cells were treated with 
TNFα (100U/ml) and IFNγ (10ng/ml) for 24hours prior to use. 
 
PBL were incubated in three conditions; 
1. Control (PBL 0), incubated with media (M199 0.15%BSA) only 
2. Adiponectin (PBL AQ), PBL incubated for 1 hour prior to assay with 
adiponectin (NovoNordisk) at a concentration of 15ug/ml. (These cells were 
washed and resuspended in fresh media before the experiment as endothelial 
cells also express AdipoR.) 
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3. PEPITEM (PBL Pep), PBL incubated with media (M199 0.15% BSA) with 
20ng/ml Pepitem added immediately prior to assay. 
1million PBL in 1ml of media (+/- adiponectin or PEPITEM) were added to each well 
(one for each condition, three wells for each individual).  The cells were incubated at 
37°C for 6minutes.  The cells were washed twice with M199 0.15% BSA media to 
remove non-adherent cells, then fixed with 4% formaldehyde. 
Using a phase-contrast microscope six images, randomly acquired from the area of 
the well covered with endothelium, were acquired. 
 
9.2.7.4 Analysis 
The images obtained from the phase contrast microscope were analysed using 
ImagePro 6.2 (Media Cybernetics) software.  Cells were identified as either 
transmigrated cells (phase dark) or adherent cells (phase bright) see Figure 9-8. 
The counts were averaged and the results expressed as a percentage of cells 
migrated and presented as a mean for each condition. 
 
9.2.8 T cell proliferation 
To assess responses to various stimuli, PBMC were first labelled with CFSE.  Whole 
PBMC were washed in PBS, counted and suspended at a concentration of 2x107 
cells/ml.  CFSE at a concentration of 2.5μM was added and the cells were agitated 
and incubated at room temperature in the dark.  After 10minutes an equal volume of 
fetal calf serum (FCS) was added to quench the reaction.  The cells were then 
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washed three times in RPMI and resuspended in RPMI 10% FCS (treated with 
Penicillin/Streptomycin) at a concentration of 200,000 cells per 200ul.  
Cells were stimulated and then incubated at 37°C in 96 well plates.  Stimulation 
occurred under the following conditions and in triplicate: 
 Control (no stimulation) 
 Stimulation with OKT3 (concentration 0.5ug/ml)  
 Simulation with pancreatic islet lysate (Oxford) (5uL in 50uL media) 
 Stimulation with purified protein derivative to M. Tuberculosis (PPD) (National 
Institute for Biological Standards and Control, UK) (concentration 500iu/ml) 
Each of the stimulated conditions was performed with and without adiponectin (Enzo 
Lifesciences) supplementation (at a concentration of 4μg/ml). After 3 days (for OKT3-
stimulated cells) or 7 days (for PPD-stimulated and islet lysate-stimulated cells) the T 
cells were collected and stained with fluorescent antibodies to CD4 (CD4-APC, BD 
Biosciences) and CD8 (CD8-eFluor 450, eBioscience) and the proportion of 
proliferated cells determined using flow-cytometry.  Results are expressed as the 
stimulation index (SI) for the condition.  Mean values for triplicates were calculated 
for each condition.  The SI is the proportion of the cell population studied that has 
proliferated in response to an antigen relative to the unstimulated control (Mannering 
et al. 2010).  A SI of greater than 2 indicates significant proliferation.  Percentage 
inhibition of proliferation with adiponectin was also calculated, this is the percentage 
change in SI. 
 
180 
 
9.2.9 Ethics 
Ethical approval for the sports science study was given by the University of 
Birmingham ethical committee in August 2012 (ERN_11-0839). 
A favourable ethical opinion for the immunity study was granted by East Birmingham 
Local Research Ethics committee in June 2006 (reference number 06/Q2703/47).   
   
9.3 Results 
 
9.3.1 Healthy Subjects from the Sports Science Study 
9.3.1.1 Description of participants 
Samples from 23 participants were obtained.  The mean age of these participants 
was 47 years old (range 31-60 years).  Six of the participants were male. 
Over the course of the exercise intervention BMI was not significantly changed 
(mean starting BMI 27.5kg/m2 and mean final BMI 26.6kg/m2) , however, fitness (as 
measured by VO2max improved from 30.9 ml/min/kg to 33.4ml/min/kg). 
 
In this group, serum adiponectin (results provided by Dr David Bartlett) did not alter 
(mean starting serum AQ 2.4 ug/ml, mean final 2.5ug/ml). 
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9.3.1.2 Adiponectin receptor levels by PCR 
Baseline adiponectin receptor levels were not statistically significantly correlated with 
age, BMI, weight or fitness.  There was however, a trend towards greater adiponectin 
receptor expression with increasing fitness. 
Analysis of adiponectin receptor levels by PCR did not show a significant change in 
adiponectin receptor gene expression with exercise training in healthy individuals 
(Figure 9-1).  The median fold change in AdipoR1 expression was 1.299, and in 
AdipoR2 expression was 1.325.  
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Figure 9-1 – AdipoR expression on PBMC pre and post training in healthy people. 
 
While the change in adiponectin receptor expression after exercise training was not 
significantly associated with age, BMI or change in serum adiponectin, it was 
associated with the change in physical fitness (as measured by VO2 max).   For 
AdipoR1 this association was statistically significant (r=-0.453, 95% CI -0.729 to -
0.0498, r2=0.205, p=0.03). 
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Figure 9-2 – The relationship between change in fitness and change in AdipoR 
expression on PBMC. 
  
9.3.1.3 Adiponectin receptor levels by flow cytometry 
Flow cytometry analysis of adiponectin receptor expression on PBMC was used to 
ascertain whether there was a differential effect of exercise on PBMC subsets.   Cells 
were gated on forward-side scatter/pulse width and then on phenotyping antibodies 
(examples are shown in Figure 9-3).  Each sample was compared against a negative 
control (isotype), which had been stained for neither AdipoR1 nor AdipoR2 see 
Figure 9-3D. 
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Figure 9-3 - Typical results from flow cytometry for adiponectin receptor 
expression for CD14+ monocytes (A), CD3+ T cells (B) and CD19+ B cells (C).  
AdipoR expression was greatest on monocytes.  Each subset was compared 
against an isotype control (which was subtracted) (D). 
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Analysis of AdipoR expression by flow-cytometry did not show a significant increase 
in AdipoR on PBMC either in percentage of cells expressing the receptor or mean 
fluorescent intensity (Figure 9-4).  There did appear to be an increase in AdipoR2, 
however, this was not statistically significant. 
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Figure 9-4 - Adiponectin receptor expression on PBMCs before and after exercise 
training by flow-cytometry.  (A) and (B) show percentage of cells expressing AdipoR, 
(C) and (D) show mean fluorescence intensity (MFI). 
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AdipoR2 expression on all PBMC subsets appeared to increase with exercise 
training, however, significant increases were seen only on PBL and NK T cells after 
exercise training (see Figure 9-5).   
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Figure 9-5 – Distribution of AR2 receptors by PBMC subset.  Significant increases 
are seen on PBLs (p=0.027) and NK T cells (p=0.0009) post training. 
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9.3.1.4 T cell proliferation 
Figure 9-6 shows representative pictures of the flow cytometry results for the T cell 
proliferation studies.  Cells were gated on fluorochromes on either CD4 or CD8 
antibodies.   Stimulation is demonstrated by serial dilution of CFSE staining. 
The T cell proliferation studies demonstrate a greater inhibition of proliferation of 
CD4+ T cells with adiponectin following exercise training (similar results were seen 
for CD8+ cells, data not shown).  This was apparent but not statistically significant 
when the PBMCs were stimulated with CD3 antibody, but was significant (p=0.016) 
when PPD was used.  The mean stimulation index for islet lysate was close to 1 
indicating that no proliferation was stimulated, and therefore no inhibition of 
proliferation was seen with adiponectin.  Overall stimulation was less after exercise 
training (see Figure 9-7A).   
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Figure 9-6 – CD4+ T cell proliferation to various stimuli.  Stimulation was with CD3 
antibody (A), PPD (B) and islet lysate (C).  Each condition was compared to an 
unstimulated control (left).   
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Figure 9-7 Percentage inhibition of proliferation (as referenced to a control) with 
adiponectin. (A) Stimulation index following stimulation of proliferation with OKT3 in 
the presence and absence of adiponectin, before and after exercise training.  
Percentage inhibition of proliferation with adiponectin after stimulation with OKT3 (B), 
PPD (C) and islet lysate (D) 
 
9.3.1.5 Endothelial transmigration in healthy people 
Endothelial transmigration of PBL was performed on only five participants at 
baseline.  However, there was significant suppression of migration with PEPITEM 
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and adiponectin when compared to the control (p=0.0085, ANOVA) (Figure 9-9).  
Only one of these participants attended for follow-up and in this participant 
suppression of migration with both PEPITEM and adiponectin was reduced after 
training (Figure 9-10).  This is consistent with the measured AdipoR in this 
participant, which fell over the training period. 
         
 
Figure 9-8 – Phase contrast microscopy of HDMEC with adherent (phase bright) PBL 
circled.  (A) control, (B) treated with adiponectin. 
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Figure 9-9 - Endothelial transmigration under three conditions (control “0”, addition of 
“Pepitem” and preincubation of T cells with adiponectin “Aq”) at baseline (healthy 
individuals in the sports science study). 
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Figure 9-10 - Change in endothelial transmigration after training in one participant 
(NB adiponectin receptor levels fell over same period of time)  
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9.3.2 Subjects with type 1 diabetes 
9.3.2.1 Serum adiponectin changes with exercise in T1D 
The median serum adiponectin in the Extod participants at baseline was 6.6 ug/ml 
(interquartile range (IQR) 8.73).  Baseline serum adiponectin was not correlated with 
age, BMI, WHR, fitness, activity, HbA1c, or HOMA2-IR.  In addition, there was no 
relationship between smoking status or number of autoantibodies and serum 
adiponectin at baseline. 
Participants in the intervention arm of the Extod study had higher serum adiponectin 
at baseline (median serum adiponectin 3.99 (IQR 6.25) ug/ml in the control arm 
compared to 7.42 (IQR 12.27) ug/ml in the intervention arm).  In those participants 
completing 6 months of the study at the time of analysis, serum adiponectin 
appeared to fall in the intervention group, while the value remained unchanged in the 
control arm.  In those participants completing twelve months at the time of analysis, 
the fall at six months was also apparent and was sustained over the second half of 
the study (see Figure 9-11). Serum adiponectin was unchanged in the control arm.  
The difference in adiponectin between the two groups was significant at baseline, 
however, there was no difference between the two groups at either of the follow-up 
time points (p=0.043, two-way ANOVA).  
 
In view of the negligible increase in MVPA in the participants who were in the 
intervention arm, we went on to examine the effect of increasing physical fitness on 
serum adiponectin.  Those participants who increased their VO2max during the study 
tended to maintain serum adiponectin and in those whose VO2max declined during 
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the study, serum adiponectin also declined.  These findings were not statistically 
significant, however (two-way ANOVA).
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Figure 9-11 – Serum Adiponectin in participants in the Extod trial.  Participants up to 
6 month time point (A) (control n=14, intervention n=19).  Participants up to 12 
months (both arms n=8). (C) and (D) compare those participants who increased their 
fitness levels with those who did not. 
 
9.3.2.2 Adiponectin receptor expression in T1D by PCR 
AdipoR1 and AdipoR2 expression were highly correlated (r=0.806, 95%CI 0.6182 to 
0.9062, r2=0.649, p<0.0001).  There was no significant relationship between baseline 
AdipoR expression on PBMC and age, BMI, weight, estimated VO2 max, HbA1c, 
fasting insulin or HOMA2-IR (Figure 9-12). 
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Figure 9-12 – Relationship between AdipoR dCT and age, BMI, fitness and 
glycaemic control.  None of these are statistically significant. 
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At 6 months adiponectin receptor expression had increased in both the control and in 
the intervention arms.  However, the increase was only statistically significant in the 
intervention arm.  This was true for both AdipoR1 and AdipoR2. 
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Figure 9-13 – There is a statistically significant increase in AdipoR in patients with 
T1D after exercise training (ANOVA). 
 
The fold change in adiponectin receptor expression was not significantly different 
between the 2 groups for either AdipoR1 or AdipoR2 (AdipoR1 control mean fold 
change 2.437, 95%CI 1.125, 3.749, AdipoR1 intervention mean fold change 2.641, 
95%CI 1.466, 3.816) but both groups have a fold change significantly greater than 
one.  This indicates that there is an increase in AdipoR in the first year after 
diagnosis of T1D. 
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There was no association between change in adiponectin receptor expression and 
age, change in any of weight, estimated VO2 max, HOMA-IR, HbA1c or circulating 
adiponectin. 
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Figure 9-14 – Relationship between change in AdipoR2 and age (A), change in 
fitness (B), weight (C) and glycaemic control (D).  The relationship with these 
parameters and AdipoR1 is similar (data not shown). 
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9.3.2.3 Adiponectin receptor expression on PBMC by flow-cytometry 
In the subset of participants who have AdipoR determined by flow cytometry, there is 
no significant difference in AdipoR1 or AdipoR2 frequency before and after exercise. 
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Figure 9-15 - AdipoR expression determined by flow cytometry.  (A) and (B) show 
data for PBMC, (C) and (D) for PBL. 
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9.3.2.4 T cell Proliferation 
Successful analysis of samples for T cell proliferation was achieved in 5 intervention 
participants and 2 controls (shown in Figure 9-16).  There is no clear relationship to 
group demonstrated. 
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Figure 9-16 – Inhibition of T cell proliferation with adiponectin was not affected by 
study arm.  Each participant is represented by a pair of markers linked by a line. 
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9.3.2.5 Endothelial Transmigration 
Samples were analysed in 12 patients at baseline and eight patients after 6 months 
in the Extod study.   
T cell transmigration was not inhibited by adiponectin in patients with T1D at 
baseline.  This is in contrast to the inhibition seen in healthy participants of the Sports 
Science Study at baseline (Figure 9-17). 
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Figure 9-17 – Comparison of endothelial transmigration of PBL in healthy subjects 
and T1D patients, before and after exercise training. 
 
After six months there was no difference in inhibition of transmigration with 
adiponectin between those participants in the intervention and control arms.  In 
keeping with the overall increase in adiponectin receptor expression in both groups of 
the study, there was a significant suppression of endothelial transmigration in the 
Extod participants as a whole after six months.  This was statistically significant 
(p=0.0029, ANOVA). 
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9.4 Discussion 
 
Here we have shown that supervised exercise training in healthy people did not 
change adiponectin receptor expression on PBMC.  It did, however, result in a 
greater inhibition of T cell proliferation.  In patients with newly diagnosed T1D, there 
was an increase in adiponectin receptor expression which was seen in both the 
intervention and control arms of the study.  We were unable to demonstrate an effect 
of this on suppression of T cell proliferation, however, we did see improved 
suppression of endothelial migration with adiponectin irrespective of treatment group. 
 
9.4.1 The effect of exercise on serum adiponectin in T1D 
Serum adiponectin was significantly higher in the intervention arm at baseline and fell 
to the level seen in the control arm by 6 months.  A previous meta-analysis 
examining the effect of exercise on circulating adiponectin found that moderate to 
high-intensity exercise increases serum adiponectin, but the effect of low intensity 
exercise is much less apparent (Simpson & Singh 2008).  The studies included in this 
meta-analysis included healthy and obese participants as well as participants with 
impaired glucose tolerance or type 2 diabetes.  Given the negligible improvement in 
MVPA seen in the Extod cohort it is unsurprising that we did not see an increase in 
adiponectin levels in this group.  It is somewhat unexpected that our intervention 
appeared to have had the effect of lowering serum adiponectin.    
Previously, in our group, Dr Terence Pang has found that patients with T1D have 
similar levels of circulating adiponectin to those in healthy controls (Pang 2010), in 
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contrast to patients with type 2 diabetes who have lower levels.  Other studies have 
shown increasing circulating adiponectin with increasing duration of diabetes 
(Lindström et al. 2006). Our longitudinal data, suggests that patients with T1D may 
be able to maintain circulating adiponectin with exercise training, while those whose 
fitness declines have reduced serum adiponectin levels, however, this finding was 
not significant and would need to be repeated on a larger sample of patients. 
 
9.4.2 The effect of exercise on adiponectin receptor expression on PBMC  
In healthy people, adiponectin receptor expression on PBMC did not alter after 
exercise training.  Our sample size was smaller than that used in work done 
previously in our group that demonstrated an improvement in AdipoR with exercise in 
patients with type 2 diabetes (Pang 2010).  There was an increase in AdipoR2 
expression on PBLs and NK T cells. There was also a trend towards an association 
between VO2max and change in VO2 max and increased adiponectin receptor 
expression on PBMC.  This was not significant in this sample size and will need to be 
repeated in a larger cohort. 
In contrast, in patients with newly diagnosed T1D, adiponectin receptor expression 
on PBMC increased by six months in both arms of the study.  The increase was only 
significant in the intervention arm.  The change in adiponectin receptor expression 
was not associated with MVPA, BMI, weight, HbA1c, VO2 max or HOMA2-IR and 
given the lack of a significant change in activity levels in this group it is not likely to be 
attributable to exercise training.  Type and intensity of exercise has been shown to 
determine changes in tissue adiponectin receptor expression in rats (Zeng et al. 
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2007).  The most significant metabolic change in the group between baseline and 
follow-up was the improvement in glycaemic control.  It is plausible that this 
influenced adiponectin receptor expression, although a significant correlation was not 
demonstrated, perhaps due to an insufficient sample size.  Furthermore, neither this 
study, nor previous work in our group (Pang 2010), have identified a link with 
adiponectin receptor expression on PBMC and glycaemic control. 
Previously, our group have demonstrated that the change in adiponectin receptor 
expression on PBMC is correlated with change in insulin resistance in patients with 
type 2 diabetes (Pang 2010).  It is possible that the smaller changes in HOMA-IR 
seen in patients with T1D who are less insulin resistant than those with type 2 
diabetes would mean an even larger sample size would be required to demonstrate 
such an association.  Further work on the changes in adiponectin receptor 
expression around the time of diagnosis of T1D will be needed to elucidate the 
factors contributing to this change. 
 
9.4.3 The effect of exercise on response of T cell proliferation to adiponectin 
In healthy people, there was a greater inhibition of T cell proliferation after exercise 
training in response to stimulation with CD3 antibody and PPD.  In T1D patients, 
there was no effect of exercise demonstrated on T cell proliferation (but the numbers 
were small). 
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9.4.4 The effect of exercise on the suppression of endothelial transmigration 
to adiponectin 
Adiponectin supressed T cell endothelial transmigration to a similar degree to that 
previously demonstrated by our group (Chimen et al. 2015) and changed in 
proportion to adiponectin receptor expression. 
In patients with T1D, inhibition of endothelial transmigration by adiponectin was not 
affected by intervention, however, at the six month time point, the effect of 
adiponectin was superior to baseline in participants in both arms, consistent with the 
improvement in adiponectin receptor expression seen in the two groups.  This 
significant improvement is notable, but this study was not able to explain the cause of 
this.  Should the reasons underlying the increase in AdipoR expression be identified, 
this could reveal a mechanism whereby adiponectin-mediated suppression of T cell 
migration could be enhanced in T1D.   
 
9.4.5 Summary 
Exercise training did not upregulate adiponectin receptor expression in these groups 
of healthy people or patients with T1D.   Improvements in adiponectin receptor 
expression were seen in all patients with T1D and these translated into greater 
suppression of endothelial migration by T cells with adiponectin.   Further work is 
required to confirm these findings in a larger group and to understand the reasons 
underlying this result. 
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9.5 Recommendations for future work 
The findings of the study on adiponectin receptor expression in healthy volunteers 
should be confirmed, ideally in a larger group.  It would be interesting to examine 
whether this related to an improvement in adiponectin-mediated suppression of T cell 
migration, unfortunately practical difficulties prevented this in this study. 
The improvement in adiponectin receptor expression in patients newly diagnosed 
with T1D is intriguing and research into the factors underlying this finding should be 
undertaken.   
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10 CONCLUSIONS 
 
Exercise confers health benefits to healthy individuals and patients with chronic 
disease, including T1D (Chief Medical Officers of England  Wales, and Northern 
Ireland 2011; Chimen et al. 2012).  Preservation of beta-cell function in T1D is 
associated with a reduced risk of microvascular disease and hypoglycaemia (Steffes 
et al. 2003; Lachin et al. 2013) and is therefore, a target of significant research 
interest.   Exercise has been demonstrated to preserve beta-cell function in healthy 
people and people with type 2 diabetes, as well as rodent models of T1D (Narendran 
et al. 2015).  The work presented in this thesis is aimed at examining whether 
exercise preserves beta-cell function in patients with T1D. 
 
10.1 Evaluating the barriers to exercise in patients with newly 
diagnosed T1D 
In chapter 5, I have described the first qualitative interview study examining the 
attitudes to exercise in a group of adult patients with newly diagnosed T1D.  Five 
distinct themes were identified: existing attitudes to exercise; feelings about 
diagnosis; perceptions about the consequences of exercise; barriers to increasing 
exercise; confidence in managing blood glucose.  I demonstrated that this group of 
patients is keen to increase their activity levels but some lack the necessary 
confidence in managing their diabetes.  Patients with T1D felt that consistent advice 
from the healthcare team and education in managing their diabetes would help to 
improve their confidence in taking up physical activities. 
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Participants in this study reported similar barriers to exercise to those reported by 
patients with more long-standing T1D (Lascar et al. 2014) and other chronic diseases 
(Korkiakangas et al. 2009; Courneya et al. 2008; Brazeau et al. 2008; Plotnikoff et al. 
2006; Slade et al. 2014; Rimmer et al. 2008), however, more emphasis was placed 
on HCP advice and fear of hypoglycaemia in the interviewees who had been recently 
diagnosed. 
It is perhaps not possible to generalise the results of the first phase of this study to 
the clinic population of T1D as participants in this study are likely to have had an 
interest in exercise prompting them to take part.  The results of this study did inform 
the design of the second phase of the Extod trial, in the form of educational materials 
for both participants and research team members. 
This study has led on to further work, some of which is currently in progress.  This 
involves: 
1. Examining the confidence of HCPs in advising patients about diabetes 
management around exercise. 
2. Exploring how and what patients with T1D want to learn about managing their 
diabetes during exercise. 
3. The development of research networks and a conference for HCPs (the 
EXTOD conference, now in its 4th year) to discuss the area of exercise in T1D. 
4. Subsequent NIHR funding (The Extod Education Grant) to develop an 
education package to aid health care professionals to support patients with 
T1D to exercise. 
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10.2 Determining whether patients newly diagnosed with T1D can be 
encouraged to take up and adhere to a programme of at least 
moderate intensity exercise for a period of one year, and the rate 
of exercise uptake in the non-intervention arm.  
In chapters 3 and 4, I have described the design, set-up and recruitment of a 
randomised, controlled pilot study to investigate the effect of exercise on beta-cell 
function in T1D. 
Recruitment to the Extod study was both low (58 participants randomised to the 
study out of 507 potential participants identified) and slower than anticipated.  It is 
common for randomised controlled trials to fail to recruit to target within the 
anticipated time frame and reporting of numbers potentially eligible for studies is 
variable (Toerien et al. 2009).  Difficulties in recruitment occur despite evidence that 
patients view clinical research as important and are willing to take part (IPSOS Mori & 
Association of Medical Research Charities 2011) and evidence of benefit to the 
individual taking part in a clinical trial (Braunholtz et al. 2001).  Despite the difficulties 
comparing the Extod study with other studies of patients with T1D (due to differences 
in population or intervention), some RCTs have reported recruitment rates as low as 
17% (DAFNE Study Group 2002).  Recruitment in the Extod study was lower than 
this and it is clear that strategies for addressing this would help any future trials.   
Similarly, the completion rate was lower than initially expected.  Further qualitative 
work examining the possible reasons behind this has been undertaken by our group. 
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Baseline activity levels for our participants were high with 78% already performing 
more than 150 minutes MVPA per week as recommended by the Chief Medical 
Officer and diabetes organisations (Chief Medical Officers of England  Wales, and 
Northern Ireland 2011; Nagi & Gallen 2010; Sigal et al. 2006).   Physical activity 
levels in both arms changed little during the course of the study.  There was 
however, an increase in fitness in the intervention arm only slightly lower than that 
seen in other studies of patients with T1D (Laaksonen et al. 2000; Wallberg-
Henriksson et al. 1986; Fuchsjager-Mayrl et al. 2002) with supervised exercise, 
although of shorter duration.  Importantly, despite high levels of activity among 
participants, hypoglycaemia rates were low, indicating that patients with newly 
diagnosed T1D can exercise safely. 
 
Future studies will need to address the issues of low recruitment and loss to follow-
up as well as design an intervention that achieves a clear difference in activity 
between the intervention and control arms.  There is evidence to suggest that 
recruitment may be improved with changes to study design to reduce the burden on 
the clinical research team (Fletcher et al. 2010), therefore, it will be important to 
review the study design carefully to see where it could be simplified.  There was an 
increase in participants identified from PIC sites following the introduction of an 
incentive to trial staff.  There may be ways to extend this approach to participants, for 
example, patients may view activity monitoring or glucose monitoring systems as 
incentives but these would also be useful for trial monitoring.  
It is likely that patients interested in taking part in a trial of exercise are already 
interested in physical activity.  As such, the group of participants is likely to be 
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already active, as seen in this group.  This will, therefore, lead to difficulties 
maintaining a difference in activity levels between the control and intervention arms.  
In a future trial, a supervised exercise intervention would allow the study team to 
increase intensity and more accurately monitor exercise duration during the trial.  
One drawback of this approach is the limitations that it puts on the participant in 
terms of choice of location and timing of activity sessions, which may in turn 
negatively affect recruitment. 
 
10.3 Determining whether adherence to this programme of exercise 
preserves beta cell function. 
The work presented in chapter 8 demonstrates that there was no evidence from the 
Extod study for the beta-cell preserving effect of exercise in T1D.  Loss of beta-cell 
function was similar in both the intervention and control groups over the course of the 
study.  However, there are important reasons why this study does not provide a 
definitive answer to this hypothesis. 
1. The study, as a pilot study, was not powered to test this hypothesis. 
2. The difference in MVPA and fitness in the intervention arm was small and is 
not likely to have been enough to demonstrate a significant effect on beta-cell 
function.  
3. The control arm had advantages in terms of factors favourable to beta-cell 
function; more patients presenting with acidosis, short median duration of 
symptoms prior to diagnosis and, a greater proportion of patients with 
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detectable autoantibodies.  All of which, I have suggested had a significant 
effect on beta-cell function in the group as a whole. 
4. The reduction in insulin resistance seen in the intervention arm causes 
difficulties in the assessment of beta-cell function by mean AUC C-peptide 
during MMTT.   This in itself would appear as a reduction in insulin secretion 
as measured by AUC C-peptide, therefore, potentially masking any effect of 
the intervention. 
Further studies are required to address the question of the role of exercise in beta-
cell preservation in T1D.  Consideration of the limitations of this study outlined above 
will be important in informing these.  Either restricting study entry to participants who 
have detectable autoantibodies or controlling for this at randomisation will be 
important, as would an intervention more effective at separating the study arms in 
terms of activity levels.   
Finally, some thought and study will need to go into how best to measure beta-cell 
function in the context of an intervention that reduces insulin resistance as current 
methods will always appear to demonstrate a loss of beta-cell function in these 
circumstances. 
 
10.4 Investigating the effect of exercise on immunity in patients newly 
diagnosed with T1D. 
The work presented in chapter 9 examined the effect of exercise on circulating 
adiponectin levels, adiponectin receptor expression and T cell activity in response to 
adiponectin in healthy people and patients with T1D. 
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I found that there was a suggestion that adiponectin receptor levels on PBMC 
increased in healthy people after exercise training, particularly on PBL subsets.  This 
appeared to translate into increased suppression of T cell proliferation in response to 
CD-3 antibody and PPD stimulation with adiponectin.  
In T1D patients recruited through the Extod study, there was a universal increase in 
adiponectin receptor expression on PBMC with time.   This did not appear to be 
related to increased activity levels or fitness.  The increase in adiponectin receptor 
expression was associated with greater suppression of T cell endothelial migration 
with adiponectin. 
It is not possible to evaluate the cause for the increase in adiponectin receptor 
expression in the T1D group from this study.  However, over the first few months in 
the study, glycaemic control improved significantly in the group as a whole.  It is 
plausible that glycaemia influences adiponectin receptor expression. 
 
The limitations of this study are related to sample size and the weaknesses of the 
Extod study for this specific research (primarily the high baseline levels and minimal 
increase in activity).  Another problem is the lack of a sedentary control group for the 
healthy volunteers.  These studies need confirming in a larger group of subjects with 
a sedentary control group for comparison.  In addition, I would suggest that work 
examining the effect of glycaemic control on adiponectin receptor expression could 
yield interesting results. 
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In summary, I have described the attitudes and barriers to exercise in a group of 
adult patients recently diagnosed with T1D.  This work has enabled me to identify 
areas where patients can be supported to increase their activity levels.  Using the 
results of this study, I have developed educational materials for patients and 
healthcare workers to support them to do so in the context of a randomised, 
controlled trial.   
I have discussed the study design and set up of a pilot trial aimed at increasing 
exercise in T1D patients, examining recruitment, completion, adherence to exercise 
programme and uptake of exercise in the control group.  I also have developed 
suggestions for how these could be improved in full scale trial. 
The work investigating the effect of exercise on beta-cell function in T1D has 
established the need to compensate for any changes in insulin resistance and further 
work examining the best way to do this is required. 
Finally, I have examined a potential mechanism for exercise to preserve beta-cell 
function in T1D; through effects on adiponectin receptor levels on PBMC and 
therefore, immunity.  The main finding of this work was that adiponectin receptor 
levels, and hence, adiponectin-mediated suppression of T cell endothelial migration, 
are upregulated after the diagnosis of T1D.  The cause for this is unclear and will 
require further study. 
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12 APPENDICES 
Appendix A  EXTOD PATIENT INFORMATION SHEET 
Patient Information Sheet 
Version 6. 
September 2011 
 
Study Title: Benefits of exercise in type 1 diabetes (T1D) 
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether you wish to take part. Thank you for reading this. 
 
Study purpose: 
 
The insulin producing beta cells within the pancreas are destroyed by the body’s own 
immune system in patients with T1D. At the time patients are diagnosed with T1D, they can 
have about a quarter of their beta cells remaining and most of these are gradually destroyed 
over a number of years. However, even in patients who have had T1D for many years, there 
is now evidence for some residual beta cell function. Protecting these beta cells from the 
immune system and preserving their function has been shown to protect the patient from the 
complications of diabetes. These complications include heart disease, kidney failure and 
blindness. There is therefore a good evidence to preserve beta cell function in patients with 
T1D. 
 
There is some evidence that regular and sustained exercise can protect beta cells in patients 
with other forms of diabetes but we not yet sure is this is the case in T1D. The aim of this 
study is to find out with confidence if exercise preserves beta cells in T1D. 
 
The study will consist of 2 parts. Firstly we would like to interview patients with T1D to find 
out why regular exercise is difficult for patients with diabetes. Second, we will exercise 
patients with diabetes to see if their beta cell function is preserved. 
 
Why have I been Chosen? 
 
You have been chosen because you have type 1 diabetes. We aim to recruit up to 80 
patients. 
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Do I have to take part? 
 
This is entirely up to you to decide. We will explain the study and go through this information 
sheet that we will then give to you. If you wish to discuss this with others, we can recommend 
both your GP or the Patient Advice Liaison Service – their telephone number is local 
information, email local information. We will then ask you to sign a consent form to show you 
have agreed to take part. You are free to withdraw at any time, without giving a reason. This 
would not affect the standard of care you receive.  If you agree to participate you may benefit 
from receiving advice on exercise or supervised exercise training, and also understanding 
the barriers to taking up exercise in patients with diabetes. 
 
What will happen if I take part? 
 
If you agree to take part in this study, you will be asked to help in one of 2 ways 
 
1) You will be asked to attend a 1-2 hour interview to find out from yourself what the 
problems are to doing exercise. This may be an individual interview or in a group with other 
patients with T1D.  
 
2) You will be placed at random in one of 2 groups in an exercise study. The first group will 
be asked to have usual diabetes care. This will involve written and spoken advice on 
exercise. This is what we currently give to patients with diabetes in our diabetes clinics. The 
second group will get usual care for their diabetes but also be encouraged and helped to 
exercise at a level that is currently recommended by the Department of Health - for 150 
minutes a week at moderate intensity. This group will be helped through provision of 
membership to leisure centres, gyms or swimming pools. They will also be provided advice 
and guidance to ensure that this exercise does not result in hypoglycaemia (low blood 
sugar), as well as motivational contact from health advisors and our diabetes nurses. This 
exercise group will be asked to maintain this level of exercise for 1 year. Though this may 
sound like a lot of exercise, this is the minimum amount that the Department of Health 
recommends lifelong, not just for one year. If however it difficult for you to maintain this, you 
can leave the study at any time. 
 
Both groups (the exercise as well as the ‘usual care’ groups) will have blood tests taken at 0, 
3, 6, 9 months, and after a year. Some of these blood samples will be stored for future 
testing.  There will also be urine tests and tests of your fitness levels (on an exercise cycle) 
at 0 and 6 months, as well as after a year. This study will finish after this one year. For the 
duration of the study, all of your diabetes care will happen at local information Hospital.  This 
may be different from your usual hospital.  One of the blood tests we will request is for 
analysis of your DNA (this contains your genes).  You have the choice whether to give 
consent for this and your decision will not affect your eligibility to participate in the study.   
 
If for any reason you are unable to finish the exercise, you will be able to leave the study 
(without giving a reason if you do not wish to), and your diabetes care will not be influenced 
in any way.  Some participants will be invited to be interviewed to give feedback on the study 
as it progresses. This is so that we can ensure that we give participants the best support.  
 
 
What are the possible disadvantages and risks of taking part? 
 
Exercise can be associated with injury, however we will ensure that your exercise is started 
gently and gradually increased to avoid this. In patients with T1D, prolonged exercise can 
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also be associated with a drop in the blood sugar (hypoglycaemia). We will avoid this by 
adjusting the insulin doses around the time of exercise and also by providing advice on how 
to treat low blood sugar levels. 
 
What are the possible benefits of taking part? 
 
Exercise has multiple benefits including well-being, reducing the risks of heart disease and 
blood pressure. If our study idea is correct, it can also preserve beta cells which means that 
your diabetes might be easier to control in the long-term.  
 
What if there is a problem?  
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions.  
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. 
 
All the data collected will remain confidential. Your GP will be informed of your participation 
in the study but will not be informed of any of the data except those that could be important to 
your health if you have consented to it. 
 
What will happen to the results of the research study? 
 
We will inform you of the results of all the questionnaires and tests that are performed on you 
personally. The scientific results of the research will be published in medical journals and 
presented in international conferences. 
 
Who is organising and funding the research? 
 
This study is funded by the Diabetes and Wellness Research Foundation, as well as the 
National Institute for Health Research, a charity which aims to improve the care of patients 
with diabetes. The study is sponsored by the University of Birmingham. 
 
Who do I contact for further information? 
Local contact details to be inserted here 
 
  
229 
 
Appendix B  EXTOD CONSENT FORM 
CONSENT FORM Version 5 
November 2011 
 
Title of Project: Benefits of Exercise in Type 1 Diabetes (T1D) 
 
Name of Researcher: Dr Parth Narendran 
 
Please initial box  
 
 
1. I confirm that I have read and understand the information sheet for the above study. I have 
had the opportunity to consider the information, ask questions and have had these answered 
satisfactorily.  
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any time  
 without giving any reason, without my medical care or legal rights being affected.  
 
3.  I understand that individuals may look at relevant sections of my medical notes and data 
collected during the study, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my records. 
 
4.  I agree to the taking and storage of blood samples for the purposes of this study (not relevant 
for interview study) 
 
5.  I agree to the taking and storage of DNA for the purposes of this study (not relevant for 
interview study) 
 
6.  I agree to my GP being informed of my participation in the study  
 
7.  I agree to take part in the above study.  
 
8.  I agree to the additional tests of heart function in the study 
 
 
 
 
_______________   ________________    _________________  
Name of Patient   Date      Signature  
 
 
 
_________________   ________________    ___________________  
Name of Person   Date      Signature  
taking consent  
 
 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
 
  
230 
 
Appendix C  GRADED EXERCISE PROGRAMME 
Week  Total 
Minutes per 
Week 
Intens
ity (% 
effort) 
Heart rate target 
(bpm) 
Borg RPE Scale 
1 75 55 
(220-age x 
intensity%) 
 
2 85 60 Light Exercise 
3 & 4 100 60  
5 & 6  110 65  
7 115 70 Moderate Intensity 
8 & 9 115 70  
10 & 11 130 75 Heavy breathing, 
sweating 
12 
onwards 
150 
(minimum) 
75  
 
This exercise program is designed to encourage a gradual increase in physical activity over the course 
of 12 weeks. The starting point on the scale depends on the individual’s current fitness level. 
From 12 weeks onwards, the aim is to achieve a minimum of 150 minutes per week of vigorous-
intensity exercise. 
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Appendix D  DIETARY COMPETENCIES 
Within 3 months Dietitian would expect a person with newly diagnosed type 1 
diabetes to: 
Identify carbohydrate containing foods and describe how these affect blood glucose 
levels. 
DUK  Eating well with type 1 diabetes leaflet given 
Recognise different carbohydrate foods may have a different effect on blood glucose 
levels and have a basic understanding of low and high glycaemic index foods. 
Introduce fundamental concepts of carbohydrate counting and meal-based insulin 
dosing. 
Build confidence to read and understand food labels. 
Identify the role of sugars, alternative sweeteners, and diabetic foods in healthy 
eating, and identify the safe daily intake of each sweetener. 
State that physical activity may cause the blood glucose levels to rise or fall. 
Hypoglycaemia may occur as a delayed response. 
Treat hypoglycaemia with 15-20g quick-acting carbohydrate and list measured 
amounts of suitable treatments. Follow up with slow-acting carbohydrate if not eating 
for 1-2 hours. 
Understand the effect of alcohol on blood glucose levels. 
Discuss snacks, amount, type and frequency and requirement, if any, for 
insulin.(optional) 
Be able to explain reasons for weight loss at diagnosis. Identify strategies for weight 
control. (optional) 
Understand the importance of hydration in relation to exercise and discuss suitable 
drinks. (optional) 
Be aware of support for people with Type 1 diabetes  e.g. local diabetes UK support 
groups, Diabetes UK website as a resource for food and physical activity tips, 
Runsweet.com website for advice on physical activity and sport. 
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Appendix E  PARTICIPANT INFORMATION BOOKLET ON 
MANAGING CARBOHYDRATE AND INSULIN AROUND EXERCISE 
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ity o
f ex
erci
se y
ou a
re d
oing
 and
 the
 
tab
le o
n th
e fo
llow
ing 
pag
e sh
ows
 how
 the
y m
atch
 up.
 
My
 ma
xim
um
 hea
rt ra
te (
220
—m
y ag
e) =
      
      
      
    b
eat
s pe
r m
inut
e. 
  
Tab
le 1
-Ra
ting
 of P
erce
ived
 Exe
rtio
n ve
rsus
 Int
ens
ity. 
  
* W
hen
 you
 pus
h yo
urse
lf ve
ry, v
ery 
har
d, y
ou s
tres
s yo
ur b
ody
 and
 thi
s m
ay 
cau
se y
our
 blo
od g
luco
se t
o in
crea
se. 
  (M
HR=
Ma
xim
al H
ear
t Ra
te) 
The
 int
ens
ity o
f th
e ex
erci
se i
s im
por
tan
t be
cau
se i
t in
flue
nce
s w
hat
 fue
l th
e 
bod
y us
es a
nd h
ow 
the
 bod
y ad
apt
s to
 the
 acti
vity
. 
Exe
rcis
ing 
at a
 hig
h in
ten
sity
, as
 in s
prin
ting
, wi
ll tr
ain 
the
 bod
y to
 wo
rk a
t a l
ow 
leve
l of 
oxy
gen
 for
 sho
rt b
urst
s. 
Exe
rcis
ing 
at a
 me
dium
 int
ens
ity, 
as i
n jo
ggin
g or
 sw
imm
ing,
 wil
l tra
in t
he h
ear
t, 
lung
s an
d m
usc
les 
to w
ork
 bett
er, 
for 
long
er, 
help
ing 
to i
ncre
ase
 end
ura
nce
. 
Ma
ny a
ctiv
ities
, lik
e fo
otb
all o
r ne
tba
ll w
ill c
ont
ain 
per
iods
 of h
igh 
and
 me
dium
 
inte
nsit
y ex
erci
se a
t di
ffer
ent
 tim
es. 
Des
crip
tion
  
Bor
g S
cale
 
(RP
E) 
% o
f MH
R 
My 
Hea
rt R
ate 
equ
ival
ent
  
(220
 – m
y ag
e) 
Exp
ecte
d 
cha
nge
 in b
loo
d 
glu
cos
e 
Eas
y 
7 
 
 
 
 
8 
 
 
 
Ver
y Li
ght 
9 
 
 
 
 
10 
50%
 
 
 
Fair
ly L
ight
 
11 
 
 
 
 
12 
60%
 
 
 
Som
ewh
at H
ard 
13 
 
 
 
 
14 
70%
 
 
 
 
15 
 
 
Har
d 
16 
80%
 
 
 
 
17 
 
 
 
Ver
y H
ard 
18 
90-%
 
 
Ver
y, V
ery 
Har
d 
19 
 
 
 
20 
 
 
   * 
We
 nee
d fu
el in
 ord
er t
o su
pply
 our
 hea
rt, l
ung
s an
d m
usc
les 
with
 the
 
ene
rgy 
req
uire
d fo
r ex
erci
se. 
 The
 ma
jor 
fue
ls a
re c
arb
ohy
dra
te (
sug
ar) 
and
 fat
.  At
 hig
her
 int
ens
ities
 of 
exe
rcis
e w
e us
e m
ore
 car
boh
ydr
ate
, wh
ile a
t lo
wer
 int
ens
ities
 we
 use
 
mo
re f
at. 
 It is
 ver
y im
por
tan
t th
at t
he r
ight
 am
oun
ts o
f th
e rig
ht f
uels
 are
 ava
ilab
le 
to t
he b
ody
 dur
ing 
exe
rcis
e.  A
s a 
resu
lt, d
urin
g ex
erci
se t
he b
ody
 pro
-
duc
es a
 lot
 of d
iffe
ren
t ho
rmo
nes
 and
 sub
stan
ces
 to 
con
trol
 the
 use
 of 
the
se f
uels
. 
 Insu
lin i
s a 
very
 imp
orta
nt h
orm
one
 in e
xerc
ise.
  It e
nsu
res 
tha
t en
oug
h 
carb
ohy
dra
te is
 ava
ilab
le a
nd c
an b
e pr
ope
rly u
sed
 by 
the
 par
ts o
f th
e 
bod
y w
hich
 nee
d it
. 
 In p
eop
le w
ith 
typ
e 1 
diab
ete
s, th
e bo
dy d
oes
 not
 ma
ke i
ts o
wn 
insu
lin 
and
 the
refo
re i
s un
able
 to 
reg
ulat
e in
suli
n or
 car
boh
ydr
ate
 dur
ing 
exe
r-
cise
.  As
 a re
sult
 you
 ma
y ex
per
ienc
e sy
mp
tom
s of
 hyp
ogly
cae
mia
 dur
ing 
exe
rcis
e, in
 the
 per
iod 
imm
edia
tely
 aft
er e
xerc
ise 
and
 for
 sev
era
l ho
urs 
afte
r th
e ex
erci
se h
as fi
nish
ed. 
 This
 doe
s no
t m
ean
 tha
t pe
ople
 wit
h ty
pe 1
 dia
bet
es s
hou
ld n
ot e
xerc
ise,
 
just
 tha
t so
me
 ext
ra p
rep
ara
tion
 is n
ece
ssar
y. 
Wh
at h
app
ens
 wh
en w
e ex
erci
se?
 
Pre
par
ing 
for 
exe
rcis
e 
  Gen
era
l Ad
vice
 for
 saf
e ex
erci
sing
 
 1. 
We
ar f
oot
wea
r ap
pro
pria
te t
o th
e ex
erci
se y
ou p
lan 
to d
o, f
or e
x-
amp
le, s
upp
orti
ve t
rain
ing 
sho
es f
or r
unn
ing/
jogg
ing.
 Rep
lace
 
the
m r
egu
larly
 as 
the
y w
ear
 out
. 
2. 
Cho
ose
 clo
the
s de
sign
ed f
or y
our
 typ
e of
 exe
rcis
e.  C
ons
ider
 hig
h-
visi
bilit
y cl
oth
ing 
if yo
u ar
e ru
nnin
g or
 cyc
ling
 on 
roa
ds. 
3. 
Ens
ure
 you
 wa
rm-
up a
nd c
ool 
dow
n fo
r 10
 min
ute
s be
fore
 and
 
afte
r ex
erci
se t
o re
duc
e th
e ch
anc
e of
 inju
ry. 
4. 
Tra
inin
g to
o ha
rd c
an c
aus
e in
jury
, yo
u w
ill n
eed
 to 
buil
d up
 you
r 
trai
ning
 pro
gra
mm
e st
ead
ily. 
5. 
Hol
d off
 exe
rcis
ing 
if yo
u ar
e un
wel
l or
 ver
y fa
tigu
ed. 
6. 
Con
side
r th
e w
eat
her
 con
diti
ons
.  If 
it is
 col
d, w
ear
 lay
ers 
you
 can
 
rem
ove
 as 
you
 wa
rm 
up a
nd i
n th
e ho
t we
ath
er e
nsu
re y
ou k
eep
 
wel
l hy
dra
ted
. 
7. 
Do 
not
 exe
rcis
e al
one
 if y
ou h
ave
 
had
 hyp
ogly
cae
mia
 in t
he p
rev
ious
 
24 h
our
s. 
It is
 imp
orta
nt t
o m
ake
 sur
e th
at y
ou e
at e
nou
gh c
arb
ohy
dra
te t
o en
sure
 
you
 hav
e en
oug
h ‘f
uel’
 to 
exe
rcis
e.   
 For
 exa
mp
le, i
f yo
u w
eigh
 70 
kg a
nd a
re d
oing
 ligh
t tra
inin
g yo
u sh
ould
 
aim
 to 
eat
  ap
pro
xim
ate
ly 2
80g
ram
mes
  (3-
5gr
ams
 of 
carb
ohy
dra
te p
er 
kilo
gra
m b
ody
 we
ight
 per
 day
).  A
s yo
u in
crea
se y
our
 exe
rcis
e in
ten
sity
, 
this
 req
uire
men
t wi
ll in
crea
se. 
 You
 sho
uld 
disc
uss
 thi
s w
ith 
the
 Ext
od 
tea
m. 
 Bef
ore
 Exe
rcis
e 
It is
 imp
orta
nt t
o ha
ve e
ate
n a 
mea
l 3-4
 hou
rs b
efo
re e
xerc
isin
g to
 en-
sure
 you
 hav
e en
oug
h ca
rbo
hyd
rate
 to 
sup
ply 
the
 inc
rea
sed
 dem
and
s of
 
you
r ac
tivit
y.  T
his 
sho
uld 
con
tain
 som
e “L
ow 
GI” 
foo
ds, 
suc
h as
 wh
ole-
me
al b
rea
d, p
orri
dge
 oat
s, b
asm
ati r
ice 
etc.
 
 Dur
ing 
Exe
rcis
e 
As a
 gen
era
l ru
le, y
ou s
hou
ld t
ake
 15g
 of c
arb
ohy
dra
te f
or e
very
 30m
ins 
you
 are
 exe
rcis
ing.
  Th
is ca
n be
 in t
he f
orm
 of a
  dr
ink 
or g
luco
se o
r “h
igh 
GI”
 foo
d.   
 Afte
r Ex
erci
se: 
At t
he e
nd o
f yo
ur e
xerc
ise 
sess
ion 
you
 sho
uld 
con
sum
e m
ore
 car
boh
y-
dra
te t
o ‘r
e-fu
el’. 
 Thi
s is 
bes
t ta
ken
 wit
h pr
ote
in e
.g. c
ere
al a
nd m
ilk, 
san
dwi
ch, 
milk
sha
ke d
rink
. 
Car
boh
ydr
ate
s 
Exa
mp
le 
 You p
lan 
to e
xerc
ise 
for 
60 m
inut
es..
... 
Che
ck y
our
 blo
od g
luco
se i
s 7-
14 m
mo
l/l. 
If n
ot t
ake
 an 
add
itio
nal 
15-
20g
 car
boh
ydra
te b
efo
re e
xerc
isin
g. 
 You
 sho
uld 
take
: 
 
15g
 car
boh
ydra
te a
fter
 20m
ins 
 
15g
 car
boh
ydra
te a
fter
 40m
ins 
 
 
and
 
 
15g
 car
boh
ydra
te a
t th
e en
d 
  
Rem
em
ber,
 eve
ryo
ne i
s di
ffer
ent
.  Yo
u m
ay r
equ
ire 
mo
re t
han
 thi
s.  
  Rev
iew
 you
r ca
rbo
hyd
rate
 int
ake
 if y
ou 
hav
e pr
ob-
lem
s du
ring
 exe
rcis
ing.
 
Exa
mp
les 
of 1
5g c
arb
ohy
dra
te: 
 The
 tab
le b
elow
 giv
es e
xam
ples
 of f
ood
s co
nta
inin
g ap
pro
xim
ate
ly 1
5g  
and
 30g
 car
boh
ydr
ate
.  Ta
ke h
igh 
GI f
ood
s im
me
diat
ely 
bef
ore
 and
 dur
-
ing 
exe
rcis
e. Carb
ohy
dra
te  
 ~15
g 
~30
g 
Hig
h G
I 
 
 
Jelly
 bab
ies 
 (lar
ge) 
3 
6 
Jelly
 bea
ns 
15g
 
30g
 
Cola
 
150
ml (
min
i ca
n) 
300
ml 
Luc
oza
de B
ody
 Fue
l En
erg
y G
el 
½ X
 45g
 tub
e 
1 x 
45g
 tub
e 
App
le ju
ice 
120
ml 
240
ml 
Luc
oza
de S
por
t Bo
dy F
uel 
250
ml 
500
ml 
Pow
era
de I
soto
nic 
200
ml 
400
ml 
Gat
ora
de 
250
ml 
500
ml 
 
 
 
Low
-me
diu
m G
I 
 
 
Cer
eal 
bar
 
½-1
 
1-2
 (48
g) 
Rais
ins 
45g
 
90g
 
Cor
nfla
kes
 
3 ta
bles
poo
ns 
6 ta
bles
poo
ns 
Kit 
Kat
 
1 x 
2 fin
ger
 
1 x 
4 fin
ger
 
Sem
i-sk
imm
ed M
ilk 
300
ml (
½ p
int)
 
600
ml (
1pin
t) 
Low
 fat
 fru
it yo
ghu
rt 
1 x 
indi
vidu
al (2
50g
) 
2x i
ndiv
idua
l (25
0g)
 
Pot
ato
 cris
ps 
1 x 
25g
 bag
 
2 x 
25g
 bag
 
Drie
d ap
rico
ts 
5 
10 
We
etab
ix 
1∙5 
3 
Shr
edd
ed W
hea
t 
1 
2 
Gly
cae
mic
 ind
ex 
 Gly
cae
mic
 Ind
ex (
GI) 
give
s an
 ind
icati
on o
f ho
w q
uick
ly a
 foo
d w
ill ra
ise 
bloo
d gl
uco
se l
eve
ls. 
 
Hig
h G
I fo
ods
 rai
se b
lood
 glu
cos
e le
vels
 qui
ckly
  
Low
 GI 
foo
ds r
aise
 blo
od g
luco
se l
eve
ls sl
owl
y  
  
  E.g. 
whi
te b
rea
d, m
ash
ed p
ota
to, 
whi
te r
ice,
 rice
 cak
es, 
pre
t-
zels
, wa
ter 
bisc
uits
, wa
ter 
me
lon,
 dat
es, 
spo
rts d
rink
s (6
-8%
 
carb
ohy
dra
te),
 spo
rts g
els,
 jell
y ba
bies
, jel
ly b
ean
s, fr
uit 
juic
e 
  E.g.
, sh
red
ded
 wh
eat
, pitt
a br
ead
, wh
olem
eal 
bre
ad, 
gno
cch
i, 
cou
sco
us, 
bak
ed p
ota
to, 
ban
ana
, ra
isin
s, p
inea
pple
, dig
esti
ve 
bisc
uits
, Ry
vita
 
  E.g.
 por
ridg
e oa
ts, b
asm
ati r
ice,
 rye
 bre
ad, 
see
ded
 mu
ltigr
ain 
bre
ad, 
spe
lt b
rea
d, s
our
dou
gh b
rea
d, a
pple
, ma
ngo
, or
ang
es, 
che
rrie
s, lo
w-f
at m
ilk, 
low
-fat
 yog
hur
t 
 
 * In
form
atio
n ta
ken
 fro
m G
I Da
tab
ase
, Un
iver
sity
 of S
ydn
ey 
Hig
h G
I 
(70
 and
 abo
ve) 
Me
dium
 GI 
(56
 to 
90)
 
Low
 GI 
(55
 and
 und
er) 
Blo
od g
luco
se (
mm
ol/l
) 
Ket
one
s pr
ese
nt?
 
Acti
on 
Car
boh
ydr
ate
 nee
ded
 
Les
s th
an 3
.5 
No 
Do 
not
 exe
rcis
e 
Tre
at h
ypo
glyc
aem
ia.  
 
You
 mu
st w
ait a
t lea
st 4
5 m
inut
es a
nd 
che
ck y
our
 blo
od g
luco
se b
efo
re y
ou 
star
t ex
erci
se. 
Tak
e ad
diti
ona
l ca
rbo
hy-
dra
te b
efo
re e
xerc
isin
g. 
Hyp
ogly
cae
mia
 tre
atm
ent
 
PLU
S 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 nex
t ex
erci
se s
essi
on.
 
3.5—
5.6 
No 
Exe
rcis
e w
ith 
cau
tion
 
Tak
e 15
g ca
rbo
hyd
rate
 and
 rec
hec
k 
bloo
d gl
uco
se a
fter
 15 
min
s. 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
5.7—
6.9 
No 
OK 
to E
xer
cise
 
Tak
e an
 add
itio
n 15
g ca
rbo
hyd
rate
 be-
fore
 exe
rcis
ing 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Gre
ate
r th
an 1
4 
No 
Exe
rcis
e w
ith 
cau
tion
 
Giv
e 30
% o
f us
ual 
cor
recti
on d
ose
 of 
insu
lin. 
  
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Gre
ate
r th
an 1
4 
Yes
 
Do 
not
 exe
rcis
e 
Giv
e us
ual 
cor
recti
on d
ose
 of i
nsu
lin 
 
7.0—
14 
No 
OK 
to E
xer
cise
 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Che
ck y
our
 blo
od g
luco
se b
efor
e yo
u st
art 
Use
 thi
s ch
art 
to d
ecid
e if 
it is
 saf
e fo
r yo
u to
 exe
rcis
e. 
Blo
od g
luco
se (
mm
ol/l
) 
Ket
one
s pr
ese
nt?
 
Acti
on 
Car
boh
ydr
ate
 nee
ded
 
Les
s th
an 3
.5 
No 
Do 
not
 exe
rcis
e 
Tre
at h
ypo
glyc
aem
ia.  
 
You
 mu
st w
ait a
t lea
st 4
5 m
inut
es a
nd 
che
ck y
our
 blo
od g
luco
se b
efo
re y
ou 
star
t ex
erci
se. 
Tak
e ad
diti
ona
l ca
rbo
hy-
dra
te b
efo
re e
xerc
isin
g. 
Hyp
ogly
cae
mia
 tre
atm
ent
 
PLU
S 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 nex
t ex
erci
se s
essi
on.
 
3.5—
5.6 
No 
Exe
rcis
e w
ith 
cau
tion
 
Tak
e 15
g ca
rbo
hyd
rate
 and
 rec
hec
k 
bloo
d gl
uco
se a
fter
 15 
min
s. 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
5.7—
6.9 
No 
OK 
to E
xer
cise
 
Tak
e an
 add
itio
n 15
g ca
rbo
hyd
rate
 be-
fore
 exe
rcis
ing 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Gre
ate
r th
an 1
4 
No 
Exe
rcis
e w
ith 
cau
tion
 
Giv
e 30
% o
f us
ual 
cor
recti
on d
ose
 of 
insu
lin. 
  
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Gre
ate
r th
an 1
4 
Yes
 
Do 
not
 exe
rcis
e 
Giv
e us
ual 
cor
recti
on d
ose
 of i
nsu
lin 
 
7.0—
14 
No 
OK 
to E
xer
cise
 
15-
30g
 car
boh
ydr
ate
 for
 eve
ry 3
0 
min
s of
 exe
rcis
e. 
Has
 you
r bl
ood
 sug
ar b
een
 < 3
.5m
mo
l/l i
n la
st 2
4 ho
urs? D
o no
t ex
erci
se
Che
ck B
GNo
Yes
<3.5
3.5-
5.6
>14
5.7-
6.9
7.0-
14
15 g Car
b
Wa
it
45 m
in Rec
hec
k BG
15 g Car
b
Wa
it
15 m
in
Ket
one
  Po
s
Give
 usu
al 
corr
ecti
on
dos
e
Ket
one
 Ne
g
Give
 30%
 of
corr
ecti
on
dos
e
Pro
cee
d to
 exe
rcis
e
Add
itio
nal
15g
 Car
b
Rec
hec
k BG
Ret
rea
t hy
po
if ne
ces
sary
Hyp
ogly
cae
mia
 
An 
epis
ode
 of h
ypo
glyc
aem
ia in
 the
 24 
hou
rs b
efo
re e
xerc
ise 
will
 bot
h 
affe
ct y
our
 abi
lity 
to p
erfo
rm 
exe
rcis
e an
d in
crea
se t
he c
han
ce o
f yo
u 
hav
ing 
ano
the
r ep
isod
e du
ring
 or 
afte
r yo
ur e
xerc
ise 
sess
ion.
 Do
 not
 ex-
erci
se i
f yo
u ha
ve b
een
 hyp
ogly
cae
mic
 (be
low
 3.5
 mm
ol/l
) in 
the
 las
t 24
 
hou
rs. (
See
 flow
 cha
rt b
elow
.) 
 It is
 no
t re
com
me
nde
d to
 exe
rcis
e in
 the
 24 
hou
rs f
ollo
win
g an
 epi
sod
e 
of s
eve
re h
ypo
glyc
aem
ia (o
ne w
hich
 you
 are
 una
ble 
to t
rea
t on
 you
r 
own
). 
 
Typ
e of
 acti
vity
 
Cha
nge
 in b
loo
d gl
uco
se d
urin
g 
exe
rcis
e  
Risk
 of 
hyp
ogly
cae
mia
 aft
er 
exe
rcis
e  
 Con
tinu
ous
 
 
 
 Sto
p an
d St
art 
e.g.
 foo
tba
ll 
or 
 
Diff
ere
nt a
ctiv
ities
 wil
l ha
ve d
iffe
ren
t eff
ects
 on 
you
r bl
ood
 glu
cos
e.  I
f 
you
 are
 uns
ure
 how
 to 
trea
t hy
pog
lyca
em
ia, p
leas
e ta
lk to
 som
eon
e 
from
 the
 Ext
od t
eam
. 
Bloo
d gl
uco
se m
eas
ure
men
t 
You
 can
 use
 thi
s to
 hel
p yo
u w
hen
 you
 are
 exe
rcis
ing.
   
 If yo
u ar
e at
 the
 gym
 try
 to 
do a
 mix
ture
 of a
ctiv
ities
, lik
e ci
rcu
it tr
aini
ng, 
or i
f yo
u ar
e ou
t ru
nnin
g tr
y to
 add
 in a
 sho
rt sp
rint
 eve
ry 2
0-3
0 m
ins.
  
This
 wil
l he
lp y
ou t
o av
oid 
hyp
ogly
cae
mia
. 
You
 sho
uld
 no
t ex
erci
se i
f yo
u h
ave
 hig
h b
loo
d su
gar
s an
d ke
ton
es, 
this
 
ind
icat
es t
hat
 you
 hav
e no
t go
t en
oug
h in
suli
n av
aila
ble.
  Ex
erci
se 
cou
ld w
ors
en y
our
 ket
osis
. 
 It i
s es
sen
tial
 tha
t yo
u w
ait 
unti
l yo
ur b
loo
d su
gar
s ar
e st
able
 and
 you
 
are
 fre
e of
 ket
one
s. 
It is
 imp
orta
nt t
o ke
ep a
 clo
se e
ye o
n yo
ur b
lood
 glu
cos
e ar
oun
d ex
er-
cise
.  Th
is w
ill h
elp 
you
 to 
avo
id h
ypo
glyc
aem
ia a
nd p
lan 
you
r ca
rbo
hy-
dra
te r
equ
irem
ent
. 
 As a
 gui
de, 
you
 sho
uld:
 
 1. 
Me
asu
re y
our
 blo
od g
luco
se b
efo
re y
ou e
xerc
ise.
 
2. 
Me
asu
re b
lood
 glu
cos
e ev
ery
 thi
rty 
min
ute
s du
ring
 exe
rcis
e. 
3. 
Che
ck y
our
 blo
od g
luco
se a
fter
 you
 hav
e fin
ishe
d ex
erci
sing
. 
4. 
Che
ck y
our
 blo
od g
luco
se a
ppr
oxim
ate
ly s
ix h
our
s aft
er y
our
 exe
r-
cise
 ses
sion
 has
 fini
she
d (if
 pra
ctic
able
). 
 If y
ou 
are
 stil
l ha
ving
 pro
blem
s w
ith 
you
r bl
ood
 sug
-
ars,
 you
 sho
uld
 get
 in c
ont
act 
wit
h yo
ur  
  Ex
tod
 tea
m 
who
 can
 sug
ges
t ot
her
 me
asu
res.
 
Rem
em
ber
:  Yo
ur b
loo
d gl
uco
se s
hou
ld b
e m
ore
 tha
n 5.
0 
mm
ol/l
 bef
ore
 you
 sta
rt d
rivi
ng a
nd 
you
 mu
st w
ait 
for 
45 
min
ute
s aft
er a
n ep
isod
e of
 hyp
ogly
cae
mia
 has
 res
olve
d b
e-
fore
 getti
ng b
ehin
d th
e w
hee
l. 
As w
ell a
s us
ing 
carb
ohy
dra
te, 
exe
rcis
e w
ill a
lso 
cau
se t
he b
ody
 to 
lose
 
fluid
.  Th
is m
ay b
e th
rou
gh s
wea
t or
 in t
he b
rea
th. 
 The
 am
oun
t of
 flui
d 
you
 los
e w
ill v
ary 
dep
end
ing 
on t
he t
ype
 and
 len
gth
 of a
ctiv
ity, 
and
 the
 
tem
per
atu
re. 
If it
 is v
ery 
hot
 we
ath
er, 
abo
ve 3
0°C
, yo
u w
ill n
eed
 sal
t 
rep
lace
men
t. 
 It is
 imp
orta
nt t
o m
ake
 sur
e th
at o
n da
ys w
hen
 you
 exe
rcis
e, y
ou r
em
ain 
wel
l hy
dra
ted
.  Yo
u sh
ould
 try
 to 
hav
e a 
drin
k in
 the
 hou
r be
fore
 you
 
star
t an
d en
sure
 tha
t yo
u ha
ve s
om
eth
ing 
to s
ip d
urin
g yo
ur e
xerc
ise.
   
 Car
ry a
 wa
ter 
bott
le . 
Sip 
coo
l wa
ter 
and
 aim
 to 
drin
k 50
0 - 6
00 m
l ea
ch 
hou
r. D
rink
 wa
ter 
with
 all 
me
als.
 Eati
ng f
ood
 pro
mo
tes 
fluid
 int
ake
. Tr
y 
to i
nclu
de f
ruit
 and
 veg
eta
bles
 as 
the
se h
ave
 a h
igh 
wat
er c
ont
ent
. If 
swe
at lo
sses
 are
 gre
at t
he u
se o
f sa
lty f
ood
s e.
g pr
etze
ls, a
dde
d sa
lt to
 a 
me
al , 
drin
king
 a s
por
ts d
rink
 wit
h so
dium
/sal
t wi
ll he
lp y
ou r
ehy
dra
te. 
 You
 ma
y w
ish 
to s
ip w
ate
r, o
r a s
por
ts d
rink
 tha
t als
o co
nta
ins 
you
r ca
r-
boh
ydr
ate
 req
uire
me
nt. 
Flui
d in
take
  
Bef
ore
 you
 exe
rcis
e 
 Che
ck y
ou h
ave
: 
 
You
r in
suli
n an
d bl
ood
 glu
cos
e/k
eto
ne m
onit
orin
g   
kit 
 
Trea
tme
nt f
or h
ypo
glyc
aem
ia 
 
Drin
ks a
nd s
nac
ks 
 Che
ck y
our
 blo
od g
luco
se: 
is it
 saf
e to
 exe
rcis
e? 
 Do 
you
 nee
d an
y ad
diti
ona
l ca
rbo
hyd
rate
 bef
ore
 you
 sta
rt? 
  Dur
ing 
exe
rcis
e  
 Che
ck y
our
 blo
od g
luco
se e
ver
y 30
 min
s. 
 You
 wil
l ne
ed a
rou
nd 1
5-3
0g c
arb
ohy
dra
te e
ver
y 30
 min
s. 
 Ma
ke s
ure
 you
 dri
nk p
lent
y of
 flui
d. 
Rem
emb
er: 
  Afte
r ex
erci
se 
 Che
ck y
our
 blo
od g
luco
se a
s so
on a
s yo
u fin
ish 
and
 six 
hou
rs 
late
r (o
r be
fore
 you
 go 
to b
ed i
f th
is is
 soo
ner
). 
 You
 wil
l ne
ed m
ore
 car
boh
ydra
te, a
bou
t ha
lf as
 mu
ch a
s yo
u 
con
sum
ed d
urin
g ex
erci
se. 
 Drin
k pl
ent
y of
 flui
d. 
You
r no
tes:
 
Con
tact
 det
ails
 of t
he E
xtod
 tea
m 
Use
ful w
ebs
ites
: 
 Dia
bet
es a
nd 
exe
rcis
e  
ww
w.r
uns
wee
t.co
m 
 Spo
rts 
Die
titia
ns U
K 
  
ww
w.s
por
tsdi
etiti
ans
.org
.uk 
    
 UK 
Spo
rt 
 
 
 
 
ww
w.u
ksp
ort.
gov
.uk 
 Dia
bet
es U
K 
 
 
 
ww
w.d
iabe
tes.
org
.uk 
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Appendix F  SOP FOR THE MIXED MEAL TOLERANCE TEST 
Equipment 
Alcohol gel and hand wash 
Gloves & apron 
Tourniquet 
Cannula and fixative dressing 
Three way tap/adaptor 
Vacutainers (3x SST (gold), 11x EDTA (lavender), 7x sodium fluoride (grey)) 
240mls Fortisip 
24 x 2ml Sarstedt tubes 
Sharps container 
Cotton wool and plasters 
ExTOD Labels 
Centrifuge 
 
Prior to Procedure 
 Explain procedure to patient 
 Ensure patient seated comfortably or lay couch 
 Check blood glucose levels (should be between 3.5-15mmol/l) 
o If blood glucose < 3.5 treat for hypoglycaemia and reschedule test 
o If blood glucose > 15 check for ketones and reschedule test 
 
Procedure 
1. Wash hands and put on PPE 
2. Tighten tourniquet on arm and locate suitable vein 
3. Cleanse skin 
4. Insert cannula into vein (at least 18 gauge into a large vein in antecubital fossa) 
5. Secure cannula with adhesive dressing 
6. Withdraw fasting blood samples for lipids, adiponectin and inflammatory factors, and 
transmigration studies (3x SST tubes, 4x EDTA tubes) 
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7. Withdraw -10min blood samples (1x EDTA, 1x sodium fluoride) 
8. Invert tubes 8-10 times 
9. Flush cannula with 2ml 0.9% saline, to ensure patency 
10. At 0 mins, withdraw and discard 2mls blood.  Then,  
11. Withdraw 0min samples (1x EDTA, 1x sodium fluoride) 
12. Invert tubes 8-10 times 
13. Flush cannula with 2ml 0.9% saline, to ensure patency 
14. Ask participant to drink 240mls fortisip 
15. Repeat steps 10-13 at 15, 30, 60, 90 and 120 mins. 
16. Check blood glucose again at the end of the test 
17. Once all samples are collected remove cannula and dispose of immediately in sharps 
bin 
18. Place a piece of cotton wool over bleeding point and ask the patient to press for a 
minute 
19. Check bleeding has stopped and ask if patient allergic to plasters. Apply dressing 
appropriately 
 
Processing of samples (see also sample processing instruction sheet) 
1. Centrifuge samples within 60 min of collection at 25°C, 1100-1300g for 10mins 
2. Pipette serum/plasma for each sample into 2 × 2ml sarstedt tubes 
3. Label with ExTOD label (see below) 
4. Store samples at -80°C  
 
Time Label 
 EDTA Sodium fluoride 
-10min samples ex---pm ex---gm 
0min samples ex---p0  ex---g0 
15min samples ex---p15 ex---g15 
30min samples ex---p30 ex---g30 
60min samples ex---p60 ex---g60 
90min samples ex---p90 ex---g90 
120min samples ex---p2h ex---g2h 
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Appendix G  SOP FOR THE FITNESS TEST 
Sub-maximal test for estimation of VO2 max 
Equipment required 
Calibrated exercise cycle with the ability to vary workload 
Heart rate monitor (chest strap and watch) 
Stop watch + spare in case of equipment failure 
Blood glucose monitoring equipment 
Ketone monitoring facility (capillary or urine) 
Hypo kit 
Water for the participant 
 
Before the test 
Ensure the participant is wearing appropriate clothing (e.g. trainers and jogging 
trousers). 
Ask the participant about alcohol and caffeine intake in the last 12 hours as these 
may affect the heart rate calculations. 
Ask the participant about hypoglycaemia in the last 24 hours.  If they report an 
episode of severe hypoglycaemia, i.e. requiring 3rd party assistance, the test should 
be rescheduled. 
If the participant has overly exerted themselves in the last 24hours, this may cause 
them to fatigue more easily to normal and give an inaccurate result, in this event, 
consider rescheduling the test. 
Ensure the participant is well hydrated and check their capillary blood glucose (refer 
to insulin/carbohydrate/fluid and exercise protocol). 
Explain the test to the participant and show them the RPE scale. 
Weigh the patient and record this on the CRF. 
Ask the participant to position the chest strap of the heart rate monitor around their 
chest.  Place the watch somewhere you can take heart rate readings easily (i.e. so 
you can see the face).  Ensure that the watch is picking up a heart rate reading 
satisfactorily. 
Make sure you have the patients target HR for part 2 on the CRF.  This is 85% of 
age-predicted maximum HR, i.e. 85% of (220-age).  If not, record and calculate it 
before you start the test.  
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The test (This will depend in part on the bicycle used) 
Position the participant comfortably on the bicycle.  The legs should not need to be 
fully extended to pedal.  Record the seat position and handlebar position (if 
necessary) on the CRF. 
 
Part 1  
Depending on size and fitness of the patient set the load at 50 – 100W (1-2kg load at 
50rpm).  Record the workload on the CRF.  Ask the participant to aim to cycle at 50 
rpm. 
The aim is for the participants heart rate to be between 120 and 170bpm at the end 
of the six minutes.  Check HR and RPE at 2 mins (if HR is <120bpm consider 
increasing work load and restarting six minute test). 
 
From 4 minutes, record HR every 15 seconds. 
At the end of the six minutes, record HR and RPE. Then: 
 If the average HR for the last 2 mins < 120bpm, repeat part 1 at a 
higher workload (if it is clear that the HR will not rise above 120 bpm 
the six minutes can be restarted earlier). 
 If the average HR is between 120 and 170, continue to part 2. 
 If the average HR is over 170bpm then finish the test and allow the 
participant to cool down (cycle against a low resistance for a few 
minutes). 
 
Part 2 
During this part of the test, the workload should be increased incrementally with the 
aim of the participant reaching their target HR by stage 3 (so that there are 3 
recordings of workload and average HR for this stage). 
For each stage, 
1. Increase the workload by 25-50W depending on participant’s fitness level and 
size. 
2. Record the workload for the stage on the CRF. 
3. Ask the participant to cycle at 50 rpm. 
4. From 2 mins 30 secs, record HR every 15 secs. 
5. At the end of three minutes, calculate the average HR for the last 30 secs and 
the RPE on the CRF. 
If after the 3 incline stages the desired heart rate is not achieved repeat this process.  
Once target HR has been achieved, finish the test and allow the participant to cool 
down (cycle against a low resistance for a few minutes). 
 
End of the test 
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Once the participant has cooled down, check their blood glucose. 
If the test had to be terminated early, record this on the CRF along with the reason 
why. 
Check the participant is happy with how the test has gone and allow them to 
shower/change prior to going home. 
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Appendix H  INTERVIEW TOPIC GUIDE 
1) Moderator’s introduction 
 
2) About the group 
 What are we going to talk about/Explain purpose 
 
3) Activity and exercise behaviour 
 What exercise do you do? 
 What does the word ‘exercise’ mean to you? (Focus on activity 
levels) 
 Why should someone exercise? 
 How active are you on a day to day basis/How do you feel about the 
amount of exercise you do? 
 Do you think you do enough exercise to keep healthy?  
 Is exercise important in the management of diabetes? 
 What are the recommended guidelines?  
 The DOH recommends 150 mins exercise per week, what do you 
think of this?  
 Do you think this is achievable? 
 How do you relate to that? 
 
4) Barriers to exercise 
 What are the mains reasons for not meeting the guidelines?  
 How do you try to overcome these barriers?  
 If you have a fear of having a hypo, do you make any adjustments? 
 If you had a magic wand what would be the one thing you could 
overcome in order to allow you to do more exercise? 
 Has the diagnosis of DM changed your attitudes towards exercise? 
 Does education and understanding have a role in the management 
of your diabetes and therefore your exercise levels? 
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5) Encouragement and facilitation of exercise 
 Can you think of any ways of improving your activity levels? 
 How can small changes be incorporated into your lifestyle? 
 Are there any major themes that would help encourage people to be 
more active? 
 Would more advice or information help? 
 If you had to choose one intervention that would help your activity 
levels – which would it be?  
 Has anyone any successful experiences of exercising in the past? 
 
We are thinking about doing a study – if you were to take part how would you like to 
be monitored/encouraged? 
 One to one advice from a health and fitness advisor 
 Attending an exercise group organised by the hospital or your GP 
 Support – someone who keeps in touch to see how you are doing 
with your exercise programme 
 Goal setting/modification/action planning 
 HR monitoring 
 Chat room with other people from the study to share ideas 
 Uploading BMI/weight loss onto website – self monitoring 
 If phone calls weren’t appropriate, what else could we do to motivate 
you? 
 
6) Summary of session, 
 Outlining main points of discussion and key issues raised 
 Questions 
 Thank everyone for their input 
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